

## Pfizer Inc

### Table of Contents

Snapshot.....	2
Company Profile.....	2
Financials.....	23
Company Contacts.....	28
Subsidiary Companies.....	29
Drug Sales and Forecasts.....	47
Drugs.....	116
Deals.....	120
Clinical Trials.....	120
Patents.....	122

Created: 11-Feb-2015

[Return to Table of Contents](#)

# Pfizer Inc

## SNAPSHOT

<b>Company Name</b>	Pfizer Inc
<b>Parent Company Name</b>	Pfizer Inc
<b>Organization Type</b>	Organization Sub-Type : Company Company Type : Public Company Size : Mega
<b>Field Of Activity</b>	Specialty & Advanced Pharmaceuticals,Biopharmaceuticals,Biotechnology & Medical Research - NEC,Bio Therapeutic Drugs
<b>Private Equity Backed Status</b>	
<b>Website</b>	http://www.pfizer.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	360
<b>Number of Inactive Drugs</b>	2106
<b>Number of Patents as Owner</b>	24935
<b>Number of Patents as Third Party</b>	293
<b>Number of Deals</b>	1416
<b>Key Indications</b>	Cancer;Pain;Hypertension;Alzheimers disease;Bacterial infection;Rheumatoid arthritis;Non-insulin dependent diabetes;Inflammatory disease;Breast tumor;Bacterial pneumonia
<b>Key Target-based Actions</b>	DNA gyrase inhibitor;Endothelin ET-A antagonist;Calcium channel inhibitor;5-Lipoxygenase inhibitor;ACAT inhibitor;Cyclooxygenase 2 inhibitor;Protein tyrosine kinase inhibitor;Matrix metalloprotease inhibitor;Cyclooxygenase inhibitor;Angiotensin II receptor antagonist
<b>Key Technologies</b>	Small molecule therapeutic;Oral formulation;Biological therapeutic;Tablet formulation;Intravenous formulation;Antibiotic;Peptide;Capsule formulation;Systemic formulation unspecified;Parenteral formulation
<b>Added Date</b>	03-Jun-2003

## COMPANY PROFILE

### SUMMARY

Pfizer Inc, founded in 1849 and headquartered in New York, NY, is a publicly owned global pharmaceutical company which discovers, develops, manufactures, and markets therapeutics for a range of conditions, prioritizing Alzheimer's disease, diabetes, pain, cancer, inflammation, schizophrenia and other mental illnesses.

In July 2013, Pfizer planned to separate its commercial operations into three businesses. One innovative business segment would include products from multiple therapeutic areas, such as inflammation and immunology, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health. A second innovative business segment would include vaccines, oncology and consumer healthcare. The third value business segment would comprise products that no longer have market exclusivity, mature, patent-protected products which will lose exclusivity by 2015, biosimilars and product collaborations. Changes would come into effect in January 2014 or once consultation with works councils or unions had been completed [1458137].

### COMPANY LOCATION

The company's corporate headquarters are in New York, NY [412155]. As well as the US, Pfizer has research facilities in Canada, Japan, France and the UK [551494].

[Return to Table of Contents](#)

In October 2014, Pfizer Japan was to establish a new unit on December 01, 2014 which would operate under the name, Pfizer Seiyaku. The new unit would take over Pfizer Japan's vaccines, oncology and innovative pharma businesses [1616483].

In June 2014, the company established of a new 280,000 square-foot research and development hub in Cambridge, MA [1569675].

In May 2013, UPM Pharmaceuticals acquired the 500,000 square-foot commercial manufacturing facility of Pfizer in Bristol, TN [1430801].

In September 2011, Pfizer signed a 10-year lease agreement with the Massachusetts Institute of Technology (MIT). In November 2011, Pfizer and the MIT held an official groundbreaking ceremony at Pfizer's new Cardiovascular, Metabolic and Endocrine diseases and Neuroscience research units in Cambridge, MA [1242056].

In June 2011, BioMarin Pharmaceutical was to acquire Pfizer's bulk biologics manufacturing plant in Shanbally, Cork, Ireland, for \$48.5 million. The purchase was expected to close in the third quarter of 2011 [1202759]

In June 2011, Pfizer inaugurated Pfizer Canada's newly refurbished head office in Montreal, Canada. An investment of \$22 million was made to incorporate all of Pfizer's Canadian offices into one facility [1201864].

In March 2011, Pfizer planned to move its antibacterials research unit from Groton, CT, to Shanghai, China [1176987]. The transfer was expected to take two years. In November 2011, the timing for the buildout of the Shanghai Anti-Infectives Research Unit was extended [1240945].

In January 2011, Rockefeller University, New York University Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College joined Pfizer's Centers for Therapeutic Innovation. At that time, Pfizer leased a facility in New York City, NY, for the collaboration. A similar Center was established in November 2010 in San Francisco, CA [1163290]. In June 2011, Pfizer launched its Centers for Therapeutic Innovation in Boston, MA and Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children's Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, and University of Massachusetts Medical School joined partnership. At that time, Pfizer leased laboratory space in Boston, MA, to serve as the global headquarters for the initiative [1198757].

In July 2010, the company invested \$100 million in the expansion of the Singapore nutrition plant [1114717].

In June 2010, Pfizer created a Rare Disease research unit within its Worldwide R&D business [1108101].

In October 2009, Pfizer revealed its strategy for future clinical development, whereby it would halve the number of countries in which it had clinical infrastructure, reduce the number of trials, and reduce the relative allocation of patients to EU sites from 40% to between 25 and 30%, and increase the allocation in lower cost/higher speed regions. The countries in which it conducted trials would be classified as core or non-core. All ongoing committed studies in all countries would continue, but in the non-core countries there would be attrition of staff, and new trials would only be run there in exceptional cases. These trials would be run by CROs. The European region was reduced from 32 countries to 14 core countries, while Asia was reduced from 11 to 9 countries, and the rest of the world from 12 to 10 countries. At that time, the attrition in non-core countries was progressing in line with the completion of committed trial work, but objective signs of an impact on cycle times were not expected to be seen until 2010 [1049799]. In November 2009, Pfizer planned to discontinue eight R&D sites and consolidate others, reducing its R&D footprint by 35%, following its acquisition of Wyeth. Operations would be discontinued at Princeton, NJ, Chazy, NY, Rouses Point, NY, Plattsburgh, NY, Sanford, NC, Research Triangle Park, NC, Gosport, UK and Slough/Taplow, UK. R&D at the New London, CT site would be consolidated to Groton, CT, and some functions would be moved from the Collegeville, PA, Pearl River, NY, and St Louis, MO sites to other locations. The Chesterfield Village Research Center in Chesterfield, MO, would be sold for \$435 million to Monsanto, while Pfizer would retain use of the facility via a lease for biotherapeutic pharmaceutical research. The deal was to close in the first half of 2010. The five remaining research hubs for biotherapeutics, pharmatherapeutics and vaccines would be in Cambridge, MA, Groton, CT, Pearl River, NY, La Jolla, CA and Sandwich, UK. Specialized research capabilities would also be maintained at nine units, including San Francisco (monoclonal antibody discovery), Cambridge, UK (regenerative medicine) and Shanghai, China. At that time, the company was also analyzing the portfolio of the combined company in order to prioritize research projects [1056181], [1055785]. In January 2010, Pfizer revealed that the 'Invest to Win' strategy was to focus research onto oncology, pain, inflammation, diabetes, Alzheimer's disease and psychiatric disease indications [1071167]. By May 2010, following the closure of the Wyeth transaction, the workforce had declined by 6,900 [1095714]. Later in May 2010, Pfizer reported its plan to reconfigure its global manufacturing plant network to combine both Pfizer and Wyeth sites. Pfizer planned to close eight sites in Ireland, Puerto Rico and the US by the end of 2015 resulting in the loss of 6,000 jobs. A reduction in operations was also expected at six sites in Germany, Ireland, Puerto Rico, the UK and the US [1100923]. In February 2011, Pfizer planned to exit from the R&D site in

[Return to Table of Contents](#)



Sandwich, UK with the loss of 2400 jobs. At that time, the company also planned to relocate selected resources from Groton, CT to Cambridge, MA. The company expected to reduce adjusted R&D expenses to between approximately \$6.5 to \$7.0 billion in 2012 [1164998]. In March 2011, Pfizer announced plans to move its antibacterials research unit from Groton, CT, to Shanghai, China, downsize its St Louis, MO, indications discovery unit and to move its Groton autism unit to Cambridge, MA [1176987]. In May 2011, Pfizer confirmed that it had closed its Oligonucleotide Therapeutics unit. At that time, undisclosed selected projects were to be retained [1193625].

In July 2009, the company was structured into primary care, specialty care, oncology, established products, emerging markets and animal health business units [1027617].

In August 2008, the company announced it had entered into a long-term lease for Alexandria Center for Science and Technology, Mission Bay, CA, for its biotherapeutics and bioinnovation center [931874].

In December 2007, Pfizer sold its manufacturing facilities in Arnprior, Ontario to Keata Pharma, a subsidiary of PharmEng International [862572].

By November 2007, Pfizer had opened an R&D facility (China R&D Center; CRDC), in the Zhangjiang Technology Park, China [877601].

In October 2007, Pfizer established a biotherapeutics and bioinnovation center [836403].

In November 2006, Pfizer closed its Augusta, GA, facility and all equipment was to be sold at a public auction in late January 2007 [739971].

In June 2005, Pfizer started production at its plant expansion in Loughberg, Ireland. The facility would manufacture torcetrapib, which Pfizer was combining with atorvastatin for the treatment of atherosclerosis and hypercholesterolemia [608845] [613139].

In April 2005, Pfizer announced the divestment of various facilities worldwide, following the acquisition of Pharmacia in 2003. These included facilities in Augusta, GA; Holland, MI; Angers and Val-de-Reuil, France; and Morpeth, UK. The company also announced the restructuring of facilities in Sandwich, UK; and Arecibo, Caguas and Cruce Davila, Puerto Rico [595966].

Earlier in April 2005, Pfizer opened a \$35 million clinical research unit in New Haven, CT, to determine drug safety. The 62,500 square-foot facility included a 1-to-1 staff-to-bed ratio [595107].

In November 2004, Pfizer purchased an R&D campus in La Jolla, CA, for \$372 million that it formerly leased from Slough Estates plc. The campus consisted of 1 million square feet of laboratory and office space on a 33-acre site and the research teams at Jolla were pursuing the development of new therapies for the treatment of cancer, HIV, hepatitis, blindness and diabetes/obesity [568155].

In June 2002, Pfizer opened a \$250 million technical development facility in Ann Arbor, MI. The facility was designed to provide state-of-the-art technology, laboratories and offices for more than 400 researchers and other staff [455928]. In December 2008, the University of Michigan bought Pfizer's Ann Arbor, MI, site [972702]. In May 2009, the University planned to complete its \$108 million purchase of Pfizer's Ann Arbor, MI, research campus in the 'coming weeks' [1010300].

In June 2000, Pfizer opened a new R&D division, Pfizer Global Research and Development, at its Groton, CT research campus. The new building was the world's largest private biomedical R&D operation [372144].

## ACQUISITIONS AND SPIN-OFFS

In February 2015, Pfizer signed a definitive agreement to acquire Hospira for \$90 per share in cash for a total value of approximately \$17 billion. By that time, both company boards had unanimously approved the merger. Pfizer was to finance the transaction with approximately two-thirds of the value from cash and one-third from new debt. At that time, the transaction was expected to close in the second half of 2015 [1631674].

In July 2014, Pfizer entered into an agreement to acquire InnoPharma for an upfront cash payment of \$225 million, with up to \$135 million of contingent milestone payments. At that time, the acquisition was expected to complete in the third quarter of 2014 [1577762]. In September 2014, the acquisition was completed [1597109].

In January 2014, Pfizer submitted a preliminary, non-binding indication of interest to the AstraZeneca board of directors for a possible merger transaction. The proposal included a combination of cash and shares in the combined entity which represents an indicative value of GBP 46.61 (US \$76.51) per share and a substantial premium of approximately 30% of AstraZeneca's closing share price of GBP 35.86 (US \$59.26), each as of January 03, 2014. Later that month, following high-level discussions AstraZeneca declined to pursue discussions.

[Return to Table of Contents](#)



In April 2014, Pfizer again contacted AstraZeneca to renew the discussions regarding development of a proposal that could be recommended by both companies to their shareholders. At that time, AstraZeneca again rejected the proposal and Pfizer considered to open its offer until May 26, 2014. Were the merger approved, a combined company under a new UK-incorporated holding company would be created, maintaining its head offices in New York and listing its shares on the New York Stock Exchange [1550721]; at that time, AstraZeneca announced that the company considered the offer to significantly undervalue the company [1550934]. In May 2014, Pfizer increased its offer to an indicative value of GBP 50.00 (US \$84.47) per share. In connection with the proposed merger, Pfizer sent several assurances to the UK Government, including that the proposed R&D hub to be built in Cambridge was to be completed, the manufacturing facilities retained in Macclesfield and 20% of the combined company's R&D workforce retained in the UK. However, the amended offer was immediately rejected by AstraZeneca board [1552434], [1552436], [1552607]. Later that month, AstraZeneca released a statement that claimed the company had the potential to generate annual revenues of greater than \$45 billion in 2023 [1553408]. Later in May 2014, Pfizer made a final offer for AstraZeneca of 1.747 shares in the combined entity and GBP 24.76 (US \$41.63) in cash, representing an indicative value of 55.00 (US \$92.48) per share [1558654]. Again in May 2014, AstraZeneca's board rejected Pfizer's final offer [1558722]; later that month, Pfizer announced that it did not intend to make a further offer for AstraZeneca [1561883], [1561968].

By August 2013, Pfizer was reported to have acquisition interest in biosimilar manufacturer Biocad, expected to be worth US \$1 billion [1472136].

In September 2012, Pfizer, Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Abbott Laboratories, Genentech and Sanofi created non-profit organization TransCelerate Biopharma [1325054].

In the second quarter of 2012, Pfizer entered into an option and merger agreement with NextWave Pharmaceuticals and made an option payment of \$20 million. In October 2012, Pfizer exercised its option to acquire NextWave for \$255 million plus additional milestone payments of up to \$425 million. At that time, the transaction was expected to close during the fourth quarter of 2012 [1333638]. In November 2012, the acquisition was completed [1345115].

In April 2012, Pfizer agreed to divest its Nutrition business to Nestle for \$11.85 billion in cash. At that time, the transaction was expected to complete by the first half of 2013 [1282283]. In November 2012, the sale was completed [1346116].

In February 2012, Pfizer acquired Alacer Corp, a maker and distributor of branded vitamin C in the US. Financial details were not disclosed [1267070].

In November 2011, Pfizer agreed to acquire Excaliard Pharmaceuticals for an undisclosed upfront payment and contingent milestone payments related to EXC-001. As an equity owner of Excaliard, Isis Pharmaceuticals would receive a \$4.4 million portion of the upfront payment and up to \$9.6 million from any milestone payments. The company would also retain its eligibility to receive milestones and royalty payments related to EXC-001 due to an earlier licensing agreement with Excaliard. At that time, the deal was expected to close before the end of 2011 [1242193], [1242278]. In December 2011, the acquisition was completed [1245358].

In July 2011, Pfizer was considering strategic alternatives for its Animal Health and Nutrition businesses. Options included a full or partial separation of each business, spin-off, sale or other transaction [1206110]. In June 2012, preparations were underway to file a US registration statement for an IPO of a minority ownership stake in the new Animal Health business, to be named Zoetis [1298565]. In January 2013, Zoetis announced an IPO of Class A common stock under the symbol 'ZTS'; following completion of the offering, Pfizer was to own all outstanding Class B shares in Zoetis and retain 80 to 83% ownership of the company [1365310], [1365538]. In February 2013, Pfizer completed its IPO of 19.8% ownership interest in Zoetis. In May 2013, Pfizer was continuing to consolidate Zoetis and retained an 80.2% ownership interest in the company [1417196]. Later that month, Pfizer proposed an exchange offer to allow Pfizer shareholders to exchange all, some or none of Pfizer common stock for Zoetis common stock; if fully subscribed, Zoetis would become a fully independent company upon completion of the offer [1426251], [1426252]. In June 2013, Pfizer was to accept for exchange 405,117,195 shares of its common stock at an exchange ratio of 0.9898 Zoetis common stock for each of Pfizer's common stock. By that time, the offer was oversubscribed with 868,006,432 Pfizer common stock shares having been validly tendered and the offer was automatically extended to June 21, 2013 [1441882]. Later in the same month following expiry of the offer, Pfizer accepted 405,117,195 of the total 1,680,439,287 Pfizer tendered shares (24%) in exchange for the 400,985,000 shares of Zoetis common stock owned by Pfizer. As a result of the offer, Pfizer no longer held any ownership interest in Zoetis [1443757], [1445325].

In June 2011, Pfizer was in preliminary discussions considering a strategic transaction with Icagen as part of an ongoing evaluation of an extension or modification of an existing collaboration between the two companies [1203297]. In July 2011, Pfizer agreed to acquire Icagen for \$56 million. Pfizer already had an 11% stake in the company and would pay \$6 per share for the remaining 8.3 million shares. At that time, the deal was expected to close by the end of 2011 [1208804]. Later in July 2011, Icagen's shareholders Merlin Nexus and New Leaf

[Return to Table of Contents](#)



Venture Partners announced they did not intend to tender their shares believing the purchase price to be undervalued [1211036]. In August 2011, the shareholders sent a second letter to Icagen's Board reiterating their disagreement with the acquisition [1214528]. In August 2011, the shareholders sent a second letter to Icagen's Board reiterating their disagreement with the acquisition [1214528]. Later in August 2011, Icagen sent a letter to shareholders reiterating its recommendation that Icagen stockholders accept the offer [1215341]. Later again in August 2011, Merlin Nexus and New Leaf Venture Partners filed a letter with the SEC [1217533]. In September 2011, Pfizer extended the expiration date of its tender offer from August 31, 2011 until September 01, 2011. At that time, 49% of Icagen's shares had been validly tendered [1219050]. Later that month, the tender offer was extended again until September 02, 2011 [1219388]. Later in September 2011, the initial cash tender offer was completed with 64% of the outstanding shares having been validly tendered or already owned by Pfizer. At that time, a subsequent offering period was initiated and was expected to expire on September 12, 2011, following which the acquisition would be completed via a merger [1220282]. Later in September 2011, the deadline was extended to September 19, 2011 [1222205]. The cash tender offer expired later in September 2011. A total of 5,393,380 Icagen shares had been tendered which when added to the shares Pfizer already owned represented 70.2% of outstanding shares. The second-step merger was to be completed following approval by Icagen shareholders at a meeting to be held as soon as practical [1224181]. In October 2011, the second-step merger was completed. Pfizer's wholly owned subsidiary, Eclipse Acquisition, was merged with and into Icagen making Icagen a wholly owned subsidiary of Pfizer. The company would be integrated into Neusentis, Pfizer's Research Unit for pain, sensory disorders and regenerative medicine [1234410].

In June 2011, Pfizer and Zhejiang Hisun Pharmaceutical signed a memorandum of understanding (MOU) to establish a joint venture for branded generics [1197124]. In February 2012, Pfizer and Zhejiang signed a framework agreement regarding the joint venture which was to be called Hisun Pfizer Pharmaceutical. Zhejiang and Pfizer would own 51 and 49% of the joint venture respectively [1264170]. In September 2012, the joint venture was launched [1323200].

In May 2011, Pfizer agreed to invest \$50 million in Shanghai Pharmaceuticals' \$1.2 billion IPO [1188313].

In February 2011, Pfizer agreed to buy Ferrosan Consumer Healthcare from Altor 2003 Fund GP. At that time, the transaction was expected to close in the second quarter of 2011 [1166115]. In December 2011, the acquisition was completed [1245001].

In December 2010, Akorn's joint venture, Akorn-Strides, entered into a purchase agreement to sell 16 abbreviated NDAs and 6 filed abbreviated NDAs to Pfizer. Under the terms of the agreement, Akorn would receive \$35 million in cash and Akorn-Strides would continue to manufacture and distribute approved products until April 30, 2011 [1158216].

In October 2010, Pfizer agreed to acquire a 40% stake in Laboratorio Teuto Brasileiro, for BRL 400 million (US \$237 million) upfront plus milestones, and to form a series of deals to develop and commercialize generic medicines. Pfizer had the option to acquire the Teuto's remaining 60% from 2014, and the company's shareholders could sell their 60% to Pfizer from 2015. The acquisition was expected to close by the end of 2010 [1140827].

In October 2010, Pfizer and King Pharmaceuticals entered into a definitive merger agreement under which Pfizer would pay \$14.25 per share, a total of \$3.6 billion, and gain access to King's Meridian auto-injector business as well as its pain relief products. The transaction was expected to be accretive to Pfizer's adjusted diluted earnings per share by \$0.02 annually in 2011 and 2012, and by \$0.03 to \$0.04 per year from 2013 to 2015. The deal was approved by both company's Boards and was expected to close in the fourth quarter of 2010 or the first quarter of 2011 [1138884]. However, at that time, the law office of Robbins Umeda launched an investigation to determine whether King's Board had breached its fiduciary duty to shareholders in failing to seek other transactions before entering into the agreement with Pfizer [1139106]. Later in October 2010, Pfizer commenced the tender offer [1141370]. In November 2010, the expiration date of the offer was extended from November 19, 2010 to December 17, 2010 [1149603]. In December 2010, the offer was extended to January 21, 2011 [1156372]. In January 2011, the tender offer was extended until January 28, 2011 [1162622]. Later in January 2011, Hart-Scott-Rodino clearance was received. At that time, the companies expected the tender offer to close as scheduled on January 28, 2011 [1164184]. In January 2011, Pfizer completed the tender offer. Approximately 230,719,938 shares were validly tendered and not withdrawn during the offering period, which represented approximately 92.5% of King's outstanding shares. Pfizer planned to complete the acquisition of King through a short-form merger on February 28, 2011, which would result in each remaining share of King being converted into the right to receive \$14.25 per share in cash. Following the merger, King would become a wholly owned subsidiary of Pfizer and would cease trading on the NYSE [1164691]. In February 2011, King notified the NYSE of its voluntary delisting from the exchange expected on March 01, 2011 [1166802]. Later in February 2011, Pfizer completed the acquisition, with King becoming a wholly owned subsidiary of Pfizer [1171898].

In October 2010, Pfizer initiated a review to consider the strategic alternatives for Capsugel, its business unit dedicated to producing hard capsules and developing drug delivery systems. At that time, Pfizer hoped to deliver value to its shareholders and believed Capsugel had the potential to grow outside of Pfizer. The review was

[Return to Table of Contents](#)

expected to complete by the end of the first quarter of 2011 [1136738]. In April 2011, Pfizer agreed to sell its Capsugel business to Kohlberg Kravis Roberts (KKR) for \$2.375 billion. Capsugel would maintain its headquarters in Peapack, NJ, and Pfizer employees in the business would be transferred to Capsugel. Pfizer would use part of the proceeds from the deal to repurchase its common stock on the open market during 2011. At that time, the transaction was expected to close in the third quarter of 2011 [1181357]. In August 2011, the acquisition was completed [1211612].

In September 2010, Pfizer agreed to acquire FoldRx Pharmaceuticals. Pfizer would make an upfront payment to FoldRx and milestone payments following certain achievements. Pfizer would gain rights to FoldRx's tafamidis meglumine. The transaction was expected to complete later in 2010 [1127725]. The transaction closed in October 2010 [1136922].

By August 2010, Strides Arcolab owned a 60% stake in Pfizer's generic's partner Ascent Pharmahealth and was intending to purchase the remaining shares in the company as soon as possible [1157652]. In December 2010, Strides agreed to acquire the remaining stake in Ascent Pharmahealth for \$0.40 per share, a total of \$100 million. The implementation scheme would be presented for shareholder approval in March 2011 [1157652].

In May 2010, Pfizer, a shareholder in Nerviano Medical Sciences, signed an agreement for the official separation of the two companies, removing Pfizer's right of first refusal [1106611].

In February 2010, Eli Lilly, Merck & Co and Pfizer established Asian Cancer Research Group (ACRG), an independent, non-profit company focused on the development of treatments for the most common cancers in Asia. ACRG would initially focus on lung and gastric cancers, and Lilly, Merck and Pfizer were to set up a pharmacogenomic cancer database containing data from 2000 tissue samples from lung and gastric cancer patients. The database would be publicly available to researchers, for which Lilly would be responsible [1076878].

In December 2009, Durata Therapeutics acquired Pfizer's subsidiary Vicuron Pharmaceuticals. Durata obtained rights to dalbavancin and two preclinical antibiotic programs, and Pfizer retained rights to the marketed anti-fungal agent Eraxis [1065287].

In April 2009, Pfizer and GlaxoSmithKline agreed to merge their existing HIV-related assets to form a specialist HIV company which would focus solely on R&D and commercialization of HIV therapeutics. A new alliance was also formed under which the two companies would continue to conduct discovery HIV R&D activities to be invested in by the new company which in turn would have exclusive rights of first negotiation regarding any new HIV-related therapeutic developed. GSK would hold 85% of the company and Pfizer would have a 15% stake. The transaction would be marginally dilutive to GSK earnings in the first two years and is expected to be neutral to Pfizer's earnings in 2009 and slightly accretive in 2010 and 2011. The deal was expected to close in the fourth quarter of 2009 [1000683], [1000673]. In July 2009, the OFT decided not to refer the merger to the Competition Commission under the provisions of the Enterprise Act 2002 [1024748]. The transaction closed on October 30, 2009 and ViiV Healthcare was launched [1054205].

In April 2009, Pfizer planned to buy a 33.77% stake in Pfizer Ltd from shareholders for Rs 675 (US \$13.6) per share. The purchase would raise Pfizer's stake in Pfizer Ltd to 75% and was expected to cost the company Rs 6.8 billion (US \$136 million) [999857]. In June 2009, Pfizer increased its offer from Rs 675 to Rs 830 (US \$16.95) per share [1020976].

In January 2009, Pfizer and Wyeth entered into a definitive agreement in which Pfizer was to acquire Wyeth in a cash-and-stock transaction for \$68 billion (\$50.19 per share). Under the terms of the agreement, each Wyeth's outstanding share would be converted into the right to receive \$33 in cash and 0.985 of a share of Pfizer common stock. A consortium of banks had also committed to provide \$22.5 billion in debt. The Boards had approved the merger and the deal was expected to close at the end of the third quarter or during the fourth quarter of 2009 [979024]. In April 2009, the US Federal Trade Commission requested additional information regarding the acquisition [998340]. In April 2009, Pfizer reported operating structure and senior leadership changes to be made following completion of the acquisition. Pfizer planned to create two research organisations, the PharmaTherapeutics Research Group and the BioTherapeutics Research Group. The PharmaTherapeutics Research Group, to be lead by Martin Mackay, currently Head, Pfizer Global R&D, would focus on the discovery of small molecules. The BioTherapeutics Research Group to be headed up by Mikael Dolsten, currently President, Wyeth Research, would specialize in large-molecule research, including vaccines, antibodies, proteins, peptides, nucleic acids and other novel modalities. The two groups would produce a portfolio of compounds and pursue collaborations with other companies. Pfizer would also form a third team to find and assess new technologies and pre-proof-of-concept small and large molecules for licensing [998701]. In June 2009, Pfizer's registration statement on Form S-4 for the issue of Pfizer stock in connection with the merger was declared effective by the SEC [1019158]. In July 2009, the EC approved the acquisition, and China's Ministry of Commerce extended its regulatory review [1026895]. In July 2009, Wyeth's stockholders approved the proposed merger, with a majority of 98%. At that time, the transaction was expected to close in the third/fourth quarter of 2009 [1026957]. In September 2009, Wyeth and Pfizer entered into an agreement to divest their animal health assets and manufacturing facilities in Fort Dodge, IA to Boehringer Ingelheim in connection with the regulatory approval

[Return to Table of Contents](#)



process for the Wyeth/Pfizer transaction. At that time, the Pfizer/Wyeth acquisition was expected to close in the fourth quarter of 2009 [1043959]. Later in September 2009, the Chinese Ministry of Commerce approved the acquisition. At that time, Pfizer expected to obtain Australian, Canadian and US regulatory approval 'shortly' and to close the acquisition in the fourth quarter of 2009 [1045669]. Also in September 2009, the Australian Competition and Consumer Commission approved the acquisition [1045981]. In October 2009, the acquisition was approved by the Canadian Competition Bureau, which meant all regulatory approvals requirements had been satisfied [1049812]; later that month, the acquisition was completed [1050110], [1049980], [1050087]. Later in October 2009, Boehringer closed its deal to acquire a portion of Pfizer's Fort Dodge Animal Health business [1051814]. In March 2010, Eli Lilly's Elanco division agreed to buy European rights to animal health assets from Pfizer. The EC requested that Pfizer divest the products as part of its acquisition of Wyeth [1080266], [1080223].

In November 2008, Pfizer launched Pfizer Regenerative Medicine, a research unit for the R&D of stem cells to prevent disability, repair failing organs and to treat degenerative diseases. The business would be split between two locations. At a site in Cambridge, MA, scientists would focus on endocrine and cardiac research and in Cambridge, UK, researchers would concentrate on neural and sensory disorders. At that time, several scientific collaborations were to be announced [963156].

In 2008, Pfizer and UCB formed Cyclofluidic to accelerate drug discovery [953761].

In June 2008, Pfizer completed its acquisition of Encysive [915114]. In April 2008, Pfizer completed its tender offer of all the outstanding shares of Encysive Pharmaceuticals [891807]; later that month, Pfizer announced that 70,238,869 shares had been tendered [893815]. Also in April 2008, the company extended the subsequent offering period for the tender offer until April 14, 2008 [894352]; The tender offer by Pfizer's subsidiary, Explorer Acquisition, to purchase all of outstanding Encysive common stock shares for \$2.35 each expired on April 14, 2008. A total of 69,076,466 shares, representing 85.33% of outstanding Encysive common stock shares, were validly tendered and purchased. Explorer would acquire all the remaining outstanding shares by means of a merger, as a result of which, Encysive would become a wholly-owned subsidiary of Pfizer and each Encysive outstanding common stock share would be converted into the right to receive \$2.35 per share in cash. Thereafter, Encysive's common stock would cease to trade on NASDAQ [896909]. In March 2008, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Pfizer's tender offer of Encysive Pharmaceuticals common stock expired. Pfizer also obtained clearance for the offer from the Federal Cartel Office of Germany [889837], [890198]. Earlier in March 2008, Pfizer initiated the tender offer to purchase all of Encysive's outstanding shares for \$2.35 per share. Following the completion of the tender offer Pfizer's wholly-owned subsidiary Explorer Acquisition would merge with Encysive; closing would be subject to Pfizer acquiring more than 50% of Encysive shares. The deal was expected to complete on March 31, 2008 [882775]. In February 2008, Pfizer entered into an agreement to acquire Encysive in a cash tender offer worth \$195 million. Encysive would merge with a subsidiary of Pfizer and Pfizer would gain rights to Thelin and the company's other pipeline candidates. Encysive's Board had approved the deal and the transaction was expected to close in the second quarter of 2008 [878228].

In May 2008, Pfizer sold Esperion, which retained an anti-dyslipidemia drug, to private investors. Pfizer was to retain selected programs and related assets and maintaining a financial interest [901817].

By April 2008, Pfizer planned to spin-out its Nagoya Laboratories subsidiary [903361]. In July 2008, pharma venture RaQualia was spun out by Pfizer. The new company was to focus on pain and gastrointestinal therapeutic areas, and inherited six drug discovery programs, six development programs and three marketed or close to market products (Geodon, Zeven and Eraxis), from Pfizer [927390].

In March 2008, Pfizer agreed to buy Serenex. The deal was scheduled to close in the second quarter of 2008 and would include SNX-5422 and Serenex's drug discovery technology and library of Hsp90 inhibitors; however SNX-1012 was not included in the deal [882126].

In December 2007, Keata Pharma acquired a manufacturing facility in Arnprior, Ontario from Pfizer Canada (a subsidiary of Pfizer) and under a supply agreement at the facility would exclusively manufacture Pfizer products for Canada for three years. Raw materials, packaging components and work in progress were included in the inventories acquired by Keata, it agreed to employ the current workforce [864119].

Also, in December 2007, Pfizer entered an agreement to acquire CoVX Pharmaceuticals, the acquisition was expected to close in the first quarter of 2008 [861931]; by February 2008, the transaction had completed [883033]. In February 2013, Pfizer closed down the CovX subsidiary with the loss of approximately 100 jobs [1385029].

In November 2007, Pfizer entered into an agreement to acquire Coley, in exchange for a \$164 million cash payment for all outstanding common stock of Coley. The acquisition was expected to close early in 2008 and was subject to closing conditions [851961]. Later that month, Pfizer announced the start of its cash tender offer, pursuant to its Offer to Purchase, for all outstanding shares of Coley's common stock for \$8.00 per share. The acquisition was still pending customary closing conditions at the time [856311]. In December 2007, Pfizer

[Return to Table of Contents](#)





received clearance from the Federal Cartel Office of Germany to purchase all outstanding shares of common stock of Coley Pharmaceutical Group. Pfizer's tender offer was expected to end on December 28th 2007 and was completed by this date. At that time, the final step of the acquisition process was to be a merger in which Coley would become an indirect wholly owned subsidiary of Pfizer. [861925], [864118]. By February 2008, the acquisition was complete [877546].

In February 2007, Pfizer entered into an agreement to acquire BioRexis Pharmaceutical. The merger was expected to close during the first or second quarter of 2007 [762602]. By April 2007, the acquisition had been completed [785962].

In December 2006, Johnson & Johnson (J&J) bought Pfizer's consumer healthcare business for \$16.6 billion [752844], [752845]. Later in December 2006, the FTC and the European Commission approve J&J's proposed acquisition of Pfizer's consumer healthcare unit. The deal was expected to close by the end of 2006 [750946]. In June 2006, J&J agreed to buy the business for \$16.6 billion in cash [675536], [675538]. In February 2006, Pfizer outlined its business strategy for that year at the meeting with financial analysts. This would involve reducing its worldwide plant network from 93 to 66 and potentially selling its consumer healthcare business for \$10 billion. To cut costs and improve efficiency, Pfizer unveiled the Adapting to Scale initiative, which was expected to make cost savings of \$3.5 billion by 2007 and \$4 billion by 2008. The initiative would enhance R&D productivity, optimize the field force, consolidate the company's manufacturing plants and maximize acquisition of goods and services [649724]. Earlier in February 2006, Pfizer revealed that was considering selling its consumer healthcare business in response to media enquiries ahead of its February 10, 2006, meeting with financial analysts [649088].

In October 2006, Pfizer agreed to acquire the DNA-based vaccine company PowderMed. The deal was subject to closing conditions, and was expected to close during the fourth quarter of 2006 [728821]. By January 2007, PowderMed had become a wholly owned subsidiary of Pfizer [762237]; and since December 2008, the PowderMed site in Oxford was closed down, following the completion of technology transfer to Pfizer [979433].

By July 2006, Pfizer had acquired Rinat Neuroscience, a private biotech company that developed therapeutic proteins for the treatment of central nervous system disorders [679198]. In April 2006, Pfizer entered into an agreement to acquire Rinat. The acquisition was expected to close by the middle of 2006; financial terms were not disclosed [660824].

In April 2006, Abraxis BioScience agreed to buy Pfizer's Barceloneta, Puerto Rico manufacturing facility. Pfizer would lease back the facility's chemical raw material plant to manufacture celecoxib [663771].

In December 2005, Pfizer bought a 12% stake in Perlegen Sciences for \$50 million. In addition, if Perlegen executed an initial public offering in 2006, Pfizer agreed to purchase up to an additional \$25 million of stock [642823].

In September 2005, Pfizer acquired Vicuron Pharmaceuticals for \$1.9 billion [622928], [622421]. The transaction was agreed in June 2005 [607651] and approved by Vicuron's stockholders in August 2005 [617901].

In August 2005, Pfizer acquired Bioren, an antibody discovery and optimization company. Bioren's technologies included the Walk-Through Mutagenesis and Look-Through Mutagenesis platforms [617888].

In June 2005, Torrent Pharmaceuticals Ltd agreed to acquire Heumann Pharma Generics, a Pfizer group company. The deal excluded manufacturing facilities which were to be retained by Heumann PCS GmbH, which would remain a wholly owned subsidiary of Pfizer. The acquisition was expected to be completed by August 2005 [611712].

By April 2005, Pfizer had agreed to acquire the research assets of QuoreX [593403].

In February 2005, Pfizer entered into an agreement to acquire Idun Pharmaceuticals Inc [587040]; this was completed in April 2005 [595966].

In January 2005, Pfizer entered an agreement to acquire Angiosyn, which would become a wholly owned subsidiary. Angiosyn's stockholders would receive payments of \$527 million and royalties on future sales, contingent on successful completion of commercial development for an ophthalmic indication and a second therapeutic area [581219].

By November 2004, Pfizer had acquired the remaining 90% ownership of Meridica Ltd from PA Consulting Group, for \$125 million and a contingent payment [570716]. The agreement was signed in September 2004 [560357].

In August 2004, Merck KGaA was planning to acquire most of NM Pharma, Pfizer's generics business in Scandinavia, for EUR 53.8 million (\$65.1 million). The new company would operate under the name of Merck NM and would be headquartered in Stockholm, Sweden [556606].

[Return to Table of Contents](#)



In August 2004, Teva Pharmaceutical Industries Ltd signed an agreement to acquire Pfizer's Italian generic pharmaceutical marketing company, Dorom Srl. The cash transaction was expected to close in December 2004 and valued Dorom at up to 2.3 times sales [555022].

In April 2004, Pfizer sold its in vitro allergy and diagnostics testing business and in June 2004, its sold its surgical ophthalmic business and certain non-core consumer healthcare products, all of which were acquired in connection with its acquisition of Pharmacia [565489].

By March 2004, Pfizer had completed the acquisition of Esperion and had made it a wholly owned subsidiary [532401]. Pfizer had originally entered into an agreement to acquire Esperion Therapeutics Inc for a \$1.3 billion cash-for-shares transaction in December 2003. Esperion was to operate as a division of the Pfizer Global R&D organization, and was to remain in Ann Arbor, MI [517665]. In February 2004, Pfizer completed its cash tender offer for over 93% of Esperion's common stock [521566].

In October 2003, Pfizer formed a new organization, Pfizer Human Healthcare, which was to include Pfizer Global Research & Development, Pfizer Global Pharmaceuticals and Pfizer Global Manufacturing [510136].

In July 2003, Pfizer was exploring strategic options for its surgical ophthalmology business and its Pharmacia Diagnostics AB business (acquired with Pharmacia), including possible sales [498846], [495397]. In January 2004, Pfizer agreed to sell Pharmacia Diagnostics to the private equity firms Triton and PPM Ventures Ltd for \$575 million. The transaction was subject to regulatory approvals and was expected to close in the first half of 2004 [519589].

In April 2003, Pfizer completed its acquisition of Pharmacia Corp and trading of the combined company began immediately on the NYSE [486179], [486180], [486217]. The EC had approved the merger in February 2003 [480150], and in March 2003, Pfizer and Pharmacia reached agreement with FTC staff on the necessary divestitures [482149]. Later that month, the FTC completed its review [483343], and in April 2003, accepted a consent decree allowing Pfizer's acquisition of Pharmacia to go ahead [485803]. The definitive agreement was originally signed in July 2002, at which time Pfizer agreed to acquire Pharmacia in a stock-for-stock transaction valued at \$60 billion. Pfizer was to exchange 1.4 shares of its common stock for each outstanding share of Pharmacia stock in a tax-free transaction valued at \$45.08 per Pharmacia share [457917]. In December 2002, Pfizer's shareholders approved the issuance of shares of Pfizer common stock and voted to amend Pfizer's certificate of incorporation to increase the number of authorized shares. Approval of these proposals was a condition of the Pfizer/Pharmacia merger. Pharmacia's shares would represent approximately 23% of the outstanding common stock after the merger on a fully diluted basis [473172]. Later in December 2002, Pharmacia's shareholders also approved the merge, with a total of 99% of the votes cast in favor of the transaction [473643].

In June 2000, Pfizer completed its merger with Warner-Lambert [371470]. The definitive agreement had originally been signed in February 2000, and the combined company would remain Pfizer Inc [354733]. By May 2000, both companies' shareholders had voted to approve the merger [366348]. It was cleared by the European Commission in May 2000 [367606], and on May 24, 2000, the FTC completed its review. A proposed consent decree with the FTC involved divestitures of one overlapping consumer product marketed only in the US, and one early clinical candidate where Pfizer and Warner-Lambert had overlapping research programs [368455].

In April 2000, Pfizer announced its plans for restructuring following the Warner-Lambert merger. The new Pfizer was to consist of four main operating units; Pfizer Pharmaceuticals Group (PPG), which was to include the US and global pharmaceutical organizations as well as manufacturing operation; Warner-Lambert Consumer Division, which was to include OTC healthcare products; the Pfizer Animal Health Group, which was to include the animal and livestock businesses; and Pfizer Global R&D, which was to operate in 14 facilities worldwide [363517].

In December 1998, Pfizer completed the sale of Howmedica, the orthopedic division of the company, for \$1.65 billion. With the close of this sale, Pfizer completed the divestiture of its Medical Technology Group (MTG); its three other MTG businesses, Valleylab, Schneider and American Medical Systems had been sold earlier in the year for more than \$2.5 billion [308206].

In April 1996, Anaderm, a three party venture between Pfizer, OSI Inc (formerly Oncogene Science) and New York University was created. The company was to focus on the discovery and development of novel compounds to treat conditions such as baldness, wrinkles and pigmentation disorders. At that time, Anaderm was 82% owned by Pfizer, 14% by OSI and New York University had the option to acquire 4% of the company. Anaderm would utilize Pfizer's drug development capabilities and compound libraries, OSI's drug discovery technology and New York University's scientific expertise in the molecular biology of the skin [272812]. In July 2002, OSI concluded its alliance with Pfizer, and by September 2002, Pfizer had paid OSI \$4.5 million of the \$8 million fee for transferring all research related to the collaboration back to Anaderm [487304].

## LICENSING AGREEMENTS

[Return to Table of Contents](#)



In April 2010, Stemgent and Pfizer entered a collaboration and research licensing agreement, whereby certain Pfizer stem cell research reagents would be made available to researchers worldwide through Stemgent. The companies would form a joint research committee and the chief scientific officer of Pfizer Regenerative Medicine would join Stemgent's scientific advisory board. Financial details were undisclosed [1091134].

In April 2010, MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, and Pfizer entered into a research collaboration to discover and develop novel antibiotics to treat multi-drug resistant tuberculosis (MDR-TB). Cumencor would apply MicuRx's discovery platform at its ZhangJiang High-Tech Park facility in China. Pfizer would provide an upfront payment, funding for the discovery process and preclinical development of any candidates, development and commercialization-based milestone payments, and royalties based on any product sales [1087562].

In April 2010, MDRNA and Pfizer entered a research study which would evaluate MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi). MDRNA would formulate Pfizer's oligonucleotides into DiLA2 formulations for in vivo preclinical evaluation by Pfizer. MDRNA would also design and synthesize UsiRNAs against Pfizer targets. Financial details were undisclosed [1087382].

In March 2010, the Juvenile Diabetes Research Foundation (JDRF) and Pfizer (through its PharmaTherapeutics Research & Development division) entered into a diabetes research alliance with Hadassah Medical Organization (Professor Benjamin Glaser) and The Hebrew University of Jerusalem (Dr Yuval Dor; Department of Developmental Biology), with the aim of discovering therapeutics able to replicate or regenerate insulin-producing cells in type 1 diabetes patients. The institutions would collaborate on preclinical evaluation of Pfizer's beta cell replication and regeneration-promoting compounds, characterizing the compounds based on their potential for prolonging beta cell health and survival. JDRF and Pfizer would jointly fund the research [1084289].

In March 2010, Pfizer agreed to collaborate on the delivery of small interfering RNA (siRNA) molecules using Tekmira Pharmaceuticals' stable nucleic acid-lipid particle (SNALP) technology. Tekmira would prepare the SNALP formulations, while Pfizer was to evaluate the formulations in preclinical models. Financial terms were not disclosed [1082460].

In January 2010, Sage Bionetworks entered a research partnership with Pfizer to build, analyze and exploit advanced network models of cancer. Pfizer would provide research funding to Sage [1067946].

In January 2010, Pfizer agreed to commercialize off-patent sterile injectable and oral products from Strides Arcolab in the US. Financial details were undisclosed [1067052].

In January 2010, Ensemble Discovery agreed to use its drug discovery platforms and Ensemblin compound libraries to discover and develop drug candidates against pharmaceutical targets for Pfizer. Ensemble would receive upfront and research payments, as well as milestones and royalties on successful commercialization [1066862].

In December 2009, Compugen entered a collaboration to discover therapeutic peptide products for Pfizer's three drug targets. Pfizer was to provide undisclosed funding for the discovery process and was to exercise options to exclusively develop and commercialize products worldwide. In return, Compugen would receive milestone payments and royalties [1065619].

In December 2009, Adimab agreed to use its antibody discovery platform to identify fully human antibodies against a Central Nervous System/Pain target selected by Pfizer. Pfizer would have the right to commercialize any antibodies generated. Adimab would receive licensing fees, upfront and milestone payments plus royalties [1064745].

In December 2009, Pfizer and Crown Bioscience collaborated to develop therapeutics for Asian cancers. Crown Bioscience would receive an undisclosed upfront payment, research funding and also milestone payments based on the achievement of preclinical and clinical goals [1063078].

In December 2009, Pfizer (through its Pfizer Canada subsidiary) entered into agreements with the BC Cancer Agency and Vancouver Coastal Health Research Institute's Vancouver Prostate Centre, to discover novel biomarkers, identify new targets, and develop potential new therapeutics for breast, ovarian and prostate cancer. Pfizer invested \$9 million into the program [1062127].

In November 2009, the sale to Pfizer of certain stem cell therapy assets from Axordia (a subsidiary of Intercytex) had been completed for \$0.75 million. Of that, GBP 0.075 million (approximately \$0.12 million) would be held in escrow until 1 May 2010 [1059640].

In November 2009, Pfizer partnered with Drugs for Neglected Diseases initiative (DNDi) to discover potential therapeutics against Human African Trypanosomiasis (HAT), Visceral Leishmaniasis (VL) and Chagas diseases. DNDi was to use Pfizer's resources for the screening of novel compounds. Financial terms were not disclosed

[Return to Table of Contents](#)



[1058147].

In September 2009, Icagen and Pfizer extended their ion channel-targeting drug discovery collaboration by an additional year. Pfizer would continue to provide research funding to the alliance, including an additional \$5 million over the next year [1043651]. In March 2008, the companies entered into an agreement with Birkbeck, University of London, to study the structural biology of sodium channels [888395]. In August 2007, Icagen and Pfizer agreed to develop compounds which relieved pain by modulating sodium ion channels. Pfizer was to pay Icagen \$12 million upfront and invest up to \$15 million in the company. Icagen would also receive up to \$359 million in milestones for each product. Pfizer was to have exclusive worldwide rights to any products resulting from the collaboration [821944].

In September 2009, Karo Bio exclusively licensed a US patent from Pfizer expanding the intellectual property portfolio for its thyroid hormone receptor (TR) platform. Financial details were undisclosed [1042759].

In August 2009, Abbott agreed to develop a companion diagnostic test that would determine a patient's genetic status and thus enable patient selection for clinical trials of Pfizer's PF-02341066. Financial details were undisclosed [1037596].

In July 2009, Pfizer entered a joint venture with Shanghai Institutes for Biological Sciences (SIBS) to assist research in China [1029691].

By June 2009, Pfizer and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) had signed an Memorandum of Understanding to codevelop bio-drugs for treating hepatic and gastric tumors. The parties were to discover targets and screen Pfizer's compounds and antibodies [1028755].

In May 2009, Pfizer established agreements with Claris Lifesciences, to commercialize 15 sterile injectable products, no longer patent-protected, and no longer retaining market exclusivity in North America, Europe, Australia and New Zealand. The products were of broad indications, including in the areas of anti-infectives and pain. This formed part of Pfizer's Established Products strategy [1011127].

In May 2009, Pfizer's generics deal with Aurobindo was expanded in emerging markets, as part of Pfizer's Emerging Markets Business Unit. Pfizer obtained rights to 55 solid oral dose products and five sterile injectable products for patients in over 70 emerging market countries. The agreement was also expanded to add products in developed markets, including the US and Europe [1011127], [1011781]. In March 2009, the agreement was expanded to include a 70 further solid oral dose and 12 sterile injectable products [988689]. In July 2008, Pfizer entered into a five solid oral dose generic products deal with Aurobindo [988689].

In May 2009, Pfizer and the Wisconsin Alumni Research Foundation (WARF), of the University of Wisconsin-Madison, signed a license agreement for human embryonic stem (hES) cell patents for the development of new drug therapies. Pfizer would have the right to work with hES cells for drug discovery. Financial details were undisclosed [1006495].

In April 2009, the Medicines For Malaria Venture (MMV) entered into a discovery agreement with Pfizer, to screen Pfizer's compound libraries and identify potential therapeutic targets with activity against *P. falciparum*, for the development of anti-malaria therapeutics. The screening tests would be conducted at ESKITIS Institute for Cell and Molecular Therapies at Griffith University [1002575].

In March 2009, MannKind entered into an agreement to purchase Pfizer's German insulin facility, assets related to bulk insulin production (including property rights, production equipment, quantities of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery), for \$33 million. At MannKind's option, up to \$30 million of the company's common stock would be issued to Pfizer at closing [989948]. In June 2009, the acquisition was completed. MannKind also agreed to maintain and store the remainder of Pfizer's bulk insulin inventory and acquired an option to purchase the remaining insulin at a specified price. The total purchase price for this transaction was \$3 million in cash [1020093].

In March 2009, Xencor signed an agreement with Pfizer to optimize the performance of therapeutic monoclonal antibodies [988341].

In December 2008, Sangamo granted Pfizer non-exclusive, worldwide rights to apply its zinc finger nuclease (ZFN) technology to develop cell-lines (Chinese Hamster Ovary) to produce therapeutic proteins. Sangamo received an upfront payment [972483].

By December 2008, Pfizer had a research collaboration with Flamel [972545].

Also December 2008, Pfizer was granted access to Novocell's pancreatic progenitor cells, derived from human embryonic stem (hES) cells, under a 2-year agreement [972164].

[Return to Table of Contents](#)





In November 2008, WuXi PharmaTech entered a 3-year in vitro screening service, and ADME assay investigational collaboration with Pfizer. Under the agreement, WuXi would synthesize new compounds for Pfizer, for ADME testing [960269].

In September 2008, Schering-Plough sold certain animal health products to Pfizer for EUR 116 million (US \$161 million) [942390].

In August 2008, Cytos Biotechnology entered into an agreement with Pfizer's Vaccines division to develop and commercialize novel vaccines for a number of diseases, based on Cytos's Immunodrug technology. Cytos would receive a CHF 10 million (US \$9.1 million) upfront payment, plus up to CHF 140 million (US \$127.8 million) in milestones and manufacturing technology transfer fees, as well as research funding and potential double-digit royalties on marketed products that reach certain annual net sales targets. Pfizer would be responsible for preclinical and clinical development, manufacture, and commercialization procedures, and would have worldwide exclusive rights to products that do not fall within the remit of Cytos's own drugs programs; Cytos would retain rights to develop and commercialize vaccines in the same therapeutic areas, but against different targets [935380]. In January 2009, Pfizer exercised its options under the agreement and licensed worldwide rights to certain vaccines, triggering payments to Cytos [973981].

In August 2008, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer committed to provide GBP 10.8 million to the Division of Signal Transduction Therapy, a collaboration aiming to attack major global diseases, over 4 years from 2008 to 2012 [932235].

In June 2008, EyeCyte secured \$3 million in series A financing from Pfizer. The financing would fund the company into 2010 and would be used to drive product development of the company's diabetic retinopathy therapeutics. In return, Pfizer would be the sole pharmaceutical partner of EyeCyte and would have right of first refusal for a buy-out of EyeCyte or its technologies [919353].

In June 2008, Pfizer entered into a research agreement with the University of Pennsylvania School of Medicine to include collaborations in the areas of scientific research, clinical development and clinical care and policy. Pfizer would pay its partner \$15 million over a three year period [916297].

In June 2008, Pfizer and University of California San Francisco (UCSF) established a drug discovery and development alliance [915394].

In May 2008, FivePrime Therapeutics entered into a collaborative research program with Pfizer to discover and develop novel antibody targets and therapeutic proteins in the fields of diabetes and cancer. The collaboration would use FivePrime's rapid protein discovery platform, which screens FivePrime's target libraries using cell-based assays and in vivo, high-throughput screening techniques. FivePrime would receive an upfront payment, equity investment and research funding for three years, while Pfizer was granted exclusive worldwide development and commercialization rights to any emerging compounds in return for future milestone and royalty payments [908030].

In May 2008, Pfizer entered into a cGMP manufacturing contract with QSV Biologics for a recombinant protein under development [902047].

In April 2008, Pfizer entered into a collaboration agreement with the University of California Santa Barbara, Caltech, the Massachusetts Institute of Technology, the University of Massachusetts and Entelos for research into insulin signaling in adipose cells to increase understanding of diabetes and obesity. Pfizer would provide \$14 million in funding for the three year Insulin Resistance Pathway Project [900061], [900287].

By 2008, Pfizer entered an agreement for use of Linguamatics' I2E knowledge discovery platform for text mining across R&D. In April 2008, the agreement was extended [897536].

In April 2008, Pfizer agreed a deal to integrate Ingenuity Systems' Ingenuity Pathways Analysis software with other informatics solutions within its organization [896750].

In February 2008, Genstruct agreed to use its systems biology technology to predict potential drug toxicity for Pfizer. Genstruct would initially focus on underlying mechanisms of drug-induced liver injury and would retain biomarker intellectual property rights [878201].

In January 2008, Pfizer announced it was collaborating with Aureon Laboratories to establish quantitative biometrics to assess therapeutic responses observed in prostate cancer studies. It will utilize Aureon's integrated systems pathology platform, where tissue morphometry, biomarkers, and in situ RNA expression data are integrated with patient-specific clinical data. This built on previous work carried out by the two companies to evaluate prostatectomy samples from patients undergoing neo-adjuvant androgen deprivation therapy (ADT). The work was used to help develop Prostate Px+, a prognostic, biopsy-based prostate cancer test, to be released in 2008 [869393].

[Return to Table of Contents](#)





In January 2008, Pfizer and Genomic Health entered a collaboration to develop a genomic test for clear cell type of renal carcinoma in patients following surgery, with stage I-III carcinoma, to approximate the risk of recurrence. Similar technology and strategy used in Genomic's Oncotype DX breast cancer test would be employed [865683].

In December 2007, Source MDx and Pfizer established a multi-year translational molecular medicine collaboration to develop and validate RNA-based pharmacodynamic and predictive biomarkers for Pfizer cancer and inflammation therapeutic development programs. Under the terms of the agreement, Pfizer agreed to make an equity investment in Source MDx and pay it a technology license payment and research and development funding. Source MDx would retain commercial rights to diagnostic biomarkers discovered and validated from the collaboration. The agreement included provisions under which Pfizer and Source MDx could commercialize companion diagnostics. Further deal terms were not disclosed [863649].

In November 2007, Graffinity Pharmaceuticals and Pfizer entered into a drug discovery collaboration, under which Pfizer would be given access to Graffinity's fragment-based screening technology. Graffinity would receive technology access fees and payments for follow-up chemistry [856167].

In November 2007, Direvo Biotech and Pfizer agreed to collaborate on developing therapeutic proteases. Direvo would use its protein engineering capabilities to discover and optimize novel proteases and Pfizer would develop and commercialize the therapeutic candidates. Direvo would receive milestones and royalties [850638].

In August 2007, XOMA licensed its bacterial cell expression technology for phage display to Pfizer, which would pay \$30 million upfront, plus milestone and royalty payments [825640].

By July 2007, Pfizer and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) signed a memorandum of understanding to develop new bio-drugs for liver and stomach cancer. Pfizer was to be involved in studies being conducted by KRIBB for an agent originating from a novel liver cancer-related gene and a drug candidate that targets liver cancer oncogene UCP1. Also, it was to screen compounds that regulate Natural Killer (NK) cells [941055]. By May 2008, another agreement had been signed, whereby KRIBB would provide its NK cells-associated screening system and Pfizer was to contribute its chemical library [970400].

In April 2007, Bristol-Myers Squibb (BMS) agreed to codevelop Pfizer's preclinical metabolic disorders program. BMS would pay Pfizer \$50 million upfront and would pay 40% of the costs in return for 40% of the profits [787553].

In April 2007, Renovis and Pfizer extended their collaboration to develop and commercialize small-molecule vanilloid receptor 1 (VR1) antagonists by 1 year. Pfizer agreed to fund the research until June 30, 2007 [782039]. In May 2005, Renovis and Pfizer agreed to codevelop and commercialize small-molecules that target the vanilloid receptor, VR1, for pain and urinary incontinence [604673].

Caliper Life Sciences agreed to conduct in vivo profiling studies to identify new indications for Pfizer's compounds in April 2007. Caliper was to test the effects of acute and chronic dosing of the drugs in mice [781739].

Earlier in April 2007, Melior Discovery licensed its in vivo theraTRACE indications discovery technology to Pfizer, for the evaluation of the activity of Pfizer's compounds [781643].

In April 2007, Pfizer agreed to develop ophthalmic drugs using pSivida's controlled drug delivery technology. The two companies would work jointly, with the work funded by Pfizer, which would have exclusive rights to any resulting products. It would pay pSivida \$155 million in milestones, as well as royalties, and would invest \$5 million in pSivida stock [780884].

In April 2007, Pfizer obtained a non-exclusive license to Genencor International's technology which enhances secreted polypeptide expression in micro-organisms, for use in the development of protein therapeutics [779656].

In February 2007, Pfizer licensed exclusive worldwide rights to its 'Method of treating eye infections with azithromycin' patent family to InSite [766614].

In January 2007, Pfizer entered into a multiyear research agreement to develop advanced ECG-based cardiac safety biomarkers using iCardiac Technologies' COMPAS technology. The companies would jointly conduct retrospective and prospective ECG data analyses and would further develop the COMPAS platform and advance ECG markers for use in safety testing of investigational and marketed products. Pfizer would make an equity investment in iCardiac and would pay the company a technology license fee plus R&D funding. iCardiac would have rights to any ECG analysis technologies developed by Pfizer [761195].

Also in January 2007, MediVas signed a collaborative research agreement to develop advanced delivery methods for Pfizer's ocular disease drug candidates. MediVas' would combine its biodegradable and biocompatible polymers with Pfizer's compounds [760002].

[Return to Table of Contents](#)

Earlier in January 2007, Barofold granted a license to Pfizer, with undisclosed terms, for research using Barofold's PreEMT high pressure technology, used for solubilizing, disaggregating and refolding proteins [756340].

In January 2007, Archemix and Pfizer agreed to develop aptamer therapeutics. Archemix would generate products against three Pfizer targets, in return for an upfront fee, milestones, research funding and royalties. Pfizer would develop and commercialize the products [756235].

In January 2007, Pfizer entered into a collaboration with PTC Therapeutics for the research and development of up to ten target compounds using PTC's gene expression (GEMS) technology. PTC has received \$10 million upfront and could receive a further \$121 in milestones per target, plus research fees. Pfizer would purchase an equity stake of \$10 million in PTC and would receive exclusive worldwide rights to any compounds identified. PTC would receive royalties on any compounds commercialized from the collaboration [755779].

In January 2007, Pfizer obtained a non-exclusive worldwide research license to use Sigma-Aldrich's DNA-directed RNAi (ddRNAi) technology [754859].

In December 2006, MorphoSys and Pfizer extended their December 2003 antibody collaboration until the end of 2011. The extension triggered a one-off payment to MorphoSys and increased the potential milestones payable to the company to over \$100 million. Pfizer gained the option to begin new projects within the collaboration [752981]. In December 2003, MorphoSys entered into a 5-year therapeutic antibody collaboration with Pfizer, under which MorphoSys would use HuCAL-GOLD to generate antibodies against multiple targets. Pfizer would carry out the preclinical and clinical development and subsequent marketing of any products arising from the collaboration, while MorphoSys would receive an upfront payment for each antibody developed, as well as research support and milestone payments. Potential payments to MorphoSys could total \$50 million, excluding royalties [517720].

In November 2006, Pfizer and the Scripps Research Institute formed a 5-year collaboration to develop drugs for various indications such as cancer, diabetes, and mental illness. The institute would receive \$100 million over the term of the alliance, plus milestones and royalties from Pfizer, which had the first right to license and discoveries made [747272], [747653].

In March 2006, Immunicon and Pfizer amended their collaboration to develop new reagents designed to detect certain undisclosed antigens on circulating tumor cells, to allow the initiation of clinical studies. A phase I trial was to start "immediately" [658443]. In December 2004, Immunicon and Pfizer extended their collaboration. The agreement, originally entered into in February 2003, and amended in April 2004, was extended until February 2006 [577310].

In January 2006, Astex Therapeutics granted a non-exclusive cytochrome P450 license to Pfizer [646760].

In January 2006, Chromos Molecular Systems and Pfizer expanded their artificial chromosome expression (ACE) system collaboration. Chromos would develop therapeutic protein production cells lines for Pfizer, which would fund the research [644091]. In May 2005, Chromos and Pfizer entered into a non-exclusive commercial license agreement covering Chromos's ACE System. Pfizer would have the right to use the technology to engineer cell lines for product research, development and manufacturing [604576]. In December 2004, Chromos and Pfizer formed a collaboration for the development of cell lines which would express recombinant proteins. The cell lines would be produced using Chromos's artificial chromosome expression (ACE) system, and would then be evaluated by Pfizer, who would fund the collaboration [576477].

In December 2005, Perlegen and Pfizer entered into a 4-year genome and replication collaboration to identify genes associated with major diseases and predict patient responses to certain drugs. Both companies would conduct whole genome studies involving DNA samples from clinical trials and would share certain intellectual property. Pfizer would provide Perlegen research payments [642899].

In September 2005, Pfizer contracted Gene Logic to seek new indications for several of its unapproved drug candidates that were not currently in active development [625399].

By June 2005, Pfizer Inc, Nektar Therapeutics, McMaster University, Hamilton Health Sciences Centre, Syracuse University and Molecular Insight Pharmaceuticals Inc were working together to develop radiolabeled insulin derivatives as imaging agents and also for the study of their biological properties [609169].

In June 2005, Pfizer licensed Oxford BioMedica's LentiVector gene delivery technology in return for an upfront license payment and an annual maintenance fee [605899].

In May 2005, Isis entered an agreement with Pfizer for the discovery of second-generation antisense inhibitors for the treatment of eye disease. The companies would use Isis's technology to identify drugs against targets selected by Pfizer. Pfizer would be responsible for clinical development and commercialization of the drug candidates for all indications. Isis would receive a \$1 million technology access fee, research funding, milestone

[Return to Table of Contents](#)

payments and royalties [603493].

In May 2005, Odyssey Thera agreed to profile 500 drug candidates using its cell-based assays to determine their mechanism of action and pathway activity, under an expanded agreement with Pfizer. The project would focus on compounds for potential use in several therapeutic areas using Odyssey Thera's PCA technology to measure pathway activity in living cells to identify on-target and off-pathway activities of the candidates [601964]. In September 2006, Odyssey Thera agreed to use its Protein-fragment Complementation Assay (PCA) technology to evaluate the selectivity of Pfizer compounds [688228]. Odyssey recognized milestone payments in December 2007 and August 2008 [860739], [932536].

In March 2005, Dowpharma, part of The Dow Chemical Co, agreed to develop a cell line using its Pseudomonas-based Pfenex Expression Technology to produce one of Pfizer's therapeutic proteins [588557].

In March 2005, Pfizer entered into an agreement to codevelop LifeSpan BioSciences's automated pathology system for rapid and accurate evaluation of tissue specimens in preclinical studies. The system would use enhanced image capture and artificial intelligence computer analysis software to evaluate stained tissue specimens for quality and tissue abnormalities [588285].

In March 2005, Pfizer extended its licensing of Ingenuity Systems' pathway analysis software [587596].

In January 2005, Inpharmatica Ltd agreed to provide Pfizer Inc with access to four core components of its PharmaCarta gene-to-candidate technology platform, along with its Biopendium subscription. Pfizer would gain access to StARLite, a database containing 20 years of medicinal chemistry information on compound structure and bioactivity linked to targets; to DrugStore, a database of all known drugs, linked with their targets; and to Admensa, Inpharmatica's technology for assessing the ADME characteristics of compounds and compound libraries [581514].

Earlier in January 2005, Ambit Biosciences Corp entered into a compound profiling agreement with Pfizer's La Jolla Laboratories. Ambit would employ its Reverse Screening technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds and therefore elucidate their molecular mechanisms of actions [580253].

In January 2005, Pfizer and Rigel Pharmaceuticals entered into a collaborative agreement based on Rigel's preclinical Syk kinase inhibitors, to develop small molecule treatments for allergic asthma and other respiratory diseases. Rigel would receive an upfront cash payment, as well as milestone payments and royalties on future sales. Pfizer would make an equity investment in Rigel and will take on the worldwide development and commercialization of any products. The agreement specifically excluded Rigel's compound R-112, although Pfizer would have a limited option to license R-112 and Rigel's Syk inhibitors in the allergic rhinitis field under different financial and other obligations [580788].

In January 2005, Sangamo BioSciences Inc and Pfizer formed a protein production collaboration. Pfizer would fund the research and would assess Sangamo's zinc finger DNA binding protein technology for use in mammalian cell-based protein production. Sangamo would generate technology, cell lines and vector systems to produce production cell lines [578375]. In January 2006, Sangamo and Pfizer expanded the collaboration [643285].

In November 2004, Genstruct signed an agreement with Pfizer to collaborate on a variety of research projects into complex diseases as part of its ongoing, multi-year relationship with the company. Genstruct would use its Molecular Epistemics platform to generate hypotheses to reveal underlying mechanisms of action and toxicity to help Pfizer prioritize and develop new drugs [569567].

In November 2004, the University of Rochester signed a patent license agreement with Pfizer, which would allow Pfizer to market a specific class of non-hormonal drugs for the treatment of hot flashes associated with menopause [568079].

In September 2004, Medarex Inc entered into a global collaboration with Pfizer for the discovery and development of up to 50 antibody products over 10 years. Pfizer would make an initial cash payment of \$80 million and would purchase \$30 million of Medarex's common stock. Medarex was to create product candidates to disease-associated targets identified by Pfizer which would be responsible for the worldwide development and commercialization of any products generated by the collaboration. Medarex had the potential to receive research funding, license fees and milestone payments exceeding \$400 million if all 50 products obtained regulatory approval, as well as royalties on any commercial sales of the products [559719].

In July 2004, Codexis Inc signed a multiyear, non-exclusive collaboration focused on process R&D for pharmaceutical life cycle management of some of Pfizer Inc's small molecule human therapeutic products. In addition to the collaboration, Pfizer was to make an equity investment of \$10 million in Codexis [550831].

In May 2004, Yamanouchi restructured its agreement with Pfizer (formerly Searle) [275105]. The companies were to continue to codevelop and copromote valdecoxib and parecoxib, but the new agreement terminated an R&D

[Return to Table of Contents](#)



agreement between the two companies and released Yamanouchi from its obligation under a license agreement between the two companies to provide Pfizer a quid pro quo product [541261].

In January 2004, XenoPort established a research collaboration with Pfizer to develop technologies to improve drug targeting in the brain using active transport mechanisms in the blood brain barrier. XenoPort was to apply its engineered drug transport technologies to identify and characterize important absorption and efflux transporters in the CNS. Pfizer was to contribute its expertise and research funding. Both companies were to share the use of technologies developed in the program [518275].

Also that month, Amersham plc signed a non-exclusive agreement giving Pfizer access to its HeliSpin magnetic resonance imaging system. Pfizer was to fund an evaluation of HeliSpin as a tool for use in its respiratory drug development program [520187].

In January 2004, Perlegen entered into a collaboration with Pfizer to conduct genetic research on metabolic syndrome. The companies were to share in the therapeutic and diagnostic rights resulting from the collaboration. Pfizer was to provide research funding to Perlegen, in addition to milestone payments [518519]. Later in January 2004, Perlegen and Pfizer formed a similar collaboration to analyze drug response in patients with major depression [518603].

Later in December 2003, Pfizer signed a license agreement with Human Genome Sciences Inc (HGS), under which Pfizer acquired non-exclusive, worldwide rights to research, develop and commercialize products based on gene sequences from *Staphylococcus aureus*. This agreement amended the companies' previous deal, signed in October 1996 [221435]. HGS was to receive a one-time license fee from Pfizer and Pfizer was to be relieved of any other obligation under the prior agreement [517561].

In October 2003, Chiron Corp granted a non-exclusive license to Pfizer for the research, development and commercialization of therapeutics against certain hepatitis C virus drug targets. As part of the licensing agreement, Chiron and Pfizer settled litigation involving Agouron Pharmaceuticals Inc. Chiron had brought a patent infringement suit against Agouron in 1998, claiming the company violated several patents related to Chiron's HCV technology. Under the terms of the current agreement with Pfizer, Chiron agreed to withdraw the lawsuit [510654].

In October 2003, Meridica licensed its dry powder inhaler device, Xcelovair, to Pfizer. Pfizer intended to use the device to support the development and commercialization of its inhaled compounds for the treatment of respiratory diseases. Meridica received an upfront payment, and was also to receive milestone and royalty payments. Pfizer also took an equity stake in Meridica. Xcelovair was designed to accommodate a wide range of drugs and dry powder formulations suitable for pulmonary delivery in both adults and children [509734].

In March 2006, ActivX and Pfizer renewed their February 2005 collaboration [655502]. ActivX would apply its chemical technologies and high-throughput protein analysis capabilities to a number of Pfizer programs, spanning drug discovery, proteomic profiling, compound selectivity, biological activity and mechanisms of toxicity [584071]. In July 2003, ActivX entered into an agreement to further characterize the protein activity of a Pfizer Inc research compound [496561].

In March 2003, Galen Holdings plc planned to buy Pfizer's women's health portfolio for \$484 million. Included in the deal were Estrostep, Loestrin and FemHRT. Pfizer was to receive an initial payment of \$359 million, with an additional \$125 million payable on maintenance of patent exclusivity. The purchase was to complete by the end of April 2003 [480987], [480986]. Later in March 2003, at a general meeting of Galen Holdings, resolutions approving the acquisition of Pfizer's women's healthcare pharmaceutical brands were passed. Galen expected to complete the acquisition on 27 March 2003. Completion of the purchase of FemHRT remained conditional upon clearance from the US Federal Trade Commission of the merger between Pfizer and Pharmacia Corp [483359].

In January 2003, Pfizer entered into a target validation agreement with Isis' GeneTrove division. Pfizer was to obtain access to Isis' antisense inhibitors and acquire a license to specific patents within Isis' intellectual property estate for use in its internal antisense-based functional genomics program. Specific financial terms of the deal were not disclosed [476985].

In January 2003, Neurion Pharmaceuticals Inc signed a research agreement with Pfizer to develop experimentally based computational models of drug binding interactions with the HERG potassium ion channel. Neurion and Pfizer were to apply Neurion's proprietary NP2 technology to study the mechanistic determinants of cardiovascular drug toxicity. This collaboration was to combine Neurion technology and capabilities in this area with Pfizer's expertise and experience, with the aim of designing drugs that do not interact with the HERG ion channel. Neurion was to receive upfront cash and milestone payments, while retaining full ownership of its core technology [476329]. In January 2004, Neurion and Pfizer agreed to renew their research collaboration for 2004. The expanded agreement was to include modeling of drug binding to the HERG potassium ion channel, as well as evaluation of Pfizer compounds using Neurion's NP2 technology [518636].

[Return to Table of Contents](#)



In January 2003, CuraGen Corp and Pfizer teamed up to evaluate compounds under consideration at Pfizer. CuraGen was to apply its Predictive Toxicogenomics Screen (PTS) and protein pathway mapping technologies to gain a better understanding of the mechanisms that enable drugs to effectively treat certain diseases [475641].

In December 2002, Pfizer entered a collaboration with Perlegen Sciences Inc to discover genetic contributions to cardiovascular disease, in order to research pharmaceutical and diagnostic products. Perlegen was to use its high-density genotyping technologies and knowledge of genetic variation to identify genes and other genetic loci associated with cardiovascular disease. Financial terms of the collaboration were not disclosed [474828].

In October 2002, ChondroGene entered a collaborative agreement with Pfizer for the identification of novel therapeutic targets and biomarkers for the treatment and diagnosis of osteoarthritis. The collaboration provided Pfizer with access to ChondroGene's database of cartilage-specific clinical and gene expression information to identify potential novel therapeutic targets for osteoarthritis. The agreement with Pfizer would also allow ChondroGene to accelerate its ongoing biomarker research program. The 2- year collaboration was valued at up to CDN\$7.5 million, exclusive of milestones and royalties. As part of the agreement, Pfizer was to acquire 1,162,462 common shares of ChondroGene at a price of \$0.33 per share, resulting in proceeds to ChondroGene of approximately CDN\$383,600 [466458]. In April 2003, Pfizer made a CDN \$1.58 million (US \$1.07 million) payment to ChondroGene Ltd for achieving the first research milestone [466458], [485054]. In November 2004, Pfizer paid ChondroGene \$1 million for the third and final research milestone under the companies' agreement to identify novel therapeutic targets and diagnostic biomarkers for osteoarthritis. At this time, Pfizer and ChondroGene were in late-stage negotiations to establish a second collaborative research agreement in OA [570990]. In December 2004, ChondroGene entered into a 2-year research collaboration with Pfizer for the identification of novel therapeutic targets and biomarkers for the treatment and diagnosis of osteoarthritis [577311].

In August 2002, Pfizer entered into a collaborative research agreement with Oxagen to investigate the association of certain Pfizer-nominated genes with asthma. The collaboration was to validate whether the candidate genes influenced susceptibility to asthma. Oxagen would perform SNP identification and genotyping of genes nominated by Pfizer with the aim of identifying SNPs associated with respiratory disease [460356].

In May 2002, Euroscreen SA completed a license agreement with Pfizer for access to Euroscreen's CCR5 patent rights [452299].

In May 2002, Pfizer entered into a strategic alliance with Affinium Pharmaceuticals for structure guided drug discovery for Pfizer therapeutic programs. The alliance was to screen targets from multiple enzyme classes and use Affinium's proprietary, automated functional, chemical and structural proteomics systems for drug discovery. Pfizer was to provide selected targets to the alliance for target production, protein-protein interaction determination, small molecule interrogation and structure determination. The 3-year agreement included payments to Affinium for R&D support, database licenses, discovery and clinical milestones and royalties from products [450662]. In September 2003, Affinium attained a discovery milestone in its strategic alliance for structure-guided drug discovery with Pfizer by achieving goals for production, functional characterization and structure determination of targets [506463].

In January 2002, Pfizer teamed up with Tripos to design, synthesize and purify high-quality, drug-like compounds to expand Pfizer's compound file collection. The companies were to collaborate in library design and analysis; large-scale, high-throughput synthesis, and high-throughput purification and analysis of compounds prior to delivery of these compound files [435041]. In January 2004, Tripos amended its collaboration with Pfizer. Tripos was to reduce file enrichment activities with Pfizer, but would begin new work on hit follow-up and large library production. Terms of the amendment also included a reduction in the remaining work to be done, resulting in a decrease in the contract value by 10% [520463]. In November 2005, Tripos reported that its file enrichment collaboration with Pfizer would end in December 2005. Tripos had received \$90 million from Pfizer over the 4 years of the project [636916].

In December 2001, Discovery Partners International (DPI) entered into a multiyear agreement with Pfizer to develop and produce libraries of high purity chemical compounds to be used in Pfizer's drug discovery programs [434377]. In February 2004, Pfizer extended its chemistry agreement with DPI. DPI was to deliver to Pfizer a broad range of pharmaceutically relevant chemical compounds for Pfizer's exclusive use. The agreement also gave Pfizer access to DPI's capability to prepare and deliver hit follow-up libraries that were designed using the results of Pfizer's high-throughput screening [523653]. In November 2005, DPI and Pfizer decided not to renew the collaboration. The alliance, which had generated \$92 million in revenue, would end on January 05, 2006. DPI would consolidate its chemistry platform in San Diego, CA, closing its South San Francisco facility and relocating or terminating all staff there. To cover restructuring costs, DPI would use \$10 million to \$12 million of its cash in 2006 [637911].

In December 2001, NeoTherapeutics' genomics division entered into an agreement with Pfizer covering the investigation of orphan GPCRs [434362].

[Return to Table of Contents](#)





In December 2001, Pfizer extended its 3-year collaboration with Mitokor to discover novel targets and therapeutics based on mitochondrial dysfunction [434273].

Also in December 2001, Pfizer began a new three-year agreement with Albany Molecular Research Inc (AMRI), continuing a relationship between AMRI and Pfizer that first began in 1996. Under the terms of the agreement, AMRI was to provide chemistry research, development and analytical services in a number of therapeutic areas selected by Pfizer [433829].

Later in December 2001, Pfizer signed a science and technology collaboration agreement with Entelos. Entelos was to prioritize specific Pfizer asthma drug candidates based on their predicted clinical efficacy using Entelos Asthma PhysioLab technology. Entelos was to also analyze phenotypic response patterns, as simulated in normal and asthmatic patients, to recommend appropriate treatment (dose and dose regimen) for each phenotype [433322].

In December 2001, Pfizer entered into an R&D agreement with Bentley Pharmaceuticals Inc whereby both companies were to formulate Pfizer compounds for enhanced delivery [431936]. In October 2002, the agreement was extended [466625].

In October 2001, Valentis granted a non-exclusive license of GeneSwitch to Pfizer for research purposes [426707].

In October 2001, Genaissance entered into an agreement to allow Pfizer access to selected data from the company's HAP Database [424922]. By February 2003, this agreement had been extended until August 2004 [478533].

In September 2001, Pfizer bought libraries of chemical compounds from Lexicon Genetics the financial terms of the agreement were not disclosed [423341]. Pfizer was granted a non-exclusive internal research use license in October 2001, to Lexicon's isogenic DNA technology in gene targeting [425163].

An asthma / allergy research collaboration with Rigel Pharmaceuticals Inc, originally entered into in January 1999, was extended for a further year in January 2001. Pfizer was to have worldwide rights to develop and market human and veterinary drugs against the targets that inhibit the switch to IgE in B cells [396950], [313102], [318080]. In May 2002, Rigel delivered six additional validated drug targets to Pfizer, thereby completing its discovery phase respiratory disease research collaboration [450381].

In January 2001, Pfizer and Xenogen Corp entered into a research collaboration to develop new methods of identifying potential therapeutic drug targets with the use of transgenic mice. The agreement was to terminate in December 2003, but could be extended at Pfizer's option for two successive 1-year periods [396826].

Also in January 2001, Pfizer and Gene Logic Inc entered into a research collaboration to co-design and develop a custom gene expression microarray, based on Affymetrix Inc's GeneChip technology, for mechanistic toxicological studies. Gene Logic and Pfizer were to design the microarray which was to be built by Affymetrix and made available exclusively to subscribers of the ToxExpress Module [395810].

In December 2000, Deltagen entered into a collaborative agreement with Pfizer to provide Pfizer with access to DeltaBase (in vivo mammalian gene function information on 750 genes selected for their commercial relevance) and the corresponding DeltaBase intellectual property rights. The initial term of the agreement was 3 years, until June 2003, with the option to extend the term for 2 additional years [394709].

In December 2000, Oxford GlycoSciences (OGS) announced the signing of a research agreement with Pfizer, whereby OGS was to apply its industrial scale proteomics technology to the discovery of new biomarkers and drug development targets in Alzheimer's disease and atherosclerosis. The collaboration was a continuation of the joint research collaboration entered into between the two companies in April 1998. Additionally, OGS was to grant Pfizer a non-exclusive license to use OGS's CSF Proteome and Serum Proteome databases [394438]. In January 2003, OGS and Pfizer signed a new contract to provide additional proteomics services. At that time, the area of research and other specific terms of the agreement had not been disclosed [475638].

Also in October 2000, VistaGen Inc and Pfizer agreed to collaborate in a joint development program to evaluate VistaGen's mouse-stem-cell-based Genesis Screen technology as a tool for clinically predictive toxicology screen assays [386745].

In October 2000, MacroChem Corp and Pfizer signed an agreement whereby Pfizer was to evaluate the use of MacroChem's SEPA technology to improve transdermal absorption of a group of Pfizer's pharmaceuticals [385850].

In September 2000, Pfizer entered into a long-term agreement with Battelle Pulmonary Therapeutics (BPT) to develop drugs to treat pulmonary and systemic diseases using BPT's electrohydrodynamic pulmonary delivery

[Return to Table of Contents](#)

technology [382771].

In September 2000, Compugen completed the third milestone included in its agreement with Pfizer. The computational capabilities delivered to Pfizer as part of this third milestone included the identification of predicted genes through clustering and assembly of genomic DNA and cDNA sequences that takes into consideration predicted splice variants and other features [382232]. In July 2002, Compugen extended its collaboration with Pfizer. The extended collaboration provided Pfizer with Compugen's LEADS platform for drug discovery, and the Z4000 and Z3 software packages for proteomic research [458775].

Also in September 2000, Pfizer paid Interneuron a \$3.0 million milestone payment for trials of pagoclone for use in panic disorder and to support regulatory approval of the product [382124].

In September 2000, Pfizer was granted a non-exclusive license to Aurora Biosciences Corp's Vivid screening technology [381180].

In May 2000, Pfizer signed an agreement with SkyePharma plc for the development of an undisclosed compound utilizing SkyePharma's DepoFoam technology. This was in addition to an earlier feasibility agreement between the two companies, signed in March 2000, involving the use of SkyePharma's Geomatrix delivery system [366909].

In the same month Pfizer gained access to Xenometrix's yeast DEL technology, including the measurement of the genotoxic potential of compounds [359641].

In March 2000, LifeSpan entered into an agreement with Pfizer Inc for a subscription to the first database of information on the expression and localization of G-protein coupled receptors [358724].

In February 2000, Pfizer entered into an agreement with Gene Logic for its GeneExpress database. Gene Logic's relatively small portfolio of international patent applications included WO-09911822, with claimed a method for predicting prognosis and treatment response for genetic abnormalities. A December 1999 press release linked the GeneExpress database with the issue of US-05994068, which first appeared as a PCT application in the name of Wisconsin Alumni, WO-09840518 [357079].

In April 2000, Pfizer filed a joint patent application with OGS describing discoveries of clinical markers made in their AD collaboration [361570].

In March 2000, Aurora and Pfizer expanded their original agreement to include additional functionality for the Automated Master Compound Store (ACMS). Pfizer also exercised its option to license Aurora's GenomeScreen technology assay development, specifically retroviral vectors [360963].

In November 1999, Pfizer entered an agreement with Celera Genomics, providing a 5-year genomics agreement including a subscription to all Celera's current database products and a collaborative gene discovery agreement [348191].

In November 1999 the agreement between Pfizer and Incyte was further expanded. Pfizer has licensed an undisclosed number of potential, future pharmaceutical products developed using Incyte's proprietary sequences. Pfizer agreed to expand its LifeSeq Gold subscription to the end of 2002 [348196].

In October 1999, Pfizer expanded its collaborative research agreement with Sangamo BioSciences to purchase additional UGT for use in the identification of gene targets [342451].

In July 1999, ArQule and Pfizer entered an agreement whereby ArQule was to generate compound libraries using its AMAP operating system [333443], this was expanded in December 2001 [434435]. In December 2001, this agreement was expanded and extended until 2008 [482550]. In March 2003, Pfizer made a \$5 million equity investment in ArQule as a result of ArQule's achievement of its 2002 collaboration goals [482449].

Again in June 1999, Pfizer entered into a series of collaborations with Cambridge Combinatorial, allowing access to Cambridge Combinatorial's novel automated process R&D, drug discovery platforms and chemistry technologies [329081].

The company entered a technology partnership with Evotec BioSystems in June 1999, which provided Pfizer with access to Evotec's screening technologies. Evotec scientists were to design a range of novel types of fluorescence-based cellular and biochemical assays to be run on the EVOscreen platform by Pfizer [328056]. In October 2002, this agreement was expanded for 3 years with Evotec providing Pfizer with additional and newly developed ultra high throughput screening instrumentation. Also, Evotec was to develop certain technologies and biological assay system for Pfizer in exchange for a potential excess of \$25 million [468643].

Also in June 1999, Pfizer entered into a 5-year technology acquisition agreement for pharmaceutical R&D with

[Return to Table of Contents](#)



Aurora [328052].

In June 1999, Pfizer signed a 3-year, non-exclusive agreement with Neurogen Corp covering Neurogen's accelerated intelligent drug discovery (AIDD) technology [356839], [328165].

In March 1999, Pfizer became the first company to receive IGEN International's M-series HTS [317815].

In November 1998, Pfizer's collaborations with Neurogen, covering GABA receptor programs in anxiety, sleep disorders and cognition enhancement, were extended for a further two years. Depression was announced as a new target indication [303782].

In November 1998, Pfizer entered into an agreement with MitoKor to use its expertise in the field of mitochondrial research in order to identify new targets and drugs for neurodegenerative diseases [303741].

In September 1998, Pfizer entered into a collaboration with EPIX to explore the efficacy of AngioMARK and MRI in the diagnosis and monitoring of female sexual arousal disorder [349124].

In September 1998, Sangamo announced that it had signed a collaborative research agreement with Pfizer, entitling the latter to the use of Sangamo's Universal GeneTools (UGT) in the identification and validation of novel gene targets for drug discovery [383565].

In April 1998, Pfizer and Oxford GlycoSciences (OGS) entered into a research collaboration to identify disease-specific proteins as potential diagnostics, clinical markers of disease and targets for the development of drugs. Initial focus was to be on Alzheimer's disease (AD), but Pfizer had the option to select a second disease [283724].

In February 1998, Pfizer entered into a research collaboration with Catalytica Pharmaceuticals to investigate novel formulations for tablets, capsules and other internally-released medications [278514].

Also in January 1998, Pfizer signed a genomics-based research collaboration with Chrysalis International Corporation to identify and validate new targets for two major disease categories. The collaboration was to last for two years with the option to expand into further areas [274571].

In January 1998, Pfizer entered into a collaboration with Abgenix Inc, whereby Abgenix was to generate antibodies against undisclosed antigen targets [274545]. In February 2000, Abgenix extended the human antibody collaboration with Pfizer for an additional two years. The company included two more antigen targets, raising the possible total number of product candidates to five. Abgenix was to use its XenoMouse technology to generate fully human antibodies to two antigen targets named by Pfizer. The original agreement, signed in 1997, provided Pfizer with the option to license XenoMouse for up to three antigen targets for the potential treatment of cancer [357451]. This agreement was further expanded in January 2001, to include up to ten additional antigen targets [395600]. In July 2003, Pfizer was to pay Abgenix a milestone payment, triggered by Pfizer's filing of an IND application in the US for an antibody product candidate generated by Abgenix's XenoMouse technology [497597]. In January 2004, Abgenix was to receive a milestone payment from Pfizer, triggered by the filing of an IND application for the third product candidate to emerge from the companies' antibody collaboration [520682].

In December 1997, Pfizer reached an agreement with Incyte Pharmaceuticals for an expanded genomic database collaboration providing Incyte with continued access to Incyte's LifeSeq gene sequence and expression database as well as access to additional genomic databases and genomic data management software [273158]. In February 1998, this agreement was extended for an additional three years [278073].

In August 1997, Pfizer licensed Affymetrix's GeneChip. Under the agreement Affymetrix was to supply Pfizer with GeneChip instrumentation, software and custom DNA probe arrays containing genes selected by Pfizer for the monitoring of gene expression levels [259342].

In 1996, Gensia Pharmaceuticals Inc and Pfizer formed a \$50 million research collaboration agreement to use Gensia's adenosine regulating agent technology to screen Pfizer's compound library for analgesic drug candidates. Pfizer was to be responsible for the clinical development of selected candidates [213875].

In April 1996, Pfizer entered into a copromotion and development agreement with Warner-Lambert for the development of Lipitor [204802].

In 1986, Pfizer signed a 10-year agreement with OSI Pharmaceuticals, for the research and development of small molecule cancer therapeutics that target oncogenes and tumor suppressor genes. This agreement was extended in 1990 and again in 1996, the latter being a 5-year extension from which OSI was to receive \$18 million in direct research funding [205762], [317514]. In April 2001, the alliance was terminated [505010].

## EARLY R&D

[Return to Table of Contents](#)

In June 2014, Pfizer was to utilize X-Chem's drug discovery platform based on a screening library of DNA-encoded small molecules to identify novel leads for the potential treatment of inflammatory and orphan diseases [1568179].

In April 2009, the company was investigating nanomolar inhibitors of biotin carboxylase for an undisclosed indication. Data were reported at CHI's Fourth Fragment-Based Drug Discovery Conference in San Diego, CA [1000398], [1035942].

In March 2008, Sangamo, Pfizer and Sigma-Aldrich published data showing that Sangamo's zinc finger DNA-binding protein nucleases could be used to generate knockout cell lines [888456].

In March 2008, Pfizer planned to discontinue 24 clinical and preclinical programs, increase the number of programs in phase III from 16 to up to 28 by December 2009 and submit up to 20 marketing applications between 2010 and 2012. The company decided to discontinue the 24 programs, in order to focus on higher-value markets. Pfizer also planned to accelerate the clinical development of 20 programs for diseases including arthritis, cancer, pain and diabetes and to establish an oncology-focused business unit, focusing its efforts on cancers common on Asia including liver esophagus nasopharynx cancer [882885].

## IP NEWS

In November 2007, Ore Pharmaceuticals announced that Pfizer had filed a patent application covering the new therapeutic use of a known Pfizer drug [853069].

## FINANCIAL

In February 2015, Pfizer began an accelerated \$5 billion share repurchase agreement of its common stock as a part of its existing share repurchase authorization under which an additional \$11 billion of authority was announced, in October 2014. Approximately 150 million of the shares to be repurchased under the transaction would be received by Pfizer on February 11, 2015. The settlement of the agreement, was expected during or prior to the third quarter of 2015 [1632549].

In July 2014, Pfizer was to purchase a 10% stake in Cellectis [1581757].

In May 2014, Pfizer announced pricing of a debt offering consisting of five tranches of notes: US \$1 billion aggregate principal amount of 1.1% notes due 2017, US \$0.5 billion aggregate principal amount of floating rate notes due 2017, US \$1.5 billion aggregate principal amount of 2.1% notes due 2019, US \$1 billion aggregate principal amount of 3.4% notes due 2024 and US \$0.5 billion aggregate principal amount of 4.4% notes due 2044. At that time, the offering was expected to close on May 15, 2014 [1556045].

By December 2013, the company had repurchased \$16.3 billion common stock shares [1519073].

In May 2013, Pfizer announced pricing of a debt offering consisting of five tranches of notes: US \$750,000,000 aggregate principal amount of 0.900% notes due 2017, US \$1,000,000,000 aggregate principal amount of 1.500% notes due 2018, US \$500,000,000 aggregate principal amount of floating rate notes due 2018, US \$1,000,000,000 aggregate principal amount of 3.000% notes due 2023 and US \$750,000,000 aggregate principal amount of 4.300% notes due 2043. At that time, the offering was expected to close on June 3, 2013 [1429691].

In April 2013, the company announced a 24-cent second quarter 2013 dividend on the company's common stock, payable June 4, 2013, to shareholders of record at the close of business on May 10, 2013 [1410713].

In November 2012, Wyeth was to redeem 5.500% notes due March 15, 2013 on December 26, 2012. At that time, the current outstanding aggregate principal amount of notes was \$1.5 billion [1344010]. In November 2013, Wyeth intended to redeem 5.500% notes due February 01, 2014 on December 16, 2013. At that time, the outstanding aggregate principal amount of notes was \$1.75 billion [1499681].

In November 2012, a new \$10 billion share repurchase program was announced [1336734].

In May 2012, net income was down 19% for the first quarter, from \$2,222 to \$1,794 million, attributed to the loss of exclusivity on several products. Most notably Lipitor [1285800].

In February 2011, the company's Board authorized a new share repurchase program for \$5 billion of its common stock. At that time, the company still had \$4 billion remaining under an earlier authorized repurchase program. By December 2010, the company had repurchased approximately 60 million shares. The company planned to repurchase \$5 billion of stock during 2011 and the remaining amount in 2012 and beyond [1164995].

In June 2009, Pfizer completed EUR 5.85 billion (US \$8.3 billion) and GBP 1.5 billion (US \$2.5 billion) senior unsecured note offerings. The offering comprised EUR 1.85 billion (US \$2.6 billion) of 3.625% notes due 2013; EUR 2 billion (US \$2.8 billion) of 4.75% notes due 2016; EUR 2 billion (US \$2.8 billion) of 5.75% notes due 2021;

[Return to Table of Contents](#)



and GBP 1.50 billion (US \$2.5 billion) of 6.5% notes due 2038. The proceeds would be used to partially fund Pfizer's \$68 billion acquisition of Wyeth. In connection with the offering, Pfizer terminated its 364-day bridge term loan credit agreement, which was to fund the Wyeth deal [1015205].

In March 2009, Pfizer raised \$13.5 billion from an offering of \$1.25 billion floating rate notes due 2011, \$3.5 billion 4.45% notes due 2012, \$3 billion 5.35% notes due 2015, \$3.25 billion 6.2% notes due 2019, and \$2.5 billion 7.2% notes due 2039. The proceeds would be used to partially fund the acquisition of Wyeth [994738].

In January 2009, Pfizer planned to implement a new cost-reduction initiative, expected to achieve incremental cost savings of approximately \$3 billion by the end of 2011. The initiative was to reduce the workforce by 10% and close 5 of 46 sites. At that time, as part of the proposed acquisition of Wyeth, Pfizer expected to save an additional \$4 billion by the end of 2012 [979051].

In the year ended December 2008, pharmaceutical revenues were \$44.2 billion, slightly lower than 2007 revenues. At that time, Pfizer employed 81,800 people, worldwide [988354].

In July 2007, TRC Capital made a mini-tender offer for 4 million Pfizer shares for \$25 each, which Pfizer recommended stockholders to reject [811869].

In January 2007, Pfizer Canada planned to lay off 285 staff over the following 6 months from all parts of the company, including head office and field-based employees. The move was part of a company-wide initiative to cut costs, which would result in the loss of 10,000 positions throughout the world over the following 2 years [762123].

In January 2007, Pfizer reported that it was to cut its worldwide workforce by 10%, shut 2 US manufacturing sites and close research sites in the US, Japan and France, in order to reduce costs by up to \$2 billion by the end of 2008, to drive improved performance and to enhance total shareholder return. By 2008 Pfizer aimed to have reduced its manufacturing network from 93 sites to 48. Pfizer would maximize its revenues from its current portfolio and increase production by simplifying its R&D organization and increasing investment in promising therapeutic areas, such as vaccines and antibodies. The company also planned to terminate its preclinical research programs in gastroenterology and dermatology but would continue to develop those compounds already in the pipeline and to seek external opportunities. The changes would help in the delivery of four new internally generated products each year by 2011 [759391]. By July 2007, Pfizer had decreased its US and Global workforce by 20% and 8%, respectively [813922].

In November 2006, Pfizer announced plans to reduce its US sales force by 20%, as part on a review of its operations [746945].

In June 2006, Pfizer announced a \$17 billion share purchase program, whereby up to \$7 billion shares would be repurchased in 2006, and up to \$10 billion in 2007 [675536].

In June 2005, Pfizer's Board of Directors approved the repatriation of an additional \$8.6 billion in foreign earnings beyond the initial \$28.3 billion as previously expected [609202].

In June 2005, Pfizer's Board authorized a \$5 billion stock buyback program. Stock acquired through program would be available for general corporate purposes [609187].

In October 2004, Pfizer's Board of Directors authorized the purchase of \$5 billion of the company's common stock. The company expected the purchases to be made from time to time in the open market or in privately negotiated transactions by the end of 2005 [567556].

In December 2003, Pfizer's Board of Directors authorized the purchase of up to \$5 billion of the company's common stock. The company said it expected the purchases to be made in the open market or in privately negotiated transactions and to be completed by the end of 2004 [517203].

Also in December 2003, Pfizer purchased 508 million shares to complete a \$16 billion share repurchase program authorized by the Board of Directors in June 2002 [517203], [456566].

## FINANCIALS

### SHARE INFORMATION

Close Price (USD)	34.25
-------------------	-------

[Return to Table of Contents](#)



<b>Change (USD)</b>	0.10 (0.29%)
<b>Previous Close Price (USD)</b>	34.15
<b>Volume</b>	39,444,633
<b>52-Week High (USD)</b>	34.51
<b>52-Week Low (USD)</b>	27.51
<b>Date</b>	11-Feb-2015
<b>Exchange</b>	NEW YORK SE(COMPOSITE)
<b>Current Number of Shares Outstanding</b>	6,300,657,237
<b>Current Market Capitalization</b>	208,992,800,551
<b>EPS (Date Reported)</b>	1.41253

## STOCK PERFORMANCE

--



[Return to Table of Contents](#)

## Consensus Recommendation

Current IBES recommendation	Buy
Number of analysts	19
Number of recommendations up	1
Number of recommendations down	1


## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
SPDR S&P 500 ETF	Mutual Fund	United States	64,871,747	1.03	-9,328,743	-0.13	31-Jan-2015
iShares Core S&P 500 ETF	Mutual Fund	United States	23,982,756	0.38	-417,222	-0.02	31-Jan-2015
iShares Russell 1000 Value ETF	Mutual Fund	United States	15,957,909	0.25	-20,309	-0	31-Jan-2015
iShares High Dividend ETF	Mutual Fund	United States	8,661,914	0.14	531,027	0.07	31-Jan-2015
iShares S&P 500 Value ETF	Mutual Fund	United States	6,196,311	0.1	9,483	0	31-Jan-2015
iShares U.S. Healthcare ETF	Mutual Fund	United States	4,469,458	0.07	280,330	0.07	31-Jan-2015
SPDR Dow Jones Industrial Average ETF	Mutual Fund	United States	4,402,712	0.07	-374,985	-0.08	31-Jan-2015
PowerShares BuyBack Achievers Portfolio	Mutual Fund	United States	4,389,528	0.07	26,859	0.01	31-Jan-2015
Schwab U.S. Dividend Equity ETF	Mutual Fund	United States	4,327,680	0.07	520,376	0.14	31-Jan-2015
DB Platinum Advisors	Investment Advisor	Luxembourg	4,281,263	0.07	85,453	0.02	31-Jan-2015
iShares Russell 1000 ETF	Mutual Fund	United States	3,291,759	0.05	6,202	0	31-Jan-2015
iShares S&P 100 ETF	Mutual Fund	United States	2,811,644	0.04	1,301	0	31-Jan-2015
Deka Investment GmbH	Investment Advisor/Hedge Fund	Germany	2,677,445	0.04	-618,981	-0.19	31-Jan-2015

[Return to Table of Contents](#)

iShares Select Dividend ETF	Mutual Fund	United States	2,610,822	0.04	7,293	0	31-Jan-2015
PowerShares Dynamic Pharmaceuticals Portfolio	Mutual Fund	United States	2,572,878	0.04	183,779	0.08	31-Jan-2015
iShares Global Healthcare ETF	Mutual Fund	United States	2,354,022	0.04	109,866	0.05	31-Jan-2015
First Trust Morningstar Dividend Leaders Index Fund	Mutual Fund	United States	2,256,345	0.04	88,563	0.04	31-Jan-2015
iShares U.S. Pharmaceuticals ETF	Mutual Fund	United States	2,123,782	0.03	137,982	0.07	31-Jan-2015
Lyxor Asset Management	Investment Advisor/Hedge Fund	France	1,781,830	0.03	0	0	31-Jan-2015
iShares Russell 3000 ETF	Mutual Fund	United States	1,781,691	0.03	37,644	0.02	31-Jan-2015

## FINANCIAL PERFORMANCE



[Return to Table of Contents](#)

	2010	2013	2011	2012	2014
<b>Sales (USD M)</b>	67,809	51,584	67,425	58,986	49,605
<b>Operating Income (USD M)</b>	17,886	16,637	19,761	18,966	13,552
<b>Net Income (USD M)</b>	8,257	11,649	8,705	9,787	9,087

#### Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	13,118	2,295	1,232.06
2014 Q3	12,361	3,676	2,666
2014 Q2	12,773	4,030	2,912
2014 Q1	11,353	3,534	2,329
2013 Q4	13,558	3,617	2,569
2013 Q3	12,643	4,366	2,582
2013 Q2	12,973	4,556	14,099
2013 Q1	13,500	4,334	2,742
2012 Q4	15,068	5,047	1,531
2012 Q3	13,976	4,447	3,208

#### BALANCE SHEET

##### Assets (USD M)

	2010	2011	2012	2013
<b>Cash &amp; Short Term Investments</b>	28,527	27,115	32,708	32,408
<b>Inventories - Total</b>	8,405	7,769	7,063	6,166
<b>Current Assets - Total</b>	60,468	57,728	61,415	56,244
<b>Property, Plant And Equipment - Net</b>	19,123	16,938	14,461	12,397
<b>Other Assets - Total</b>	103,776	101,637	95,773	85,500
<b>Total Assets</b>	193,825	186,802	185,798	170,547

[Return to Table of Contents](#)



### Liabilities (USD M)

	2010	2011	2012	2013	
Accounts Payable	4,026	3,836	4,264	3,234	
Short Term Debt & Current Portion Of Long Term Debt	5,623	4,018	6,424	6,027	
Current Liabilities - Total	28,609	28,069	28,619	23,366	
Long Term Debt	38,410	34,931	31,036	30,462	
Deferred Taxes	17,459	18,397	21,593	24,036	
Other Liabilities	5,601	6,199	11,549	8,760	
Total Liabilities	105,560	104,181	104,120	93,927	

### Stockholders Equity (USD M)

	2010	2011	2012	2013	
Minority Interest	452	431	418	313	
Preferred Stock	52	45	39	33	
Common Stock	444	445	448	453	
Treasury Stock	22,712	31,801	40,121	67,923	
Total Liabilities & Shareholders' Equity	193,825	186,802	185,798	170,547	

### FORECASTS

#### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	2.23	2.23	2.22
31-Dec-2016	2.31	2.31	2.29
31-Dec-2017	2.44	2.4	2.44

#### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	1.08	2.79	18666.36	48001.01
31-Dec-2016	1.15	2.79	18911.36	47921.2
31-Dec-2017	1.22	3.45	19374.92	49280.34

[Return to Table of Contents](#)



## COMPANY CONTACTS

Address	Business Development Contact
235 E 42ND ST NEW YORK NEW YORK 10017 US	Ms Polly Murphy R&D Business Development 235 East 42nd St New York, NY 10017-5755 US
Telephone: +12125732323	Telephone: +1 212 733 2323 E-mail: <a href="mailto:pollymurphy@pfizer.com">pollymurphy@pfizer.com</a>

## SUBSIDIARY COMPANIES

Names
A H Robins (Philippines) Co Inc
A H Robins Co Inc
A H Robins Co Ltd
A H Robins International Co
ACO Lakemedel AB
AL Specialty Chemicals Inc
Abbott Laboratories (India) Ltd
Adams (Thailand) Ltd
Adams France
Adenylchemie GmbH
Adforce Inc
Adria Laboratories Inc
Adria Laboratories of Canada Ltd
Adria SP Inc
Agouron Acquisition Corp
Agouron Pharmaceuticals Inc
Agrivet AB
Alanex Corp
Alginate Industries (Scotland) Ltd
Alginate Industries Ltd
Allergan Aps
Allergan Hydron Europe Ltd
Allergan Hydron GmbH
Allergan Hydron Holdings BV
Allergan Hydron Italia Srl
Allergan Norden AB
Allergan Warenvertriebsgesellschaft MbH

[Return to Table of Contents](#)



Names
Alpharma GmbH & Co KG
Alpharma Inc
Alpharma Ireland Ltd
American Cyanamid Co
American Home Products Holdings (UK) Ltd
Anaderm Research Corp
Andreae-Noris Zahn AG
Angiomedics
Angiosyn Inc
Angnes
Apollon Inc
Ayerst McKenna & Harrison Inc
Ayerst Wyeth Pharmaceuticals Inc
Barre National Inc
Belphar
Benoist Girard & Cie SA
Bioindustria Farm SpA
Biolab Industrias Farmaceuticas SA
Biolink Activated Polymers AB
Biomed Inc
Bioquimica Industrial Espanola SA (BINESA)
Biorell GmbH
Bioren Inc
Biorexis Pharmaceutical Corp
Biosearch Italia SpA
Biovac Inc
C H Buer GmbH
CAL Pfizer SA
CMS Diffusion
CP Pharmaceuticals International CV
Cadsand Medica BV
Cadsand Medica NV
Calgene Inc
Cardel Ste
Carlo Erba Ecuador SA
Carlo Erba Farmitalia International (Indonesia) Pt

[Return to Table of Contents](#)

## Names

Carlo Erba Ilac Fabricasi Ltd Sirketi

Carlo Erba Reagenti Srl

Cesalna Srl

Chemoswed

Chemstraand Overseas SA

Chicle Adams CA Ltd

Chicle Adams SA de CV

Chilcott Laboratories Canada Inc

Cicab AB

Cicab ApS

Coley Pharmaceutical Group Inc

Coley Pharmaceuticals GmbH

Continental Pharma Inc

Corlens SA

Corvita Corp

CovX Pharmaceuticals Inc

Davpar Co

Deknatel Medizinische Produkte GmbH

Deknatel SA

Delfia Inc

Delta West Pte Ltd

Delta West Pty Ltd

Deltec

Deutsche KabiVitrum GmbH

Distribuidora del Centro SA de CV Cia

Diversomer Technologies Inc

Dumex A/S

Dumex AbOy

Dumex BV

Dumex GmbH

Dumex Indonesia PT

Dumex Ltd

Dumex-Alpha AS

Duran Equipos Medicos SA

Electro-Nucleonics

Ellem Industria Farmaceutica SRL

[Return to Table of Contents](#)



Names
Emresas Warner Lambert SA
Encysive Pharmaceuticals Inc
Erbafin SpA
Erbamont Inc
Erbamont Italia BV
Esperion LUV Development Inc
Euronett Inc
Eurorga SA
Excaliard Pharmaceuticals Inc
Exchic CA
Excorim KB
FIRAP NV
Family Products Corp
Farmaceutica Park-Davis SA Cia
Farmaceutica Upjohn SA Cia
Farmitalia Carlo Erba (Asia) Ltd
Farmitalia Carlo Erba (Portugal) Prod Quimicas Farmaceuticos
Farmitalia Carlo Erba AB
Farmitalia Carlo Erba AG
Farmitalia Carlo Erba Export SA
Farmitalia Carlo Erba GmbH
Farmitalia Carlo Erba Hellas AE
Farmitalia Carlo Erba KK
Farmitalia Carlo Erba Laboratorio SA
Farmitalia Carlo Erba SA
Farmitalia Carlo Erba SA (Pty) Ltd
Farmitalia Carlo Erba SA de CV
Farmitalia Carlo Erba Srl
Ferropas SA
Ferrosan AB
Ferrosan Ab Oy
Fides SA
Flavor Technology Corp
FoldRx Pharmaceuticals Inc
Forster & Hug KG
GD Searle & Co

[Return to Table of Contents](#)



## Names

GD Searle (Nederland) BV
GD Searle (New Zealand) Ltd
GD Searle (Philippines) Inc
GD Searle (South Africa) Pty Ltd
GD Searle (Swaziland) (Pty) Ltd
GD Searle (Thailand) Ltd
GD Searle AB
GD Searle GmbH
GD Searle Holding GmbH
GD Searle Inter-American Co
GD Searle International (Hong Kong) Ltd
GD Searle LLC
GDS Pharma GmbH
GDS Pharma GmbH & Co KG
Genecorp Inc
Genetics Institute LLC
Genidrug AB
Gesellschaft Unospharma mbH
Gesellschaft zur Beseitigung von Sondermüll in Bayern
Goedecke AG
Goedecke Ges mbH
Goedecke GmbH
Golosinas Venezolanas Golovensa SA
Greenstone Healthcare Solutions
Greenstone LLC
HILENA Biologische und Chemische Erzeugnisse GmbH
Hall Bros (Whitefield) Ltd
Hansa Bryggeri A/S
Haptogen Ltd
Harmag Inc
Health Care Ventures Inc
Heinrich Mack Nachft
Hepar Chimie SA
Hepar Industries Inc
Hilekes BV
Hilekes GmbH

[Return to Table of Contents](#)



Names
Hilekes Medical Supplies NV
Hornet Fastighetsbolag KB
HybriTech Seed International Inc
Hybribulls Ltd
INTEC Industrielle et Technique SA Ste
Icagen Inc
ImmunoPharmaceutics Inc
Impex Ltda SACIFIA
Infusaid Inc
InnoPharma Inc
Innoven II Corp
Institut de Recherche Jouveinal SA (IRJ)
Instituto Pasteur do Portugal Ltda
Intermedics Intraocular Inc
Intermedics Ophthalmics GmbH
Intermedics Ophthalmics Japan KK
Intermedics Orthopedics (Denver) Inc
Invicta Pharmaceuticals Ltd
Iovision Inc
Isis Chemie GmbH
Isis Pharma GmbH
Isom
Iznard-Lyraz SA
JAFCO Japan Health Care Investment Co Ltd
Jacobs Pita A/S
Jacquet Orthopedie SA
Japan Upjohn Ltd
John Wyeth & Brother Ltd
Jones Pharma Inc
Jouveinal Laboratories Inc
Jouveinal Laboratories SA
Jouveinal Pharma AG
Jouveinal SA
Kabi Baxter Infusion AB
Kabi Diagnostica AB
Kabi Invent AB

[Return to Table of Contents](#)

Names
Kabi Pharmaceuticals
Kabi Pharmacia AB
Kabi Pharmacia Ltd
KabiFides SA
KabiGen AB
KabiVitrum A/S
KabiVitrum AB
KabiVitrum AG
KabiVitrum Ab Oy
KabiVitrum Arzneimittelvertrieb Ges mbH
KabiVitrum BV
KabiVitrum Handelsgesellschaft mbH
KabiVitrum Inc
KabiVitrum International AB
KabiVitrum Japan Ltd
KabiVitrum Lipid Chemicals AB
KabiVitrum Norden AB
KabiVitrum Nutrition AB
KabiVitrum Pty Ltd
KabiVitrum SA
KabiVitrum Srl
KabiVitrum Sverige AB
Kelco International Ltd
Kenral Inc
Keystone Chemurgic Corp
Kinetik Systems Inc
King Pharmaceuticals Inc
King Pharmaceuticals R&D Inc
Kirchimie Ltee
Korag Co Ltd
Korea Pharma Holding Co Ltd
Korea Upjohn Ltd
LKB (Japan) Ltd
LKB Biomaterial AB
LKB Diagnostics Inc
LKB Far East Ltd

[Return to Table of Contents](#)



## Names

LKB Instrument A/S

LKB Instrument AG

LKB Instrument Ges mbH

LKB Instrument GmbH

LKB Instrument NV SA

LKB Instruments Inc

LKB Instruments Ltd

LKB Instruments SA

LKB Pribori

LKB Produkten BV

LKB Produkter AB

LKB Strumenti SpA

LKB Sverige AB

Laboratoire Beral SA

Laboratoire Hydron SA

Laboratoire Phygiene SA

Laboratoires F Bouchard SA

Laboratoires Paillusseau SA

Laboratoires Pfizer SA

Laboratoires Searle SA

Laboratoires Upjohn SARL

Laboratoires Wyeth France SA

Laboratorios Farmiberia SA

Laboratorios Pfizer Ltda

Laboratorios Substantia CA

Laboratorios Upjohn CA

Laboratorios Pfizer SA

Lambert & Feasley Inc

Lambert-Pharmacal Co

Larolatina SA

Lederle Laboratories

Leibinger GmbH

Lejonets Kemiska & Farmaceutiska Fabriker AB

Leo & Ferrosan AB

Leo AB

Leo AG

[Return to Table of Contents](#)





Names
Leo Arzneimittel GmbH
Leo International NV
Leo-Fennica AB Oy
Leo-Intressenter AB
Liber AB
Logifarm Srl
Loginvest Srl
Lorex Pharmaceuticals Inc
Lorex Pharmaceuticals of Canada Ltd
Ludwig Brunner GmbH
Lyrax SARL
Measureaim Ltd
Med-Tech Ventures Inc
MedInvent SA
Medical Workshop USA Inc
Medicinal La Campana SA de CV Cia
Medico Kemisk Teknisk Fabrik AB
Medihus AB
Medimech International Ltd
Medisan AB
Medisan Pharmaceuticals AB
Mekos AB
Meridian Medical Technologies Inc
Meridica Ltd
Midwestern Diagnostic Lab Inc
Mon Gard Ltd
Mon Sure Ltd
Monagro Kimia PT
Monarch Pharmaceuticals Inc
Montedison Farmaceutica SACIFI y A
NAMIC
NMC Laboratories Inc
Neusentis Ltd
NextWave Pharmaceuticals Inc
Nippon Lederle KK
Nippon Wyeth KK

[Return to Table of Contents](#)

Names
Norsk Pharmacia A/S
North Haven Chemical Inc
Nouvelle des Pastilles de Vichy Ste
Novon Polymers AG
Orsim SA
P-D Co Inc
Panserv-Anziehen-Service GmbH
Parke-Davis & Co
Parke-Davis & Co Inc (Philippines)
Parke-Davis & Co Ltd
Parke-Davis (France)
Parke-Davis (Thailand) Ltd
Parke-Davis GmbH
Parke-Davis International Ltd
Parke-Davis Korea Ltd
Parke-Davis Pty Ltd
Parke-Davis SA
Parke-Davis Sales Corp
Parke-Davis Sdn Bhd
Parke-Davis SpA
Parke-Davis de Venezuela CA
Perma Sharp Boudros Hellas SA
Pficonprod Pty Ltd
Pfizer (India) Ltd
Pfizer (Malaysia) Sdn Bhd
Pfizer (NZ) Ltd
Pfizer (Namibia) (Pty) Ltd
Pfizer A/S
Pfizer AB
Pfizer AG
Pfizer Asia Pacific Pte Ltd
Pfizer BV
Pfizer Bioquimicos SA
Pfizer Brasil LTDA
Pfizer CA
Pfizer Canada Inc

[Return to Table of Contents](#)

Names
Pfizer Cardiovascular Lipid Research Grant
Pfizer Central Research
Pfizer CentreSource
Pfizer Chemical Corp
Pfizer Consumer Healthcare
Pfizer Corp
Pfizer Corp Austria GmbH
Pfizer Corporation Hong Kong Limited
Pfizer Diagnostic Products International Ltd
Pfizer Diagnostic Products SARL
Pfizer Egypt SAE
Pfizer Enterprises Inc
Pfizer Genetics Inc
Pfizer Global Pharmaceuticals
Pfizer Global Research & Development
Pfizer Global Supply Japan
Pfizer GmbH
Pfizer Group Ltd
Pfizer Health AB
Pfizer Health Solutions
Pfizer Hellas AE
Pfizer Holding Ltd
Pfizer Hospital Products Group Inc
Pfizer Hospital Products Group Ltd
Pfizer Hospital Products Ltd
Pfizer Hospital Products Ltd (Canada)
Pfizer Human Healthcare
Pfizer Ilaclari AS
Pfizer Inc (Philippines)
Pfizer Indonesia PT
Pfizer International Corp SA
Pfizer International Inc
Pfizer International Trading (Shanghai) Co., Ltd
Pfizer Italiana SpA
Pfizer Japan Inc
Pfizer Laboratories (Bangladesh) Ltd

[Return to Table of Contents](#)

Names
Pfizer Laboratories (Pty) Ltd
Pfizer Laboratories Ltd (Kenya)
Pfizer Laboratories Ltd (New Zealand)
Pfizer Laboratories Ltd (Pakistan)
Pfizer Ltd
Pfizer Ltd (Ghana)
Pfizer Ltd (South Korea)
Pfizer Ltd (Sri Lanka)
Pfizer Ltd (Taiwan)
Pfizer Ltd (Tanzania)
Pfizer Ltd (Thailand)
Pfizer Ltd (Uganda)
Pfizer Ltd (Zambia)
Pfizer Ltda (Angola)
Pfizer Ltda (Mozambique)
Pfizer MSP KK
Pfizer Med-Inform Beratungs GmbH
Pfizer Medical Systems Inc
Pfizer Ophthalmics
Pfizer Overseas Inc
Pfizer Oy
Pfizer Pharmaceuticals Inc
Pfizer Pharmaceuticals Korea Ltd
Pfizer Pharmaceuticals Ltd
Pfizer Products Inc
Pfizer Pte Ltd
Pfizer Pty Ltd (Australia)
Pfizer Pvt Ltd (Zimbabwe)
Pfizer Quigley UK Ltd
Pfizer Research & Development Co NV/SA
Pfizer SA (Belgium)
Pfizer SA (Colombia)
Pfizer SA (Costa Rica)
Pfizer SA (France)
Pfizer SA (Morocco)
Pfizer SA (Spain)

[Return to Table of Contents](#)

Names
Pfizer SA (Venezuela)
Pfizer SACI
Pfizer Seiyaku KK
Pfizer Shoji Co Ltd
Pfizer Vaccines
Pfrimmer & Co Pharmazeutische Werke Erlangen GmbH & Co KG
Pfrimmer Kabi GmbH & Co KG
Pharmacia & Upjohn AB
Pharmacia & Upjohn Co
Pharmacia & Upjohn Diagnostics AB
Pharmacia & Upjohn Inc
Pharmacia & Upjohn Ltd
Pharmacia & Upjohn SpA
Pharmacia (Australia) Pty Ltd
Pharmacia Biosensor AB
Pharmacia Biosystems AB
Pharmacia Biotechnologia Diagnostico e Tratamento Ltda
Pharmacia Biotechnology AB
Pharmacia Biotechnology International AB
Pharmacia Canada Inc
Pharmacia Corp
Pharmacia Deltic Inc
Pharmacia Development Co Inc
Pharmacia FSC Inc
Pharmacia Fond AB
Pharmacia France SA
Pharmacia Genetic Engineering Inc
Pharmacia Ges mbH
Pharmacia GmbH
Pharmacia Holding BV
Pharmacia Iberica SA
Pharmacia Inc
Pharmacia Infusion AB
Pharmacia Intermedics Ophthalmics Inc
Pharmacia International Ges mbH
Pharmacia Italia SpA

[Return to Table of Contents](#)



Names
Pharmacia KK
Pharmacia LKB Biochrom Ltd
Pharmacia Nederland BV
Pharmacia Ophthalmics AB
Pharmacia Oy
Pharmacia P-L Biochemicals Inc
Pharmacia Pharmaceuticals AB
Pharmacia Production BV
Pharmacia SA NV
Pharmacia SOD Inc
Pharmacia Spain SA
Pharmacia pdf (Schweiz) AG
Pharmacia-Diephuis BV
Pharmaleo GmbH
Phivco-1 Llc
Pierrel SpA
PowderMed Ltd
Pripps Bryggerier AB
Procordia Corp
Prodotti Formenti Srl
Productos Adams SA
Promotoria Ipsa SA
Quigley Canada Inc
Quigley Co Inc
Quigley Co of Europe Ltd
Quigley Italiana SpA
Quigley Magnesite Ltd
Quorex Pharmaceuticals Inc
Radiologic Sciences Inc
Redmond Holdings Inc
Redvax GmbH
Renrall KK
Richard Hudnut Ltd
Rinat Neuroscience Corp
Roerig AB
Roerig BV

[Return to Table of Contents](#)

Names
Roerig Farmaceutici Italiana Srl
Roerig SA
Roerig SA (Belgium)
Rogar/STB Inc
SCI Corp
STI International Ltd
SUGEN Europe AG
SUGEN Inc
Santuron Praeparate
Schick Nederland BV
SciGenics Inc
Sciamco Inc
Scienta Instrument AB
Searlatina SA
Searle (India) Ltd
Searle Australia Pty Ltd
Searle CIBA-GEIGY Korea Ltd
Searle Canada Inc
Searle Caribbean Inc
Searle Chemicals Inc
Searle Costa Rica Inc
Searle EPE
Searle Iberica SA
Searle Industrie SA
Searle Klinische Forschung und Zulassung GmbH
Searle Malaysia Sdn Bhd
Searle Norge AS
Searle Oy
Searle Pakistan Ltd
Searle SA
Searle Singapore Pte Ltd
Searle Tech Inc
Searle Yakuhin KK
Searle de France SA
Searle de Mexico SA de CV
Searle de Venezuela CA

[Return to Table of Contents](#)



Names
Searle do Brasil Ltda
Sensor Invest KB
Sensus Drug Development Corp
Sepharmaceuticals Srl
Sera Inc
Serenex Inc
Shiley A/S
Shiley Inc
Shiley International Inc
Shiley Ltd
Shiley Oy
Shiley Scandinavia AB
Silene Srl
Sipsy Corp
Sipsy International BV
Sipsy SA
Sitrac AB
Sopaco SA
South Texas Immunology Lab Inc
Stedim SA
Stoeckert Instrumente GmbH
Strato Medical Corp
Substantia-Productos Farmaceuticos Ltda
SudFarma Srl
Swedish Lakemedelsindustri HB Consortium
Tecnobiomedica SpA
Teknosan A/S
Teknosan ApS
Tenedora Pfizer SA de CV
Tetra Heintierbedarf GmbH
Tetra Werke Dr rer nat Ulrich Baensch GmbH
The Kodiak Co Ltd
The Nutrasweet Co
The Upjohn Manufacturing Co
Thiakris Ltd
Trauma Products Inc

[Return to Table of Contents](#)

Names
Tuco Chemical Co Ltd
Unicliffe Ltd
Unipharma SA
Upjohn Cia Ltda
Upjohn Co Ltd
Upjohn Co SA
Upjohn Coordination Center NV
Upjohn Coordination Centre NV
Upjohn Farmoquimica Ltda
Upjohn Farmoquimica SA
Upjohn Holding Co
Upjohn Holding Co C
Upjohn Inc
Upjohn Indonesia PT
Upjohn Inter-American Corp
Upjohn International Inc
Upjohn Ltd
Upjohn Pharmaceuticals Ltd
Upjohn Pty Ltd
Upjohn SA
Upjohn SA (Belgium)
Upjohn SA de CV
Upjohn SpA
Upjohn Suzhou Pharmaceutical Co
Upjohn Trading Corp
Upjohn World Wide Inc
Van Cadsand Beheer BV
Vanart Metropolitan SA de CV
Velarca SA
Vilnus Srl
Virgin Islands Pharmacia Inc
Vitagermine SA
W-L Distributie NV
Warner Lambert (Belgium) NV
Warner Lambert (Schweiz) AG
Warner Lambert (Services) Pty Ltd

[Return to Table of Contents](#)



Names
Warner Lambert Pty Ltd
Warner Lambert R&D Ireland Ltd
Warner Wellcome Consumer Healthcare
Warner-Lambert (East Africa) Ltd
Warner-Lambert (Manufacturing) Sdn Bhd
Warner-Lambert (NZ) Ltd
Warner-Lambert (Portugal) Comercio e Industria Ltda
Warner-Lambert (Thailand) Ltd
Warner-Lambert (UK) Ltd
Warner-Lambert AE
Warner-Lambert Canada Inc
Warner-Lambert Co
Warner-Lambert Co AG
Warner-Lambert Distributors (Ireland) Ltd
Warner-Lambert Espana SA
Warner-Lambert Export Ltd
Warner-Lambert GmbH
Warner-Lambert Holland BV
Warner-Lambert Inc
Warner-Lambert International Co
Warner-Lambert International NV
Warner-Lambert Ireland Ltd
Warner-Lambert KK
Warner-Lambert LLC
Warner-Lambert Ltd
Warner-Lambert Manufacturing (Ireland) Ltd
Warner-Lambert Philippines Inc
Warner-Lambert SA (Pty) Ltd
Warner-Lambert Scandinavia AB
Warner-Lambert Technologies Inc
Warner-Lambert Verkoop BV
Warner-Lambert de Mexico SA de CV
Warner-Lambert de Panama SA
Warner-Lambert de Puerto Rico Corp
Warner-Lambert de Venezuela SA
Warner-Schick KK

[Return to Table of Contents](#)







Names
Wyeth
Wyeth AG
Wyeth BioPharma
Wyeth Consumer Healthcare
Wyeth Holdings Corp
Wyeth KK
Wyeth Laboratories Corp
Wyeth Laboratories Inc
Wyeth Laboratories Ltd
Wyeth Ltd (Canada)
Wyeth Ltd (India)
Wyeth Pharmaceuticals
Wyeth Research
Wyeth Research (UK) Ltd
Wyeth SA
Wyeth-Ayerst (Pty) Ltd
Wyeth-Ayerst International Inc
Wyeth-Ayerst Pharmaceuticals Inc
Zilc Inc
Zoomedica Frickhinger GmbH

[Return to Table of Contents](#)

## DRUG SALES AND FORECASTS



## Drug Sales as a Share of the Total Sales 2013



[Return to Table of Contents](#)

## BROKER RESEARCH

2014

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	17.00

### MKM Partners LLC

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Oct-14	1106.00
atorvastatin	WW	29-Oct-14	2033.00
atorvastatin + amlodipine	WW - JP	29-Oct-14	75.00
axitinib	WW	29-Oct-14	399.00
azithromycin	WW	29-Oct-14	319.00
bazedoxifene + conjugated estrogens, Pfizer	WW	29-Oct-14	5.00
bosutinib	WW	29-Oct-14	100.00
celecoxib	WW	29-Oct-14	2568.00
CP 526555-18	WW	29-Oct-14	639.00
crizotinib	WW	29-Oct-14	429.00
dacomitinib	WW	29-Oct-14	0.00
desvenlafaxine	WW	29-Oct-14	740.00
doxazosin	WW	29-Oct-14	264.00
etanercept	WW - US	29-Oct-14	3841.00
latanoprost	WW	29-Oct-14	506.00
linezolid	WW	29-Oct-14	1359.00
meningococcal B rLP2086 vaccine, Pfizer	WW	29-Oct-14	0.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	29-Oct-14	3.00
nonacog alfa	WW	29-Oct-14	862.00
palbociclib	WW	29-Oct-14	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Oct-14	313.00
pregabalin	WW	29-Oct-14	5172.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Oct-14	653.00
sertraline	WW	29-Oct-14	422.00
somatropin (growth disorder), Pfizer	WW	29-Oct-14	728.00
sunitinib	WW	29-Oct-14	1177.00
tafamidis	WW	29-Oct-14	20.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Oct-14	306.00
tolterodine	WW	29-Oct-14	162.00
venlafaxine hydrochloride	WW	29-Oct-14	351.00
voriconazole	WW	29-Oct-14	780.00

[Return to Table of Contents](#)



## Jefferies and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	1132.00
atorvastatin	WW	15-Jan-15	2003.00
atorvastatin + amlodipine	WW - JP	15-Jan-15	50.00
axitinib	WW	15-Jan-15	410.00
azithromycin	WW	15-Jan-15	323.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	38.00
bococizumab	WW	13-Oct-14	0.00
bosutinib	WW	13-Oct-14	100.00
celecoxib	WW	13-Oct-14	2863.00
CP 526555-18	WW	15-Jan-15	636.00
crizotinib	WW	13-Oct-14	441.00
dacomitinib	WW	13-Oct-14	0.00
doxazosin	WW	13-Oct-14	263.00
ertugliflozin	JP	13-Oct-14	0.00
etanercept	WW - US	15-Jan-15	3832.00
EXC-001	WW	15-Jan-15	0.00
fosdagrocorat	WW	15-Jan-15	0.00
gedatolisib	WW	15-Jan-15	0.00
inotuzumab ozogamicin	WW	13-Oct-14	0.00
latanoprost	WW	13-Oct-14	497.00
linezolid	WW	15-Jan-15	1346.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	0.00
nonacog alfa	WW	15-Jan-15	865.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	0.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	0.00
palbociclib	WW	13-Oct-14	0.00
PF-04634817	WW	15-Jan-15	0.00
PF-06290510	WW	15-Jan-15	0.00
PF-4236921	WW	15-Jan-15	0.00
PF-547659	WW	15-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	306.00
ponezumab	WW	15-Jan-15	0.00
pregabalin	WW	15-Jan-15	5132.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	646.00
SAM-760	WW	15-Jan-15	0.00
sertraline	WW	15-Jan-15	413.00
sildenafil citrate	WW	15-Jan-15	277.00
sildenafil citrate	WW	15-Jan-15	1682.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	722.00
sunitinib	WW	15-Jan-15	1169.00

[Return to Table of Contents](#)



tolterodine	WW	15-Jan-15	148.00
venlafaxine hydrochloride	WW	15-Jan-15	356.00
voriconazole	WW	15-Jan-15	790.00
<b>Credit Suisse First Boston</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
gedatolisib	WW	08-Jan-15	0.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	0.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	0.00
PF-06290510	WW	08-Jan-15	0.00
Pprevnar	WW	21-Oct-14	250.00
<b>Atlantic Equities</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
amlodipine	WW	26-Jan-15	1111.00
atorvastatin	WW	26-Jan-15	4084.00
atorvastatin + amlodipine	WW - JP	26-Jan-15	203.00
axitinib	WW	26-Jan-15	413.00
azithromycin	WW	26-Jan-15	325.00
bazedoxifene + conjugated estrogens, Pfizer	WW	26-Jan-15	26.00
bosutinib	WW	26-Jan-15	88.00
celecoxib	WW	26-Jan-15	2595.00
CP 526555-18	WW	26-Jan-15	631.00
crizotinib	WW	26-Jan-15	448.00
desvenlafaxine	WW	26-Jan-15	745.00
doxazosin	WW	26-Jan-15	266.00
etanercept	WW - US	26-Jan-15	3871.00
exemestane	WW	26-Jan-15	154.00
latanoprost	WW	26-Jan-15	502.00
linezolid	WW	26-Jan-15	1363.00
nonacog alfa	WW	26-Jan-15	866.00
pantoprazole	US	26-Jan-15	182.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	26-Jan-15	305.00
pregabalin	WW	26-Jan-15	4709.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	26-Jan-15	653.00
sertraline	WW	26-Jan-15	421.00
sildenafil citrate	WW	26-Jan-15	284.00
sildenafil citrate	WW	26-Jan-15	1670.00
sirolimus	WW	26-Jan-15	364.00

[Return to Table of Contents](#)



somatropin (growth disorder), Pfizer	WW	26-Jan-15	729.00
sunitinib	WW	26-Jan-15	1175.00
taliglucerase alfa	WW	26-Jan-15	33.00
tigecycline	WW	26-Jan-15	325.00
tofacitinib (oral, inflammation), Pfizer	WW	26-Jan-15	311.00
tolterodine	WW	26-Jan-15	216.00
venlafaxine hydrochloride	WW	26-Jan-15	358.00
voriconazole	WW	26-Jan-15	788.00

## Suntrust Robinson Humphrey Capital Markets

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	255.00
amlodipine	WW	09-Nov-14	1118.00
atorvastatin	WW	09-Nov-14	2114.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	192.00
axitinib	WW	09-Nov-14	416.00
azithromycin	WW	09-Nov-14	320.00
bazedoxifene	WW	09-Nov-14	112.00
bococizumab	WW	09-Nov-14	0.00
celecoxib	WW	09-Nov-14	2847.00
CP 526555-18	WW	09-Nov-14	642.00
crizotinib	WW	22-Oct-14	452.00
dacomitinib	WW	09-Nov-14	0.00
dalteparin sodium	WW - US	09-Nov-14	365.00
desvenlafaxine	WW	09-Nov-14	745.00
doxazosin	WW	09-Nov-14	267.00
eletriptan	WW	09-Nov-14	381.00
eplerenone	WW	09-Nov-14	257.00
etanercept	WW - US	09-Nov-14	3888.00
fesoterodine fumarate	WW	09-Nov-14	289.00
fluconazole	WW	09-Nov-14	228.00
latanoprost	WW	09-Nov-14	507.00
linezolid	WW	09-Nov-14	1373.00
medroxyprogesterone	WW	09-Nov-14	200.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	0.00
nonacog alfa	WW	09-Nov-14	868.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	0.00
palbociclib	WW	27-Jan-15	0.00
pegvisomant	WW	09-Nov-14	234.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	310.00
pregabalin	WW	09-Nov-14	5245.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	659.00

[Return to Table of Contents](#)





sertraline	WW	09-Nov-14	424.00
sildenafil citrate	WW	09-Nov-14	279.00
sildenafil citrate	WW	09-Nov-14	1690.00
sirolimus	WW	09-Nov-14	366.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	725.00
sunitinib	WW	09-Nov-14	1178.00
tafamidis	WW	09-Nov-14	0.00
tigecycline	WW	09-Nov-14	325.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	309.00
venlafaxine hydrochloride	WW	09-Nov-14	363.00
voriconazole	WW	09-Nov-14	791.00

### Sanford C Bernstein and Co Inc

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Jan-15	1112.00
atorvastatin	WW	29-Jan-15	2062.00
axitinib	WW	29-Jan-15	410.00
azithromycin	WW	29-Jan-15	314.00
bococizumab	WW	29-Jan-15	0.00
celecoxib	WW	02-Dec-14	2706.00
CP 526555-18	WW	29-Jan-15	648.00
crizotinib	WW	29-Jan-15	438.00
desvenlafaxine	WW	29-Jan-15	736.00
eletriptan	WW	29-Jan-15	383.00
etanercept	WW - US	29-Jan-15	3850.00
linezolid	WW	29-Jan-15	1352.00
nonacog alfa	WW	02-Dec-14	857.00
palbociclib	WW	29-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	303.00
pregabalin	WW	29-Jan-15	5167.00
Prevnar 13	WW	29-Jan-15	4524.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	630.00
sertraline	WW	29-Jan-15	423.00
sildenafil citrate	WW	29-Jan-15	1140.00
sunitinib	WW	29-Jan-15	1174.00
tigecycline	WW	29-Jan-15	323.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	308.00
voriconazole	WW	29-Jan-15	755.00

[Return to Table of Contents](#)



## Undisclosed

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	29-Oct-14	296.00
alprazolam	WW	04-Feb-15	252.00
alprazolam	WW	13-Jan-15	255.00
amlodipine	WW	04-Feb-15	1112.00
amlodipine	WW	27-Oct-14	1148.00
amlodipine	WW	13-Jan-15	1105.00
amlodipine	WW	06-Jan-15	1096.00
amlodipine	WW	27-Jan-15	1112.00
anidulafungin	WW	13-Jan-15	150.00
anidulafungin	WW	04-Feb-15	139.00
atorvastatin	WW	28-Jan-15	2062.00
atorvastatin	WW	04-Feb-15	2062.00
atorvastatin	WW	15-Jan-15	1995.00
atorvastatin	WW	27-Oct-14	2026.00
atorvastatin	WW	27-Jan-15	2062.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	229.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	150.00
axitinib	WW	27-Jan-15	410.00
axitinib	WW	04-Feb-15	411.00
axitinib	WW	13-Jan-15	410.00
axitinib	WW	06-Jan-15	399.00
azithromycin	WW	06-Jan-15	312.00
azithromycin	WW	13-Jan-15	305.00
azithromycin	WW	04-Feb-15	313.00
bazedoxifene	WW	13-Jan-15	95.00
bazedoxifene + conjugated estrogens, Pfizer	WW	04-Feb-15	48.00
bococizumab	WW	28-Jan-15	0.00
bococizumab	WW	28-Jan-15	0.00
bosutinib	WW	28-Jan-15	0.00
bosutinib	WW	04-Feb-15	51.00
celecoxib	WW	28-Jan-15	2698.00
celecoxib	WW	28-Jan-15	2698.00
celecoxib	WW	27-Jan-15	2699.00
celecoxib	WW	15-Jan-15	2855.00
celecoxib	WW	27-Oct-14	2975.00
clindamycin	WW	04-Feb-15	195.00
clindamycin	WW	13-Jan-15	190.00
CP 526555-18	WW	04-Feb-15	647.00
CP 526555-18	WW	06-Jan-15	626.00
CP 526555-18	WW	27-Jan-15	648.00

[Return to Table of Contents](#)



CP 526555-18	WW	27-Oct-14	633.00
CP 526555-18	WW	15-Jan-15	635.00
crizotinib	WW	06-Jan-15	431.00
crizotinib	WW	04-Feb-15	439.00
crizotinib	WW	27-Jan-15	438.00
crizotinib	WW	13-Jan-15	430.00
dacomitinib	WW	13-Jan-15	0.00
dalteparin sodium	WW - US	28-Jan-15	74.00
desvenlafaxine	WW	13-Jan-15	735.00
desvenlafaxine	WW	04-Feb-15	737.00
desvenlafaxine	WW	27-Oct-14	751.00
desvenlafaxine	WW	27-Jan-15	736.00
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	130.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	113.50
dofetilide	WW	13-Jan-15	135.00
doxazosin	WW	04-Feb-15	262.00
doxazosin	WW	06-Jan-15	262.00
eletriptan	WW	04-Feb-15	382.00
eletriptan	WW	13-Jan-15	365.00
epirubicin	WW	13-Jan-15	90.00
eplerenone	WW	04-Feb-15	234.00
eplerenone	WW	13-Jan-15	250.00
ertugliflozin	JP	28-Oct-14	0.00
ertugliflozin	JP	04-Feb-15	0.00
etanercept	WW - US	27-Oct-14	3895.00
etanercept	WW - US	04-Feb-15	3850.00
etanercept	WW - US	28-Jan-15	3850.00
etanercept	WW - US	15-Jan-15	3825.00
etanercept	WW - US	27-Jan-15	3850.00
EXC-001	WW	13-Jan-15	0.00
exemestane	WW	13-Jan-15	150.00
exemestane	WW	04-Feb-15	177.00
fesoterodine fumarate	WW	04-Feb-15	288.00
fesoterodine fumarate	WW	13-Jan-15	280.00
fluconazole	WW	04-Feb-15	220.00
fluconazole	WW	13-Jan-15	210.00
fosdagrocorat	WW	13-Jan-15	0.00
gabapentin	WW	04-Feb-15	210.00
gabapentin	WW	13-Jan-15	205.00
gedatolisib	WW	13-Jan-15	0.00

[Return to Table of Contents](#)



inotuzumab ozogamicin	WW	04-Feb-15	0.00
inotuzumab ozogamicin	WW	13-Jan-15	0.00
irinotecan	WW	13-Jan-15	65.00
irinotecan	WW	04-Feb-15	47.00
lansoprazole	WW - US	13-Jan-15	10.00
latanoprost	WW	04-Feb-15	495.00
latanoprost	WW	06-Jan-15	494.00
latanoprost	WW	13-Jan-15	490.00
latanoprost	WW	27-Oct-14	499.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	30.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	15-Jan-15	1355.00
linezolid	WW	27-Jan-15	1352.00
linezolid	WW	28-Jan-15	1352.00
linezolid	WW	27-Oct-14	1347.00
linezolid	WW	04-Feb-15	1352.00
medroxyprogesterone	WW	13-Jan-15	200.00
meningococcal B rLP2086 vaccine, Pfizer	WW	06-Jan-15	0.00
metaxalone	US	04-Feb-15	76.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	29-Oct-14	68.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	60.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	0.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	29.40
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	0.00
nonacog alfa	WW	27-Jan-15	856.00
nonacog alfa	WW	25-Jan-15	848.00
nonacog alfa	WW	06-Jan-15	854.00
nonacog alfa	WW	13-Jan-15	860.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	0.00
palbociclib	WW	04-Feb-15	0.00
palbociclib	WW	27-Jan-15	0.00
palbociclib	WW	15-Jan-15	0.00
palbociclib	WW	28-Jan-15	0.00
pantoprazole	US	13-Jan-15	185.00
pantoprazole	US	04-Feb-15	50.00
parecoxib	WW	13-Jan-15	140.00
pegaptanib	WW - US	13-Jan-15	5.00
pegvisomant	WW	27-Jan-15	229.00
pegvisomant	WW	13-Jan-15	235.00

[Return to Table of Contents](#)



PF-04634817	WW	13-Jan-15	0.00
PF-04937319	WW	13-Jan-15	0.00
PF-06290510	WW	13-Jan-15	0.00
PF-2545920	WW	13-Jan-15	0.00
PF-4236921	WW	13-Jan-15	0.00
PF-489791	WW	13-Jan-15	0.00
PF-547659	WW	13-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	315.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	303.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	301.00
ponezumab	WW	13-Jan-15	0.00
pregabalin	WW	27-Jan-15	3533.00
pregabalin	WW	15-Jan-15	5120.00
pregabalin	WW	04-Feb-15	5167.00
pregabalin	WW	29-Jan-15	5167.00
pregabalin	WW	28-Jan-15	5167.00
Prevna 13	WW	15-Jan-15	4355.00
quinapril hydrochloride	WW	13-Jan-15	40.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	630.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	630.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	630.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	644.00
rivipansel sodium	WW	13-Jan-15	0.00
SAM-760	WW	13-Jan-15	0.00
sertraline	WW	06-Jan-15	418.00
sertraline	WW	04-Feb-15	424.00
sertraline	WW	13-Jan-15	425.00
sildenafil citrate	WW	13-Jan-15	280.00
sildenafil citrate	WW	04-Feb-15	276.00
sildenafil citrate	WW	15-Jan-15	1670.00
sildenafil citrate	WW	27-Jan-15	1140.00
sildenafil citrate	WW	27-Oct-14	1683.00
sildenafil citrate	WW	28-Jan-15	1685.00
sildenafil citrate	WW	04-Feb-15	1685.00
sirolimus	WW	06-Jan-15	366.00
sirolimus	WW	04-Feb-15	342.00
sirolimus	WW	13-Jan-15	350.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	723.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	720.00
somatropin (growth disorder), Pfizer	WW	27-Oct-14	729.00

[Return to Table of Contents](#)



somatropin (growth disorder), Pfizer	WW	27-Jan-15	723.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	709.00
sunitinib	WW	27-Oct-14	1176.00
sunitinib	WW	27-Jan-15	1174.00
sunitinib	WW	04-Feb-15	1174.00
sunitinib	WW	15-Jan-15	1175.00
sunitinib	WW	28-Jan-15	1174.00
taliglucerase alfa	WW	13-Jan-15	40.00
temsirolimus	WW	13-Jan-15	135.00
temsirolimus	WW	04-Feb-15	111.00
Thrombin-JMI	WW	13-Jan-15	90.00
tigecycline	WW	04-Feb-15	323.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	305.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	309.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	309.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	309.00
tolterodine	WW	04-Feb-15	220.00
tolterodine	WW	13-Jan-15	190.00
venlafaxine hydrochloride	WW	28-Jan-15	344.00
venlafaxine hydrochloride	WW	13-Jan-15	360.00
venlafaxine hydrochloride	WW	06-Jan-15	358.00
voriconazole	WW	27-Jan-15	755.00
voriconazole	WW	27-Oct-14	781.00
voriconazole	WW	06-Jan-15	766.00
voriconazole	WW	13-Jan-15	790.00
voriconazole	WW	04-Feb-15	755.00
zaleplon	US	23-Jan-15	0.60
ziprasidone	WW - JP	13-Jan-15	130.00
ziprasidone	WW - JP	04-Feb-15	76.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	1112.00
atorvastatin	WW	28-Jan-15	2062.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	180.00
axitinib	WW	28-Jan-15	410.00
azithromycin	WW	28-Jan-15	314.00
bosutinib	WW	28-Jan-15	43.00
celecoxib	WW	28-Jan-15	2699.00
CP 526555-18	WW	28-Jan-15	646.00
crizotinib	WW	28-Jan-15	438.00
dalteparin sodium	WW - US	16-Jan-15	265.00

[Return to Table of Contents](#)





desvenlafaxine	WW	28-Jan-15	737.00
doxazosin	WW	28-Jan-15	264.00
etanercept	WW - US	28-Jan-15	3850.00
exemestane	WW	28-Jan-15	169.00
inotuzumab ozogamicin	WW	16-Jan-15	0.00
latanoprost	WW	16-Jan-15	495.00
linezolid	WW	28-Jan-15	1351.00
nonacog alfa	WW	28-Jan-15	856.00
palbociclib	WW	28-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	16-Jan-15	310.00
pregabalin	WW	28-Jan-15	5168.00
Pprevnar 13	WW	16-Jan-15	4185.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	631.00
sertraline	WW	28-Jan-15	423.00
sildenafil citrate	WW	28-Jan-15	276.00
sildenafil citrate	WW	28-Jan-15	1685.00
sirolimus	WW	28-Jan-15	339.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	723.00
sunitinib	WW	28-Jan-15	1175.00
tigecycline	WW	28-Jan-15	323.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	309.00
tolterodine	WW	28-Jan-15	200.00
venlafaxine hydrochloride	WW	28-Jan-15	344.00
voriconazole	WW	28-Jan-15	755.00
ziprasidone	WW - JP	28-Jan-15	91.00

## 2015

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	54.40

### MKM Partners LLC

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Oct-14	999.00
atorvastatin	WW	29-Oct-14	1350.00
axitinib	WW	29-Oct-14	498.00
azithromycin	WW	29-Oct-14	319.00
bazedoxifene + conjugated estrogens, Pfizer	WW	29-Oct-14	40.00
bosutinib	WW	29-Oct-14	100.00

[Return to Table of Contents](#)



celecoxib	WW	29-Oct-14	1159.00
CP 526555-18	WW	29-Oct-14	647.00
crizotinib	WW	29-Oct-14	574.00
dacomitinib	WW	29-Oct-14	0.00
desvenlafaxine	WW	29-Oct-14	766.00
doxazosin	WW	29-Oct-14	238.00
etanercept	WW - US	29-Oct-14	3956.00
latanoprost	WW	29-Oct-14	456.00
linezolid	WW	29-Oct-14	1140.00
meningococcal B rLP2086 vaccine, Pfizer	WW	29-Oct-14	145.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	29-Oct-14	42.00
nonacog alfa	WW	29-Oct-14	818.00
palbociclib	WW	29-Oct-14	85.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Oct-14	289.00
pregabalin	WW	29-Oct-14	4473.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Oct-14	620.00
sertraline	WW	29-Oct-14	404.00
somatropin (growth disorder), Pfizer	WW	29-Oct-14	691.00
sunitinib	WW	29-Oct-14	1202.00
tafamidis	WW	29-Oct-14	20.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Oct-14	534.00
tolterodine	WW	29-Oct-14	140.00
venlafaxine hydrochloride	WW	29-Oct-14	289.00
voriconazole	WW	29-Oct-14	782.00

## Jefferies and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	989.00
atorvastatin	WW	15-Jan-15	1719.00
atorvastatin + amlodipine	WW - JP	13-Oct-14	122.00
axitinib	WW	15-Jan-15	465.00
azithromycin	WW	15-Jan-15	262.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	63.00
bococizumab	WW	13-Oct-14	0.00
bosutinib	WW	13-Oct-14	140.00
celecoxib	WW	13-Oct-14	1116.00
CP 526555-18	WW	15-Jan-15	608.00
crizotinib	WW	13-Oct-14	600.00
dacomitinib	WW	13-Oct-14	0.00
doxazosin	WW	13-Oct-14	231.00
ertugliflozin	JP	13-Oct-14	0.00
etanercept	WW - US	15-Jan-15	3605.00

[Return to Table of Contents](#)



EXC-001	WW	15-Jan-15	0.00
fosdagrocorat	WW	15-Jan-15	0.00
gedatolisib	WW	15-Jan-15	0.00
inotuzumab ozogamicin	WW	13-Oct-14	0.00
latanoprost	WW	13-Oct-14	402.00
linezolid	WW	15-Jan-15	880.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	0.00
nonacog alfa	WW	15-Jan-15	867.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	0.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	0.00
palbociclib	WW	13-Oct-14	500.00
PF-04634817	WW	15-Jan-15	0.00
PF-06290510	WW	15-Jan-15	0.00
PF-4236921	WW	15-Jan-15	0.00
PF-547659	WW	15-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	227.00
ponezumab	WW	15-Jan-15	0.00
pregabalin	WW	15-Jan-15	5359.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	629.00
SAM-760	WW	15-Jan-15	0.00
sertraline	WW	15-Jan-15	341.00
sildenafil citrate	WW	15-Jan-15	183.00
sildenafil citrate	WW	15-Jan-15	1576.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	655.00
sunitinib	WW	15-Jan-15	1054.00
tolterodine	WW	15-Jan-15	79.00
venlafaxine hydrochloride	WW	15-Jan-15	279.00
voriconazole	WW	15-Jan-15	745.00

### Credit Suisse First Boston

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
gedatolisib	WW	08-Jan-15	0.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	0.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	0.00
PF-06290510	WW	08-Jan-15	0.00
Prevnar	WW	21-Oct-14	245.00

[Return to Table of Contents](#)



## Atlantic Equities

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	26-Jan-15	946.00
atorvastatin	WW	26-Jan-15	1576.00
atorvastatin + amlodipine	WW - JP	26-Jan-15	192.00
axitinib	WW	26-Jan-15	504.00
azithromycin	WW	26-Jan-15	274.00
bazedoxifene + conjugated estrogens, Pfizer	WW	26-Jan-15	78.00
bosutinib	WW	26-Jan-15	164.00
celecoxib	WW	26-Jan-15	1070.00
CP 526555-18	WW	26-Jan-15	596.00
crizotinib	WW	26-Jan-15	586.00
desvenlafaxine	WW	26-Jan-15	768.00
doxazosin	WW	26-Jan-15	215.00
etanercept	WW - US	26-Jan-15	3542.00
exemestane	WW	26-Jan-15	124.00
latanoprost	WW	26-Jan-15	403.00
linezolid	WW	26-Jan-15	1024.00
nonacog alfa	WW	26-Jan-15	854.00
pantoprazole	US	26-Jan-15	176.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	26-Jan-15	252.00
pregabalin	WW	26-Jan-15	4337.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	26-Jan-15	634.00
sertraline	WW	26-Jan-15	374.00
sildenafil citrate	WW	26-Jan-15	249.00
sildenafil citrate	WW	26-Jan-15	1585.00
sirolimus	WW	26-Jan-15	276.00
somatropin (growth disorder), Pfizer	WW	26-Jan-15	678.00
sunitinib	WW	26-Jan-15	1080.00
taliglucerase alfa	WW	26-Jan-15	64.00
tigecycline	WW	26-Jan-15	299.00
tofacitinib (oral, inflammation), Pfizer	WW	26-Jan-15	564.00
tolterodine	WW	26-Jan-15	175.00
venlafaxine hydrochloride	WW	26-Jan-15	308.00
voriconazole	WW	26-Jan-15	731.00

[Return to Table of Contents](#)



## Suntrust Robinson Humphrey Capital Markets

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	230.00
amlodipine	WW	09-Nov-14	1022.00
atorvastatin	WW	09-Nov-14	1953.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	165.00
axitinib	WW	27-Jan-15	521.00
azithromycin	WW	09-Nov-14	320.00
bazedoxifene	WW	09-Nov-14	134.00
bococizumab	WW	09-Nov-14	0.00
celecoxib	WW	09-Nov-14	1581.00
CP 526555-18	WW	09-Nov-14	684.00
crizotinib	WW	27-Jan-15	574.00
dacomitinib	WW	27-Jan-15	15.00
dalteparin sodium	WW - US	09-Nov-14	373.00
desvenlafaxine	WW	09-Nov-14	764.00
doxazosin	WW	09-Nov-14	254.00
eletriptan	WW	09-Nov-14	379.00
eplerenone	WW	09-Nov-14	200.00
etanercept	WW - US	09-Nov-14	3108.00
fesoterodine fumarate	WW	09-Nov-14	319.00
fluconazole	WW	09-Nov-14	214.00
latanoprost	WW	09-Nov-14	449.00
linezolid	WW	09-Nov-14	1181.00
medroxyprogesterone	WW	09-Nov-14	255.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	100.00
nonacog alfa	WW	09-Nov-14	888.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	5.00
palbociclib	WW	27-Jan-15	140.00
pegvisomant	WW	09-Nov-14	249.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	273.00
pregabalin	WW	09-Nov-14	4206.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	697.00
sertraline	WW	09-Nov-14	397.00
sildenafil citrate	WW	09-Nov-14	225.00
sildenafil citrate	WW	09-Nov-14	1601.00
sirolimus	WW	09-Nov-14	200.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	675.00
sunitinib	WW	09-Nov-14	1064.00
tafamidis	WW	09-Nov-14	8.00
tigecycline	WW	09-Nov-14	319.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	512.00

[Return to Table of Contents](#)



venlafaxine hydrochloride	WW	09-Nov-14	289.00
voriconazole	WW	09-Nov-14	769.00
<b>Sanford C Bernstein and Co Inc</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
amlodipine	WW	29-Jan-15	1003.00
atorvastatin	WW	29-Jan-15	1759.00
axitinib	WW	29-Jan-15	476.00
azithromycin	WW	29-Jan-15	272.00
bococizumab	WW	29-Jan-15	0.00
celecoxib	WW	02-Dec-14	1059.00
CP 526555-18	WW	29-Jan-15	619.00
crizotinib	WW	29-Jan-15	497.00
desvenlafaxine	WW	29-Jan-15	746.00
eletriptan	WW	29-Jan-15	413.00
etanercept	WW - US	29-Jan-15	3635.00
linezolid	WW	29-Jan-15	1016.00
nonacog alfa	WW	02-Dec-14	868.00
palbociclib	WW	29-Jan-15	360.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	263.00
pregabalin	WW	29-Jan-15	4645.00
Prevnar 13	WW	29-Jan-15	4747.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	644.00
sertraline	WW	29-Jan-15	381.00
sildenafil citrate	WW	29-Jan-15	1115.00
sunitinib	WW	29-Jan-15	1067.00
tigecycline	WW	29-Jan-15	312.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	547.00
voriconazole	WW	29-Jan-15	752.00
<b>Undisclosed</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
alprazolam	WW	29-Oct-14	321.00
alprazolam	WW	13-Jan-15	235.00
alprazolam	WW	04-Feb-15	221.00
amlodipine	WW	27-Oct-14	1123.00
amlodipine	WW	04-Feb-15	1000.00
amlodipine	WW	27-Jan-15	1008.00
amlodipine	WW	13-Jan-15	1055.00

[Return to Table of Contents](#)



amlodipine	WW	06-Jan-15	1003.00
anidulafungin	WW	04-Feb-15	142.00
anidulafungin	WW	13-Jan-15	160.00
atorvastatin	WW	28-Jan-15	1777.00
atorvastatin	WW	04-Feb-15	1703.00
atorvastatin	WW	27-Oct-14	1917.00
atorvastatin	WW	15-Jan-15	1850.00
atorvastatin	WW	27-Jan-15	1769.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	232.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	125.00
axitinib	WW	13-Jan-15	580.00
axitinib	WW	27-Jan-15	522.00
axitinib	WW	04-Feb-15	435.00
axitinib	WW	06-Jan-15	487.00
azithromycin	WW	06-Jan-15	292.00
azithromycin	WW	13-Jan-15	285.00
azithromycin	WW	04-Feb-15	228.00
bazedoxifene	WW	13-Jan-15	105.00
bococizumab	WW	28-Jan-15	0.00
bococizumab	WW	28-Jan-15	0.00
bosutinib	WW	04-Feb-15	103.00
bosutinib	WW	28-Jan-15	225.00
celecoxib	WW	28-Jan-15	892.00
celecoxib	WW	15-Jan-15	1300.00
celecoxib	WW	28-Jan-15	913.00
celecoxib	WW	27-Jan-15	928.00
celecoxib	WW	27-Oct-14	994.00
clindamycin	WW	04-Feb-15	196.00
clindamycin	WW	13-Jan-15	180.00
CP 526555-18	WW	15-Jan-15	650.00
CP 526555-18	WW	27-Oct-14	640.00
CP 526555-18	WW	06-Jan-15	592.00
CP 526555-18	WW	04-Feb-15	688.00
CP 526555-18	WW	27-Jan-15	667.00
crizotinib	WW	04-Feb-15	520.00
crizotinib	WW	27-Jan-15	589.00
crizotinib	WW	06-Jan-15	575.00
crizotinib	WW	13-Jan-15	580.00
dacomitinib	WW	13-Jan-15	0.00
dalteparin sodium	WW - US	28-Jan-15	327.00

[Return to Table of Contents](#)





desvenlafaxine	WW	13-Jan-15	800.00
desvenlafaxine	WW	27-Jan-15	748.00
desvenlafaxine	WW	04-Feb-15	758.00
desvenlafaxine	WW	27-Oct-14	795.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	134.10
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	140.00
dofetilide	WW	13-Jan-15	150.00
doxazosin	WW	06-Jan-15	228.00
doxazosin	WW	04-Feb-15	229.00
eletriptan	WW	13-Jan-15	345.00
eletriptan	WW	04-Feb-15	388.00
epirubicin	WW	13-Jan-15	80.00
eplerenone	WW	04-Feb-15	239.00
eplerenone	WW	13-Jan-15	265.00
ertugliflozin	JP	04-Feb-15	0.00
ertugliflozin	JP	28-Oct-14	0.00
etanercept	WW - US	27-Jan-15	3713.00
etanercept	WW - US	04-Feb-15	3524.00
etanercept	WW - US	28-Jan-15	3505.00
etanercept	WW - US	27-Oct-14	4012.00
etanercept	WW - US	15-Jan-15	3820.00
EXC-001	WW	13-Jan-15	0.00
exemestane	WW	13-Jan-15	135.00
exemestane	WW	04-Feb-15	147.00
fesoterodine fumarate	WW	04-Feb-15	317.00
fesoterodine fumarate	WW	13-Jan-15	305.00
fluconazole	WW	04-Feb-15	189.00
fluconazole	WW	13-Jan-15	195.00
fosdagrocorat	WW	13-Jan-15	0.00
gabapentin	WW	13-Jan-15	175.00
gabapentin	WW	04-Feb-15	185.00
gedatolisib	WW	13-Jan-15	0.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
inotuzumab ozogamicin	WW	13-Jan-15	50.00
irinotecan	WW	13-Jan-15	45.00
irinotecan	WW	04-Feb-15	41.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	27-Oct-14	449.00
latanoprost	WW	04-Feb-15	376.00
latanoprost	WW	06-Jan-15	397.00

[Return to Table of Contents](#)



latanoprost	WW	13-Jan-15	425.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	35.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	04-Feb-15	932.00
linezolid	WW	15-Jan-15	980.00
linezolid	WW	27-Oct-14	1015.00
linezolid	WW	28-Jan-15	1063.00
linezolid	WW	27-Jan-15	919.00
medroxyprogesterone	WW	13-Jan-15	210.00
meningococcal B rLP2086 vaccine, Pfizer	WW	06-Jan-15	68.00
metaxalone	US	04-Feb-15	50.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	50.00
misoprostol + diclofenac (oral), Searle	WW	29-Oct-14	43.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	150.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	18.70
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	0.00
nonacog alfa	WW	25-Jan-15	755.00
nonacog alfa	WW	27-Jan-15	866.00
nonacog alfa	WW	13-Jan-15	745.00
nonacog alfa	WW	06-Jan-15	858.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	0.00
palbociclib	WW	27-Jan-15	200.00
palbociclib	WW	04-Feb-15	363.00
palbociclib	WW	28-Jan-15	350.00
palbociclib	WW	15-Jan-15	0.00
pantoprazole	US	04-Feb-15	153.00
pantoprazole	US	13-Jan-15	170.00
parecoxib	WW	13-Jan-15	150.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	27-Jan-15	188.00
pegvisomant	WW	13-Jan-15	255.00
PF-04634817	WW	13-Jan-15	0.00
PF-04937319	WW	13-Jan-15	0.00
PF-06290510	WW	13-Jan-15	0.00
PF-2545920	WW	13-Jan-15	0.00
PF-4236921	WW	13-Jan-15	0.00
PF-489791	WW	13-Jan-15	0.00
PF-547659	WW	13-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	269.00

[Return to Table of Contents](#)



piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	260.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	252.00
ponezumab	WW	13-Jan-15	0.00
pregabalin	WW	27-Jan-15	3711.00
pregabalin	WW	04-Feb-15	4000.00
pregabalin	WW	15-Jan-15	4360.00
pregabalin	WW	29-Jan-15	4705.00
pregabalin	WW	28-Jan-15	4356.00
Prevna 13	WW	28-Jan-15	5205.00
Prevna 13	WW	15-Jan-15	4730.00
quinapril hydrochloride	WW	13-Jan-15	30.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	585.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	661.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	649.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	558.00
rivipansel sodium	WW	13-Jan-15	0.00
SAM-760	WW	13-Jan-15	0.00
sertraline	WW	06-Jan-15	386.00
sertraline	WW	04-Feb-15	322.00
sertraline	WW	13-Jan-15	385.00
sildenafil citrate	WW	13-Jan-15	260.00
sildenafil citrate	WW	04-Feb-15	179.00
sildenafil citrate	WW	15-Jan-15	1590.00
sildenafil citrate	WW	27-Oct-14	1639.00
sildenafil citrate	WW	28-Jan-15	1590.00
sildenafil citrate	WW	27-Jan-15	1145.00
sildenafil citrate	WW	04-Feb-15	1604.00
sirolimus	WW	27-Jan-15	145.00
sirolimus	WW	13-Jan-15	285.00
sirolimus	WW	04-Feb-15	270.00
somatropin (growth disorder), Pfizer	WW	27-Jan-15	671.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	680.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	651.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	654.00
somatropin (growth disorder), Pfizer	WW	27-Oct-14	711.00
sunitinib	WW	28-Jan-15	1102.00
sunitinib	WW	27-Oct-14	1199.00
sunitinib	WW	27-Jan-15	1187.00
sunitinib	WW	15-Jan-15	1220.00
sunitinib	WW	04-Feb-15	1098.00

[Return to Table of Contents](#)



taliglucerase alfa	WW	13-Jan-15	60.00
temsirolimus	WW	04-Feb-15	79.00
temsirolimus	WW	13-Jan-15	145.00
Thrombin-JMI	WW	13-Jan-15	80.00
tigecycline	WW	04-Feb-15	325.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	526.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	522.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	600.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	510.00
tolterodine	WW	13-Jan-15	175.00
tolterodine	WW	04-Feb-15	135.00
venlafaxine hydrochloride	WW	06-Jan-15	312.00
venlafaxine hydrochloride	WW	13-Jan-15	325.00
venlafaxine hydrochloride	WW	28-Jan-15	300.00
voriconazole	WW	27-Jan-15	783.00
voriconazole	WW	27-Oct-14	780.00
voriconazole	WW	06-Jan-15	684.00
voriconazole	WW	13-Jan-15	790.00
voriconazole	WW	04-Feb-15	692.00
zaleplon	US	23-Jan-15	0.70
ziprasidone	WW - JP	04-Feb-15	90.00
ziprasidone	WW - JP	13-Jan-15	135.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	1024.00
atorvastatin	WW	28-Jan-15	1630.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	510.00
azithromycin	WW	28-Jan-15	272.00
bosutinib	WW	28-Jan-15	140.00
celecoxib	WW	28-Jan-15	1250.00
CP 526555-18	WW	28-Jan-15	635.00
crizotinib	WW	28-Jan-15	610.00
dalteparin sodium	WW - US	16-Jan-15	250.00
desvenlafaxine	WW	28-Jan-15	760.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	3700.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	5.00
latanoprost	WW	28-Jan-15	450.00
linezolid	WW	28-Jan-15	925.00

[Return to Table of Contents](#)



nonacog alfa	WW	28-Jan-15	805.00
palbociclib	WW	28-Jan-15	150.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	260.00
pregabalin	WW	28-Jan-15	4750.00
Prevnar 13	WW	16-Jan-15	4490.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	615.00
sertraline	WW	28-Jan-15	375.00
sildenafil citrate	WW	28-Jan-15	120.00
sildenafil citrate	WW	28-Jan-15	1595.00
sirolimus	WW	28-Jan-15	145.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	1160.00
tigecycline	WW	28-Jan-15	305.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	550.00
tolterodine	WW	28-Jan-15	110.00
venlafaxine hydrochloride	WW	28-Jan-15	245.00
voriconazole	WW	28-Jan-15	640.00
ziprasidone	WW - JP	28-Jan-15	70.00

## 2016

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	103.40

### MKM Partners LLC

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Oct-14	904.00
atorvastatin	WW	29-Oct-14	1012.00
axitinib	WW	29-Oct-14	538.00
azithromycin	WW	29-Oct-14	304.00
bazedoxifene + conjugated estrogens, Pfizer	WW	29-Oct-14	75.00
bosutinib	WW	29-Oct-14	135.00
celecoxib	WW	29-Oct-14	1010.00
CP 526555-18	WW	29-Oct-14	655.00
crizotinib	WW	29-Oct-14	718.00
dacomitinib	WW	29-Oct-14	75.00
desvenlafaxine	WW	29-Oct-14	793.00
doxazosin	WW	29-Oct-14	215.00
etanercept	WW - US	29-Oct-14	4075.00

[Return to Table of Contents](#)



latanoprost	WW	29-Oct-14	393.00
linezolid	WW	29-Oct-14	700.00
meningococcal B rLP2086 vaccine, Pfizer	WW	29-Oct-14	350.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	29-Oct-14	50.00
nonacog alfa	WW	29-Oct-14	778.00
palbociclib	WW	29-Oct-14	325.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Oct-14	267.00
pregabalin	WW	29-Oct-14	4145.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Oct-14	589.00
sertraline	WW	29-Oct-14	389.00
somatropin (growth disorder), Pfizer	WW	29-Oct-14	657.00
sunitinib	WW	29-Oct-14	1227.00
tafamidis	WW	29-Oct-14	25.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Oct-14	682.00
tolterodine	WW	29-Oct-14	114.00
venlafaxine hydrochloride	WW	29-Oct-14	152.00
voriconazole	WW	29-Oct-14	705.00

## Jefferies and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	885.00
atorvastatin	WW	15-Jan-15	1630.00
atorvastatin + amlodipine	WW - JP	13-Oct-14	104.00
axitinib	WW	15-Jan-15	524.00
azithromycin	WW	15-Jan-15	232.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	113.00
bococizumab	WW	13-Oct-14	0.00
bosutinib	WW	13-Oct-14	180.00
celecoxib	WW	13-Oct-14	821.00
CP 526555-18	WW	15-Jan-15	599.00
crizotinib	WW	13-Oct-14	720.00
dacomitinib	WW	13-Oct-14	0.00
doxazosin	WW	13-Oct-14	208.00
ertugliflozin	JP	13-Oct-14	0.00
etanercept	WW - US	15-Jan-15	3497.00
EXC-001	WW	15-Jan-15	0.00
fosdagrocorat	WW	15-Jan-15	0.00
gedatolisib	WW	15-Jan-15	0.00
inotuzumab ozogamicin	WW	13-Oct-14	33.00
latanoprost	WW	13-Oct-14	342.00
linezolid	WW	15-Jan-15	596.00
multipotent adult progenitor cell therapy (ischemia/cerebral	WW	15-Jan-15	0.00

[Return to Table of Contents](#)



palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	0.00
nonacog alfa	WW	15-Jan-15	910.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	98.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	32.00
palbociclib	WW	13-Oct-14	1500.00
PF-04634817	WW	15-Jan-15	0.00
PF-06290510	WW	15-Jan-15	0.00
PF-4236921	WW	15-Jan-15	0.00
PF-547659	WW	15-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	176.00
ponezumab	WW	15-Jan-15	0.00
pregabalin	WW	15-Jan-15	5693.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	654.00
SAM-760	WW	15-Jan-15	0.00
sertraline	WW	15-Jan-15	290.00
sildenafil citrate	WW	15-Jan-15	155.00
sildenafil citrate	WW	15-Jan-15	1478.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	635.00
sunitinib	WW	15-Jan-15	1001.00
tolterodine	WW	15-Jan-15	67.00
venlafaxine hydrochloride	WW	15-Jan-15	232.00
voriconazole	WW	15-Jan-15	665.00

### Credit Suisse First Boston

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
gedatolisib	WW	08-Jan-15	0.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	100.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	50.00
PF-06290510	WW	08-Jan-15	0.00
Pevnar	WW	21-Oct-14	240.00

### Atlantic Equities

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	26-Jan-15	907.00
atorvastatin	WW	26-Jan-15	1340.00
atorvastatin + amlodipine	WW - JP	26-Jan-15	181.00
axitinib	WW	26-Jan-15	586.00
azithromycin	WW	26-Jan-15	261.00
bazedoxifene + conjugated estrogens, Pfizer	WW	26-Jan-15	156.00

[Return to Table of Contents](#)





bosutinib	WW	26-Jan-15	232.00
celecoxib	WW	26-Jan-15	834.00
CP 526555-18	WW	26-Jan-15	588.00
crizotinib	WW	26-Jan-15	699.00
desvenlafaxine	WW	26-Jan-15	800.00
doxazosin	WW	26-Jan-15	205.00
etanercept	WW - US	26-Jan-15	3613.00
exemestane	WW	26-Jan-15	112.00
latanoprost	WW	26-Jan-15	304.00
linezolid	WW	26-Jan-15	653.00
nonacog alfa	WW	26-Jan-15	879.00
pantoprazole	US	26-Jan-15	171.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	26-Jan-15	240.00
pregabalin	WW	26-Jan-15	4396.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	26-Jan-15	650.00
sertraline	WW	26-Jan-15	368.00
sildenafil citrate	WW	26-Jan-15	183.00
sildenafil citrate	WW	26-Jan-15	1537.00
sirolimus	WW	26-Jan-15	238.00
somatropin (growth disorder), Pfizer	WW	26-Jan-15	681.00
sunitinib	WW	26-Jan-15	1069.00
taliglucerase alfa	WW	26-Jan-15	92.00
tigecycline	WW	26-Jan-15	296.00
tofacitinib (oral, inflammation), Pfizer	WW	26-Jan-15	879.00
tolterodine	WW	26-Jan-15	154.00
venlafaxine hydrochloride	WW	26-Jan-15	293.00
voriconazole	WW	26-Jan-15	554.00

## Suntrust Robinson Humphrey Capital Markets

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	216.00
amlodipine	WW	09-Nov-14	972.00
atorvastatin	WW	09-Nov-14	1870.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	147.00
axitinib	WW	27-Jan-15	640.00
azithromycin	WW	09-Nov-14	323.00
bazedoxifene	WW	09-Nov-14	158.00
bococizumab	WW	09-Nov-14	15.00
celecoxib	WW	09-Nov-14	1234.00
CP 526555-18	WW	09-Nov-14	681.00
crizotinib	WW	27-Jan-15	682.00
dacomitinib	WW	27-Jan-15	23.00

[Return to Table of Contents](#)



dalteparin sodium	WW - US	09-Nov-14	381.00
desvenlafaxine	WW	09-Nov-14	791.00
doxazosin	WW	09-Nov-14	241.00
eletriptan	WW	09-Nov-14	322.00
eplerenone	WW	09-Nov-14	155.00
etanercept	WW - US	09-Nov-14	2983.00
fesoterodine fumarate	WW	09-Nov-14	344.00
fluconazole	WW	09-Nov-14	204.00
latanoprost	WW	09-Nov-14	418.00
linezolid	WW	09-Nov-14	670.00
medroxyprogesterone	WW	09-Nov-14	293.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	165.00
nonacog alfa	WW	09-Nov-14	905.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	13.00
palbociclib	WW	27-Jan-15	450.00
pegvisomant	WW	09-Nov-14	262.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	245.00
pregabalin	WW	09-Nov-14	4070.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	735.00
sertraline	WW	09-Nov-14	377.00
sildenafil citrate	WW	09-Nov-14	189.00
sildenafil citrate	WW	09-Nov-14	1548.00
sirolimus	WW	09-Nov-14	139.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	640.00
sunitinib	WW	09-Nov-14	1010.00
tafamidis	WW	09-Nov-14	20.00
tigecycline	WW	09-Nov-14	273.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	790.00
venlafaxine hydrochloride	WW	09-Nov-14	253.00
voriconazole	WW	09-Nov-14	571.00

### Sanford C Bernstein and Co Inc

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Jan-15	908.00
atorvastatin	WW	29-Jan-15	1734.00
axitinib	WW	29-Jan-15	534.00
azithromycin	WW	29-Jan-15	256.00
bococizumab	WW	29-Jan-15	0.00
celecoxib	WW	02-Dec-14	945.00
CP 526555-18	WW	29-Jan-15	627.00
crizotinib	WW	29-Jan-15	503.00
desvenlafaxine	WW	29-Jan-15	780.00

[Return to Table of Contents](#)



eletriptan	WW	29-Jan-15	416.00
etanercept	WW - US	29-Jan-15	3426.00
linezolid	WW	29-Jan-15	455.00
nonacog alfa	WW	02-Dec-14	825.00
palbociclib	WW	29-Jan-15	1092.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	243.00
pregabalin	WW	29-Jan-15	4805.00
Pprevnar 13	WW	29-Jan-15	5122.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	669.00
sertraline	WW	29-Jan-15	332.00
sildenafil citrate	WW	29-Jan-15	1104.00
sunitinib	WW	29-Jan-15	1016.00
tigecycline	WW	29-Jan-15	246.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	797.00
voriconazole	WW	29-Jan-15	547.00

## Undisclosed

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	04-Feb-15	207.00
alprazolam	WW	29-Oct-14	349.00
alprazolam	WW	13-Jan-15	215.00
amlodipine	WW	06-Jan-15	984.00
amlodipine	WW	13-Jan-15	1005.00
amlodipine	WW	27-Jan-15	995.00
amlodipine	WW	04-Feb-15	950.00
anidulafungin	WW	13-Jan-15	170.00
anidulafungin	WW	04-Feb-15	146.00
atorvastatin	WW	27-Jan-15	1753.00
atorvastatin	WW	15-Jan-15	1820.00
atorvastatin	WW	28-Jan-15	1710.00
atorvastatin	WW	04-Feb-15	1575.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	222.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	100.00
axitinib	WW	06-Jan-15	540.00
axitinib	WW	27-Jan-15	678.00
axitinib	WW	04-Feb-15	515.00
axitinib	WW	13-Jan-15	740.00
azithromycin	WW	13-Jan-15	275.00
azithromycin	WW	06-Jan-15	292.00
azithromycin	WW	04-Feb-15	190.00
bazedoxifene	WW	13-Jan-15	115.00
bococizumab	WW	28-Jan-15	0.00

[Return to Table of Contents](#)



bococizumab	WW	28-Jan-15	0.00
bosutinib	WW	28-Jan-15	275.00
bosutinib	WW	04-Feb-15	114.00
celecoxib	WW	28-Jan-15	835.00
celecoxib	WW	15-Jan-15	1005.00
celecoxib	WW	27-Jan-15	913.00
celecoxib	WW	28-Jan-15	641.00
clindamycin	WW	13-Jan-15	165.00
clindamycin	WW	04-Feb-15	192.00
CP 526555-18	WW	04-Feb-15	697.00
CP 526555-18	WW	27-Jan-15	668.00
CP 526555-18	WW	15-Jan-15	645.00
CP 526555-18	WW	06-Jan-15	581.00
crizotinib	WW	13-Jan-15	740.00
crizotinib	WW	06-Jan-15	700.00
crizotinib	WW	04-Feb-15	612.00
crizotinib	WW	27-Jan-15	697.00
dacomitinib	WW	13-Jan-15	0.00
dalteparin sodium	WW - US	28-Jan-15	311.00
desvenlafaxine	WW	04-Feb-15	764.00
desvenlafaxine	WW	27-Jan-15	325.00
desvenlafaxine	WW	13-Jan-15	870.00
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	150.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	161.40
dofetilide	WW	13-Jan-15	160.00
doxazosin	WW	04-Feb-15	213.00
doxazosin	WW	06-Jan-15	210.00
eletriptan	WW	04-Feb-15	379.00
eletriptan	WW	13-Jan-15	325.00
epirubicin	WW	13-Jan-15	70.00
eplerenone	WW	04-Feb-15	235.00
eplerenone	WW	13-Jan-15	285.00
ertugliflozin	JP	04-Feb-15	0.00
ertugliflozin	JP	28-Oct-14	53.00
etanercept	WW - US	04-Feb-15	3358.00
etanercept	WW - US	28-Jan-15	3505.00
etanercept	WW - US	15-Jan-15	3965.00
etanercept	WW - US	27-Jan-15	3570.00
EXC-001	WW	13-Jan-15	0.00
exemestane	WW	04-Feb-15	115.00

[Return to Table of Contents](#)



exemestane	WW	13-Jan-15	135.00
fesoterodine fumarate	WW	13-Jan-15	330.00
fesoterodine fumarate	WW	04-Feb-15	343.00
fluconazole	WW	04-Feb-15	165.00
fluconazole	WW	13-Jan-15	180.00
fosdagrocorat	WW	13-Jan-15	0.00
gabapentin	WW	13-Jan-15	155.00
gabapentin	WW	04-Feb-15	161.00
gedatolisib	WW	13-Jan-15	0.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
inotuzumab ozogamicin	WW	13-Jan-15	100.00
irinotecan	WW	04-Feb-15	37.00
irinotecan	WW	13-Jan-15	25.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	04-Feb-15	332.00
latanoprost	WW	13-Jan-15	360.00
latanoprost	WW	06-Jan-15	353.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	40.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	27-Jan-15	769.00
linezolid	WW	15-Jan-15	505.00
linezolid	WW	04-Feb-15	389.00
linezolid	WW	28-Jan-15	356.00
medroxyprogesterone	WW	13-Jan-15	220.00
meningococcal B rLP2086 vaccine, Pfizer	WW	06-Jan-15	136.00
metaxalone	US	04-Feb-15	25.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	29-Oct-14	39.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	40.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	200.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	19.20
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	0.00
nonacog alfa	WW	13-Jan-15	665.00
nonacog alfa	WW	25-Jan-15	703.00
nonacog alfa	WW	27-Jan-15	866.00
nonacog alfa	WW	06-Jan-15	892.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	25.00
palbociclib	WW	15-Jan-15	250.00
palbociclib	WW	04-Feb-15	1445.00
palbociclib	WW	28-Jan-15	1250.00

[Return to Table of Contents](#)



palbociclib	WW	27-Jan-15	800.00
pantoprazole	US	04-Feb-15	127.00
pantoprazole	US	13-Jan-15	155.00
parecoxib	WW	13-Jan-15	160.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	13-Jan-15	275.00
pegvisomant	WW	27-Jan-15	129.00
PF-04634817	WW	13-Jan-15	0.00
PF-04937319	WW	13-Jan-15	0.00
PF-06290510	WW	13-Jan-15	0.00
PF-2545920	WW	13-Jan-15	0.00
PF-4236921	WW	13-Jan-15	0.00
PF-489791	WW	13-Jan-15	0.00
PF-547659	WW	13-Jan-15	0.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	199.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	261.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	230.00
ponezumab	WW	13-Jan-15	0.00
pregabalin	WW	28-Jan-15	4336.00
pregabalin	WW	15-Jan-15	4300.00
pregabalin	WW	04-Feb-15	3985.00
pregabalin	WW	27-Jan-15	3932.00
pregabalin	WW	29-Jan-15	4761.00
Prevnar 13	WW	28-Jan-15	5378.00
Prevnar 13	WW	15-Jan-15	5100.00
quinapril hydrochloride	WW	13-Jan-15	20.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	720.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	513.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	540.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	671.00
rivipansel sodium	WW	13-Jan-15	0.00
SAM-760	WW	13-Jan-15	0.00
sertraline	WW	06-Jan-15	384.00
sertraline	WW	04-Feb-15	301.00
sertraline	WW	13-Jan-15	355.00
sildenafil citrate	WW	04-Feb-15	132.00
sildenafil citrate	WW	13-Jan-15	245.00
sildenafil citrate	WW	04-Feb-15	1573.00
sildenafil citrate	WW	28-Jan-15	1583.00
sildenafil citrate	WW	27-Jan-15	1145.00

[Return to Table of Contents](#)



sildenafil citrate	WW	15-Jan-15	1490.00
sirolimus	WW	04-Feb-15	232.00
sirolimus	WW	27-Jan-15	137.00
sirolimus	WW	13-Jan-15	230.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	660.00
somatropin (growth disorder), Pfizer	WW	27-Jan-15	671.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	620.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	613.00
sunitinib	WW	27-Jan-15	1179.00
sunitinib	WW	15-Jan-15	1290.00
sunitinib	WW	04-Feb-15	1073.00
sunitinib	WW	28-Jan-15	1102.00
taliglucerase alfa	WW	13-Jan-15	80.00
temsirolimus	WW	04-Feb-15	57.00
temsirolimus	WW	13-Jan-15	155.00
Thrombin-JMI	WW	13-Jan-15	70.00
tigecycline	WW	04-Feb-15	265.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	896.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	680.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	685.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	975.00
tolterodine	WW	13-Jan-15	180.00
tolterodine	WW	04-Feb-15	122.00
venlafaxine hydrochloride	WW	28-Jan-15	248.00
venlafaxine hydrochloride	WW	06-Jan-15	293.00
venlafaxine hydrochloride	WW	13-Jan-15	290.00
voriconazole	WW	04-Feb-15	494.00
voriconazole	WW	27-Jan-15	746.00
voriconazole	WW	06-Jan-15	458.00
voriconazole	WW	13-Jan-15	610.00
zaleplon	US	23-Jan-15	0.70
ziprasidone	WW - JP	04-Feb-15	90.00
ziprasidone	WW - JP	13-Jan-15	135.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	1004.00
atorvastatin	WW	28-Jan-15	1545.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	600.00
azithromycin	WW	28-Jan-15	252.00
bosutinib	WW	28-Jan-15	170.00

[Return to Table of Contents](#)



celecoxib	WW	28-Jan-15	750.00
CP 526555-18	WW	28-Jan-15	655.00
crizotinib	WW	28-Jan-15	800.00
dalteparin sodium	WW - US	16-Jan-15	250.00
desvenlafaxine	WW	28-Jan-15	795.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	3800.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	25.00
latanoprost	WW	28-Jan-15	410.00
linezolid	WW	28-Jan-15	600.00
nonacog alfa	WW	28-Jan-15	730.00
palbociclib	WW	28-Jan-15	850.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	230.00
pregabalin	WW	28-Jan-15	4650.00
Prevnar 13	WW	16-Jan-15	4835.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	605.00
sertraline	WW	28-Jan-15	330.00
sildenafil citrate	WW	28-Jan-15	85.00
sildenafil citrate	WW	28-Jan-15	1600.00
sirolimus	WW	28-Jan-15	120.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	1145.00
tigecycline	WW	28-Jan-15	290.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	850.00
tolterodine	WW	28-Jan-15	85.00
venlafaxine hydrochloride	WW	28-Jan-15	210.00
voriconazole	WW	28-Jan-15	620.00
ziprasidone	WW - JP	28-Jan-15	60.00

## 2017

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	149.90

### MKM Partners LLC

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Oct-14	820.00
atorvastatin	WW	29-Oct-14	759.00

[Return to Table of Contents](#)





axitinib	WW	29-Oct-14	565.00
azithromycin	WW	29-Oct-14	290.00
bazedoxifene + conjugated estrogens, Pfizer	WW	29-Oct-14	83.00
bosutinib	WW	29-Oct-14	169.00
celecoxib	WW	29-Oct-14	883.00
CP 526555-18	WW	29-Oct-14	663.00
crizotinib	WW	29-Oct-14	789.00
dacomitinib	WW	29-Oct-14	225.00
desvenlafaxine	WW	29-Oct-14	821.00
doxazosin	WW	29-Oct-14	194.00
etanercept	WW - US	29-Oct-14	4197.00
latanoprost	WW	29-Oct-14	354.00
linezolid	WW	29-Oct-14	627.00
meningococcal B rLP2086 vaccine, Pfizer	WW	29-Oct-14	600.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	29-Oct-14	75.00
nonacog alfa	WW	29-Oct-14	739.00
palbociclib	WW	29-Oct-14	475.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Oct-14	247.00
pregabalin	WW	29-Oct-14	3900.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Oct-14	560.00
sertraline	WW	29-Oct-14	375.00
somatropin (growth disorder), Pfizer	WW	29-Oct-14	624.00
sunitinib	WW	29-Oct-14	1254.00
tafamidis	WW	29-Oct-14	28.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Oct-14	865.00
tolterodine	WW	29-Oct-14	108.00
venlafaxine hydrochloride	WW	29-Oct-14	121.00
voriconazole	WW	29-Oct-14	670.00

## Jefferies and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	794.00
atorvastatin	WW	15-Jan-15	1524.00
atorvastatin + amlodipine	WW - JP	13-Oct-14	88.00
axitinib	WW	15-Jan-15	574.00
azithromycin	WW	15-Jan-15	199.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	163.00
bococizumab	WW	13-Oct-14	0.00
bosutinib	WW	13-Oct-14	200.00
celecoxib	WW	13-Oct-14	739.00
CP 526555-18	WW	15-Jan-15	559.00
crizotinib	WW	13-Oct-14	828.00

[Return to Table of Contents](#)



dacomitinib	WW	13-Oct-14	65.00
doxazosin	WW	13-Oct-14	187.00
ertugliflozin	JP	13-Oct-14	98.00
etanercept	WW - US	15-Jan-15	3322.00
EXC-001	WW	15-Jan-15	19.00
fosdagrocorat	WW	15-Jan-15	38.00
gedatolisib	WW	15-Jan-15	19.00
inotuzumab ozogamicin	WW	13-Oct-14	98.00
latanoprost	WW	13-Oct-14	291.00
linezolid	WW	15-Jan-15	501.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	38.00
nonacog alfa	WW	15-Jan-15	955.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	163.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	85.00
palbociclib	WW	13-Oct-14	2500.00
PF-04634817	WW	15-Jan-15	38.00
PF-06290510	WW	15-Jan-15	19.00
PF-4236921	WW	15-Jan-15	38.00
PF-547659	WW	15-Jan-15	38.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	137.00
ponezumab	WW	15-Jan-15	0.00
pregabalin	WW	15-Jan-15	5906.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	677.00
SAM-760	WW	15-Jan-15	0.00
sertraline	WW	15-Jan-15	246.00
sildenafil citrate	WW	15-Jan-15	132.00
sildenafil citrate	WW	15-Jan-15	1313.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	616.00
sunitinib	WW	15-Jan-15	951.00
tolterodine	WW	15-Jan-15	57.00
venlafaxine hydrochloride	WW	15-Jan-15	193.00
voriconazole	WW	15-Jan-15	562.00

### Credit Suisse First Boston

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
gedatolisib	WW	08-Jan-15	0.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	125.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	100.00
PF-06290510	WW	08-Jan-15	0.00
Prevnar	WW	21-Oct-14	235.00

[Return to Table of Contents](#)



## Atlantic Equities

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	26-Jan-15	868.00
atorvastatin	WW	26-Jan-15	1206.00
atorvastatin + amlodipine	WW - JP	26-Jan-15	172.00
axitinib	WW	26-Jan-15	663.00
azithromycin	WW	26-Jan-15	248.00
bazedoxifene + conjugated estrogens, Pfizer	WW	26-Jan-15	234.00
bosutinib	WW	26-Jan-15	279.00
celecoxib	WW	26-Jan-15	825.00
CP 526555-18	WW	26-Jan-15	580.00
crizotinib	WW	26-Jan-15	781.00
desvenlafaxine	WW	26-Jan-15	832.00
doxazosin	WW	26-Jan-15	194.00
etanercept	WW - US	26-Jan-15	3685.00
exemestane	WW	26-Jan-15	101.00
latanoprost	WW	26-Jan-15	287.00
linezolid	WW	26-Jan-15	539.00
nonacog alfa	WW	26-Jan-15	897.00
pantoprazole	US	26-Jan-15	166.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	26-Jan-15	228.00
pregabalin	WW	26-Jan-15	4537.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	26-Jan-15	664.00
sertraline	WW	26-Jan-15	362.00
sildenafil citrate	WW	26-Jan-15	151.00
sildenafil citrate	WW	26-Jan-15	1514.00
sirolimus	WW	26-Jan-15	214.00
somatropin (growth disorder), Pfizer	WW	26-Jan-15	685.00
sunitinib	WW	26-Jan-15	1055.00
taliglucerase alfa	WW	26-Jan-15	111.00
tigecycline	WW	26-Jan-15	245.00
tofacitinib (oral, inflammation), Pfizer	WW	26-Jan-15	1282.00
tolterodine	WW	26-Jan-15	141.00
venlafaxine hydrochloride	WW	26-Jan-15	278.00
voriconazole	WW	26-Jan-15	448.00

[Return to Table of Contents](#)



## Suntrust Robinson Humphrey Capital Markets

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	203.00
amlodipine	WW	09-Nov-14	929.00
atorvastatin	WW	09-Nov-14	1792.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	137.00
axitinib	WW	27-Jan-15	765.00
azithromycin	WW	09-Nov-14	329.00
bazedoxifene	WW	09-Nov-14	182.00
bococizumab	WW	09-Nov-14	65.00
celecoxib	WW	09-Nov-14	1152.00
CP 526555-18	WW	09-Nov-14	680.00
crizotinib	WW	27-Jan-15	793.00
dacomitinib	WW	27-Jan-15	30.00
dalteparin sodium	WW - US	09-Nov-14	389.00
desvenlafaxine	WW	09-Nov-14	813.00
doxazosin	WW	09-Nov-14	229.00
eletriptan	WW	09-Nov-14	122.00
eplerenone	WW	09-Nov-14	123.00
etanercept	WW - US	09-Nov-14	2850.00
fesoterodine fumarate	WW	09-Nov-14	369.00
fluconazole	WW	09-Nov-14	195.00
latanoprost	WW	09-Nov-14	391.00
linezolid	WW	09-Nov-14	520.00
medroxyprogesterone	WW	09-Nov-14	328.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	268.00
nonacog alfa	WW	09-Nov-14	915.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	20.00
palbociclib	WW	27-Jan-15	810.00
pegvisomant	WW	09-Nov-14	274.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	227.00
pregabalin	WW	09-Nov-14	4152.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	774.00
sertraline	WW	09-Nov-14	361.00
sildenafil citrate	WW	09-Nov-14	162.00
sildenafil citrate	WW	09-Nov-14	1463.00
sirolimus	WW	09-Nov-14	113.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	611.00
sunitinib	WW	09-Nov-14	942.00
tafamidis	WW	09-Nov-14	32.00
tigecycline	WW	09-Nov-14	237.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	1138.00

[Return to Table of Contents](#)



venlafaxine hydrochloride	WW	09-Nov-14	228.00
voriconazole	WW	09-Nov-14	466.00
<b>Sanford C Bernstein and Co Inc</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
amlodipine	WW	29-Jan-15	837.00
atorvastatin	WW	29-Jan-15	1629.00
axitinib	WW	29-Jan-15	572.00
azithromycin	WW	29-Jan-15	241.00
bococizumab	WW	29-Jan-15	90.00
celecoxib	WW	02-Dec-14	921.00
CP 526555-18	WW	29-Jan-15	632.00
crizotinib	WW	29-Jan-15	487.00
desvenlafaxine	WW	29-Jan-15	812.00
eletriptan	WW	29-Jan-15	142.00
etanercept	WW - US	29-Jan-15	3088.00
linezolid	WW	29-Jan-15	426.00
nonacog alfa	WW	02-Dec-14	778.00
palbociclib	WW	29-Jan-15	1736.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	230.00
pregabalin	WW	29-Jan-15	5079.00
Prevnar 13	WW	29-Jan-15	5445.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	651.00
sertraline	WW	29-Jan-15	301.00
sildenafil citrate	WW	29-Jan-15	1093.00
sunitinib	WW	29-Jan-15	941.00
tigecycline	WW	29-Jan-15	187.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	950.00
voriconazole	WW	29-Jan-15	509.00
<b>Undisclosed</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
alprazolam	WW	13-Jan-15	195.00
alprazolam	WW	29-Oct-14	379.00
alprazolam	WW	04-Feb-15	197.00
amlodipine	WW	27-Jan-15	999.00
amlodipine	WW	13-Jan-15	965.00
amlodipine	WW	04-Feb-15	916.00
amlodipine	WW	06-Jan-15	965.00

[Return to Table of Contents](#)



anidulafungin	WW	13-Jan-15	180.00
anidulafungin	WW	04-Feb-15	150.00
atorvastatin	WW	04-Feb-15	1549.00
atorvastatin	WW	27-Jan-15	1754.00
atorvastatin	WW	28-Jan-15	1710.00
atorvastatin	WW	15-Jan-15	1800.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	211.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	80.00
axitinib	WW	06-Jan-15	567.00
axitinib	WW	13-Jan-15	850.00
axitinib	WW	04-Feb-15	553.00
axitinib	WW	27-Jan-15	862.00
azithromycin	WW	13-Jan-15	265.00
azithromycin	WW	04-Feb-15	161.00
azithromycin	WW	06-Jan-15	292.00
bazedoxifene	WW	13-Jan-15	125.00
bococizumab	WW	28-Jan-15	0.00
bococizumab	WW	28-Jan-15	0.00
bosutinib	WW	28-Jan-15	325.00
bosutinib	WW	04-Feb-15	126.00
celecoxib	WW	15-Jan-15	975.00
celecoxib	WW	28-Jan-15	603.00
celecoxib	WW	27-Jan-15	904.00
celecoxib	WW	28-Jan-15	835.00
clindamycin	WW	13-Jan-15	150.00
clindamycin	WW	04-Feb-15	188.00
CP 526555-18	WW	04-Feb-15	699.00
CP 526555-18	WW	27-Jan-15	663.00
CP 526555-18	WW	06-Jan-15	581.00
CP 526555-18	WW	15-Jan-15	650.00
crizotinib	WW	27-Jan-15	785.00
crizotinib	WW	13-Jan-15	850.00
crizotinib	WW	06-Jan-15	750.00
crizotinib	WW	04-Feb-15	710.00
dacomitinib	WW	13-Jan-15	25.00
desvenlafaxine	WW	27-Jan-15	443.00
desvenlafaxine	WW	04-Feb-15	763.00
desvenlafaxine	WW	13-Jan-15	940.00
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	160.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	166.30

[Return to Table of Contents](#)



dofetilide	WW	13-Jan-15	170.00
doxazosin	WW	06-Jan-15	193.00
doxazosin	WW	04-Feb-15	197.00
eletriptan	WW	04-Feb-15	370.00
eletriptan	WW	13-Jan-15	305.00
epirubicin	WW	13-Jan-15	60.00
eplerenone	WW	13-Jan-15	305.00
ertugliflozin	JP	28-Oct-14	105.00
ertugliflozin	JP	04-Feb-15	210.00
etanercept	WW - US	15-Jan-15	4085.00
etanercept	WW - US	04-Feb-15	3230.00
etanercept	WW - US	27-Jan-15	3435.00
etanercept	WW - US	28-Jan-15	3435.00
EXC-001	WW	13-Jan-15	25.00
exemestane	WW	13-Jan-15	140.00
exemestane	WW	04-Feb-15	88.00
fesoterodine fumarate	WW	13-Jan-15	350.00
fesoterodine fumarate	WW	04-Feb-15	364.00
fluconazole	WW	13-Jan-15	165.00
fluconazole	WW	04-Feb-15	138.00
fosdagrocorat	WW	13-Jan-15	25.00
gabapentin	WW	04-Feb-15	129.00
gabapentin	WW	13-Jan-15	135.00
gedatolisib	WW	13-Jan-15	25.00
inotuzumab ozogamicin	WW	13-Jan-15	150.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
irinotecan	WW	04-Feb-15	33.00
irinotecan	WW	13-Jan-15	15.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	04-Feb-15	297.00
latanoprost	WW	13-Jan-15	300.00
latanoprost	WW	06-Jan-15	334.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	45.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	04-Feb-15	327.00
linezolid	WW	15-Jan-15	410.00
linezolid	WW	27-Jan-15	764.00
linezolid	WW	28-Jan-15	225.00
medroxyprogesterone	WW	13-Jan-15	230.00
meningococcal B rLP2086 vaccine, Pfizer	WW	06-Jan-15	238.00

[Return to Table of Contents](#)



miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	30.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	250.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	18.20
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	25.00
nonacog alfa	WW	27-Jan-15	866.00
nonacog alfa	WW	06-Jan-15	905.00
nonacog alfa	WW	25-Jan-15	672.00
nonacog alfa	WW	13-Jan-15	575.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	50.00
palbociclib	WW	04-Feb-15	3082.00
palbociclib	WW	28-Jan-15	1750.00
palbociclib	WW	15-Jan-15	500.00
palbociclib	WW	27-Jan-15	1464.00
pantoprazole	US	13-Jan-15	140.00
pantoprazole	US	04-Feb-15	106.00
parecoxib	WW	13-Jan-15	170.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	27-Jan-15	97.00
pegvisomant	WW	13-Jan-15	295.00
PF-04634817	WW	13-Jan-15	25.00
PF-04937319	WW	13-Jan-15	10.00
PF-06290510	WW	13-Jan-15	25.00
PF-2545920	WW	13-Jan-15	25.00
PF-4236921	WW	13-Jan-15	25.00
PF-489791	WW	13-Jan-15	25.00
PF-547659	WW	13-Jan-15	25.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	261.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	155.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	200.00
ponezumab	WW	13-Jan-15	25.00
pregabalin	WW	28-Jan-15	4566.00
pregabalin	WW	29-Jan-15	4865.00
pregabalin	WW	15-Jan-15	4655.00
pregabalin	WW	04-Feb-15	3965.00
pregabalin	WW	27-Jan-15	4090.00
Prevnar 13	WW	15-Jan-15	5470.00
Prevnar 13	WW	28-Jan-15	5538.00
quinapril hydrochloride	WW	13-Jan-15	10.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	789.00

[Return to Table of Contents](#)





recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	482.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	495.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	671.00
rivipansel sodium	WW	13-Jan-15	25.00
SAM-760	WW	13-Jan-15	25.00
sertraline	WW	04-Feb-15	285.00
sertraline	WW	13-Jan-15	325.00
sertraline	WW	06-Jan-15	381.00
sildenafil citrate	WW	13-Jan-15	230.00
sildenafil citrate	WW	04-Feb-15	125.00
sildenafil citrate	WW	06-Jan-15	1570.00
sildenafil citrate	WW	15-Jan-15	1390.00
sildenafil citrate	WW	28-Jan-15	1383.00
sildenafil citrate	WW	04-Feb-15	1477.00
sirolimus	WW	04-Feb-15	195.00
sirolimus	WW	13-Jan-15	175.00
sirolimus	WW	27-Jan-15	133.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	606.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	576.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	640.00
somatropin (growth disorder), Pfizer	WW	27-Jan-15	671.00
sunitinib	WW	28-Jan-15	1058.00
sunitinib	WW	04-Feb-15	1049.00
sunitinib	WW	15-Jan-15	1360.00
sunitinib	WW	27-Jan-15	1174.00
taliglucerase alfa	WW	13-Jan-15	100.00
temsirolimus	WW	13-Jan-15	165.00
temsirolimus	WW	04-Feb-15	45.00
Thrombin-JMI	WW	13-Jan-15	60.00
tigecycline	WW	04-Feb-15	236.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	900.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	1325.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1250.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	871.00
tolterodine	WW	13-Jan-15	190.00
tolterodine	WW	04-Feb-15	116.00
venlafaxine hydrochloride	WW	13-Jan-15	255.00
venlafaxine hydrochloride	WW	06-Jan-15	277.00
venlafaxine hydrochloride	WW	28-Jan-15	134.00
voriconazole	WW	13-Jan-15	595.00

[Return to Table of Contents](#)



voriconazole	WW	27-Jan-15	730.00
voriconazole	WW	04-Feb-15	409.00
voriconazole	WW	06-Jan-15	311.00
zaleplon	US	23-Jan-15	0.70
ziprasidone	WW - JP	04-Feb-15	90.00
ziprasidone	WW - JP	13-Jan-15	145.00
<b>Leerink Swann</b>			
<b>Drug Details</b>			
Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	979.00
atorvastatin	WW	28-Jan-15	1425.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	680.00
azithromycin	WW	28-Jan-15	227.00
bosutinib	WW	28-Jan-15	195.00
celecoxib	WW	28-Jan-15	650.00
CP 526555-18	WW	28-Jan-15	675.00
crizotinib	WW	28-Jan-15	1000.00
dalteparin sodium	WW - US	16-Jan-15	250.00
desvenlafaxine	WW	28-Jan-15	820.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	3900.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	50.00
latanoprost	WW	28-Jan-15	405.00
linezolid	WW	28-Jan-15	430.00
nonacog alfa	WW	28-Jan-15	605.00
palbociclib	WW	28-Jan-15	2000.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	165.00
pregabalin	WW	28-Jan-15	4725.00
Pprevnar 13	WW	16-Jan-15	5190.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	605.00
sertraline	WW	28-Jan-15	300.00
sildenafil citrate	WW	28-Jan-15	70.00
sildenafil citrate	WW	28-Jan-15	1625.00
sirolimus	WW	28-Jan-15	105.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	1105.00
tigecycline	WW	28-Jan-15	255.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1200.00
tolterodine	WW	28-Jan-15	75.00
venlafaxine hydrochloride	WW	28-Jan-15	175.00

[Return to Table of Contents](#)



voriconazole	WW	28-Jan-15	620.00
ziprasidone	WW - JP	28-Jan-15	60.00

## 2018

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	194.80

### MKM Partners LLC

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Oct-14	744.00
atorvastatin	WW	29-Oct-14	569.00
axitinib	WW	29-Oct-14	593.00
azithromycin	WW	29-Oct-14	277.00
bazedoxifene + conjugated estrogens, Pfizer	WW	29-Oct-14	91.00
bosutinib	WW	29-Oct-14	194.00
celecoxib	WW	29-Oct-14	839.00
CP 526555-18	WW	29-Oct-14	482.00
crizotinib	WW	29-Oct-14	852.00
dacomitinib	WW	29-Oct-14	375.00
desvenlafaxine	WW	29-Oct-14	850.00
doxazosin	WW	29-Oct-14	175.00
etanercept	WW - US	29-Oct-14	4323.00
latanoprost	WW	29-Oct-14	318.00
linezolid	WW	29-Oct-14	595.00
meningococcal B rLP2086 vaccine, Pfizer	WW	29-Oct-14	800.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	29-Oct-14	100.00
nonacog alfa	WW	29-Oct-14	702.00
palbociclib	WW	29-Oct-14	625.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Oct-14	229.00
pregabalin	WW	29-Oct-14	3172.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Oct-14	532.00
sertraline	WW	29-Oct-14	362.00
somatropin (growth disorder), Pfizer	WW	29-Oct-14	593.00
sunitinib	WW	29-Oct-14	1281.00
tafamidis	WW	29-Oct-14	30.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Oct-14	978.00
tolterodine	WW	29-Oct-14	103.00
venlafaxine hydrochloride	WW	29-Oct-14	97.00

[Return to Table of Contents](#)



voriconazole	WW	29-Oct-14	636.00
Jefferies and Co Inc			
Drug Details			
Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	712.00
atorvastatin	WW	15-Jan-15	1357.00
atorvastatin + amlodipine	WW - JP	13-Oct-14	79.00
axitinib	WW	15-Jan-15	610.00
azithromycin	WW	15-Jan-15	172.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	200.00
bococizumab	WW	13-Oct-14	0.00
bosutinib	WW	13-Oct-14	200.00
celecoxib	WW	13-Oct-14	628.00
CP 526555-18	WW	15-Jan-15	523.00
crizotinib	WW	13-Oct-14	869.00
dacomitinib	WW	13-Oct-14	195.00
doxazosin	WW	13-Oct-14	169.00
ertugliflozin	JP	13-Oct-14	163.00
etanercept	WW - US	15-Jan-15	2990.00
EXC-001	WW	15-Jan-15	31.00
fosdagrocorat	WW	15-Jan-15	63.00
gedatolisib	WW	15-Jan-15	56.00
inotuzumab ozogamicin	WW	13-Oct-14	163.00
latanoprost	WW	13-Oct-14	247.00
linezolid	WW	15-Jan-15	451.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	63.00
nonacog alfa	WW	15-Jan-15	984.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	293.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	149.00
palbociclib	WW	13-Oct-14	3500.00
PF-04634817	WW	15-Jan-15	63.00
PF-06290510	WW	15-Jan-15	31.00
PF-4236921	WW	15-Jan-15	63.00
PF-547659	WW	15-Jan-15	63.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	107.00
ponezumab	WW	15-Jan-15	28.00
pregabalin	WW	15-Jan-15	6099.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	697.00
SAM-760	WW	15-Jan-15	0.00
sertraline	WW	15-Jan-15	211.00
sildenafil citrate	WW	15-Jan-15	106.00

[Return to Table of Contents](#)



sildenafil citrate	WW	15-Jan-15	662.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	598.00
sunitinib	WW	15-Jan-15	904.00
tolterodine	WW	15-Jan-15	49.00
venlafaxine hydrochloride	WW	15-Jan-15	161.00
voriconazole	WW	15-Jan-15	449.00
<b>Credit Suisse First Boston</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
gedatolisib	WW	08-Jan-15	15.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	150.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	125.00
PF-06290510	WW	08-Jan-15	0.00
Pevnar	WW	21-Oct-14	230.00
<b>Atlantic Equities</b>			
<b>Drug Details</b>			
<b>Drug Name</b>	<b>Region</b>	<b>Publication Date</b>	<b>Value (USD million)</b>
amlodipine	WW	26-Jan-15	832.00
atorvastatin	WW	26-Jan-15	1085.00
atorvastatin + amlodipine	WW - JP	26-Jan-15	162.00
axitinib	WW	26-Jan-15	731.00
azithromycin	WW	26-Jan-15	236.00
bazedoxifene + conjugated estrogens, Pfizer	WW	26-Jan-15	293.00
bosutinib	WW	26-Jan-15	313.00
celecoxib	WW	26-Jan-15	860.00
CP 526555-18	WW	26-Jan-15	572.00
crizotinib	WW	26-Jan-15	833.00
desvenlafaxine	WW	26-Jan-15	863.00
doxazosin	WW	26-Jan-15	184.00
etanercept	WW - US	26-Jan-15	3685.00
exemestane	WW	26-Jan-15	90.00
latanoprost	WW	26-Jan-15	272.00
linezolid	WW	26-Jan-15	479.00
nonacog alfa	WW	26-Jan-15	911.00
pantoprazole	US	26-Jan-15	161.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	26-Jan-15	216.00
pregabalin	WW	26-Jan-15	4655.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	26-Jan-15	679.00
sertraline	WW	26-Jan-15	356.00

[Return to Table of Contents](#)



sildenafil citrate	WW	26-Jan-15	130.00
sildenafil citrate	WW	26-Jan-15	889.00
sirolimus	WW	26-Jan-15	192.00
somatropin (growth disorder), Pfizer	WW	26-Jan-15	688.00
sunitinib	WW	26-Jan-15	1037.00
taliglucerase alfa	WW	26-Jan-15	125.00
tigecycline	WW	26-Jan-15	187.00
tofacitinib (oral, inflammation), Pfizer	WW	26-Jan-15	1713.00
tolterodine	WW	26-Jan-15	130.00
venlafaxine hydrochloride	WW	26-Jan-15	264.00
voriconazole	WW	26-Jan-15	384.00

### Suntrust Robinson Humphrey Capital Markets

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	192.00
amlodipine	WW	09-Nov-14	893.00
atorvastatin	WW	09-Nov-14	1728.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	129.00
axitinib	WW	27-Jan-15	865.00
azithromycin	WW	09-Nov-14	333.00
bazedoxifene	WW	09-Nov-14	209.00
bococizumab	WW	09-Nov-14	127.00
celecoxib	WW	09-Nov-14	1148.00
CP 526555-18	WW	09-Nov-14	679.00
crizotinib	WW	27-Jan-15	858.00
dacomitinib	WW	27-Jan-15	36.00
dalteparin sodium	WW - US	09-Nov-14	399.00
desvenlafaxine	WW	09-Nov-14	836.00
doxazosin	WW	09-Nov-14	220.00
eletriptan	WW	09-Nov-14	98.00
eplerenone	WW	09-Nov-14	106.00
etanercept	WW - US	09-Nov-14	2739.00
fesoterodine fumarate	WW	09-Nov-14	401.00
fluconazole	WW	09-Nov-14	192.00
latanoprost	WW	09-Nov-14	366.00
linezolid	WW	09-Nov-14	447.00
medroxyprogesterone	WW	09-Nov-14	356.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	362.00
nonacog alfa	WW	09-Nov-14	921.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	27.00
palbociclib	WW	27-Jan-15	1156.00
pegvisomant	WW	09-Nov-14	280.00

[Return to Table of Contents](#)



piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	213.00
pregabalin	WW	09-Nov-14	4234.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	813.00
sertraline	WW	09-Nov-14	348.00
sildenafil citrate	WW	09-Nov-14	122.00
sildenafil citrate	WW	09-Nov-14	995.00
sirolimus	WW	09-Nov-14	101.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	594.00
sunitinib	WW	09-Nov-14	887.00
tafamidis	WW	09-Nov-14	43.00
tigecycline	WW	09-Nov-14	208.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	1529.00
venlafaxine hydrochloride	WW	09-Nov-14	208.00
voriconazole	WW	09-Nov-14	415.00

### Sanford C Bernstein and Co Inc

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Jan-15	795.00
atorvastatin	WW	29-Jan-15	1541.00
axitinib	WW	29-Jan-15	600.00
azithromycin	WW	29-Jan-15	230.00
bococizumab	WW	29-Jan-15	220.00
celecoxib	WW	02-Dec-14	921.00
CP 526555-18	WW	29-Jan-15	633.00
crizotinib	WW	29-Jan-15	459.00
desvenlafaxine	WW	29-Jan-15	835.00
eletriptan	WW	29-Jan-15	116.00
etanercept	WW - US	29-Jan-15	2721.00
linezolid	WW	29-Jan-15	420.00
nonacog alfa	WW	02-Dec-14	703.00
palbociclib	WW	29-Jan-15	2277.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	218.00
pregabalin	WW	29-Jan-15	5342.00
Prevnar 13	WW	29-Jan-15	5720.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	636.00
sertraline	WW	29-Jan-15	280.00
sildenafil citrate	WW	29-Jan-15	164.00
sunitinib	WW	29-Jan-15	860.00
tigecycline	WW	29-Jan-15	190.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	1082.00
voriconazole	WW	29-Jan-15	505.00

[Return to Table of Contents](#)



## Undisclosed

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	13-Jan-15	175.00
alprazolam	WW	04-Feb-15	187.00
alprazolam	WW	29-Oct-14	412.00
amlodipine	WW	27-Jan-15	1002.00
amlodipine	WW	04-Feb-15	886.00
amlodipine	WW	06-Jan-15	965.00
amlodipine	WW	13-Jan-15	925.00
anidulafungin	WW	13-Jan-15	190.00
anidulafungin	WW	04-Feb-15	154.00
atorvastatin	WW	28-Jan-15	1710.00
atorvastatin	WW	27-Jan-15	1752.00
atorvastatin	WW	15-Jan-15	1750.00
atorvastatin	WW	04-Feb-15	1519.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	65.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	202.00
axitinib	WW	04-Feb-15	565.00
axitinib	WW	06-Jan-15	578.00
axitinib	WW	13-Jan-15	950.00
axitinib	WW	27-Jan-15	1049.00
azithromycin	WW	04-Feb-15	145.00
azithromycin	WW	13-Jan-15	245.00
azithromycin	WW	06-Jan-15	292.00
bazedoxifene	WW	13-Jan-15	135.00
bococizumab	WW	28-Jan-15	200.00
bococizumab	WW	28-Jan-15	56.00
bosutinib	WW	04-Feb-15	137.00
bosutinib	WW	28-Jan-15	350.00
celecoxib	WW	15-Jan-15	945.00
celecoxib	WW	28-Jan-15	578.00
celecoxib	WW	27-Jan-15	900.00
celecoxib	WW	28-Jan-15	831.00
clindamycin	WW	13-Jan-15	135.00
clindamycin	WW	04-Feb-15	184.00
CP 526555-18	WW	27-Jan-15	658.00
CP 526555-18	WW	15-Jan-15	655.00
CP 526555-18	WW	04-Feb-15	700.00
CP 526555-18	WW	06-Jan-15	581.00
crizotinib	WW	06-Jan-15	750.00

[Return to Table of Contents](#)





crizotinib	WW	04-Feb-15	811.00
crizotinib	WW	27-Jan-15	861.00
crizotinib	WW	13-Jan-15	950.00
dacomitinib	WW	13-Jan-15	50.00
desvenlafaxine	WW	13-Jan-15	1010.00
desvenlafaxine	WW	04-Feb-15	759.00
desvenlafaxine	WW	27-Jan-15	620.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	169.60
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	170.00
dofetilide	WW	13-Jan-15	180.00
doxazosin	WW	06-Jan-15	178.00
doxazosin	WW	04-Feb-15	175.00
eletriptan	WW	13-Jan-15	285.00
eletriptan	WW	04-Feb-15	361.00
epirubicin	WW	13-Jan-15	50.00
eplerenone	WW	13-Jan-15	325.00
ertugliflozin	JP	04-Feb-15	360.00
ertugliflozin	JP	28-Oct-14	142.00
etanercept	WW - US	04-Feb-15	3061.00
etanercept	WW - US	27-Jan-15	3307.00
etanercept	WW - US	15-Jan-15	4205.00
etanercept	WW - US	28-Jan-15	3263.00
EXC-001	WW	13-Jan-15	50.00
exemestane	WW	13-Jan-15	145.00
exemestane	WW	04-Feb-15	75.00
fesoterodine fumarate	WW	13-Jan-15	370.00
fesoterodine fumarate	WW	04-Feb-15	379.00
fluconazole	WW	13-Jan-15	150.00
fluconazole	WW	04-Feb-15	122.00
fosdagrocorat	WW	13-Jan-15	50.00
gabapentin	WW	13-Jan-15	115.00
gabapentin	WW	04-Feb-15	117.00
gedatolisib	WW	13-Jan-15	50.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
inotuzumab ozogamicin	WW	13-Jan-15	200.00
irinotecan	WW	04-Feb-15	29.00
irinotecan	WW	13-Jan-15	10.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	06-Jan-15	317.00
latanoprost	WW	04-Feb-15	267.00

[Return to Table of Contents](#)



latanoprost	WW	13-Jan-15	240.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	50.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	28-Jan-15	225.00
linezolid	WW	04-Feb-15	319.00
linezolid	WW	15-Jan-15	315.00
linezolid	WW	27-Jan-15	761.00
medroxyprogesterone	WW	13-Jan-15	240.00
meningococcal B rLP2086 vaccine, Pfizer	WW	06-Jan-15	321.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	20.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	300.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	17.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	50.00
nonacog alfa	WW	13-Jan-15	485.00
nonacog alfa	WW	27-Jan-15	866.00
nonacog alfa	WW	25-Jan-15	639.00
nonacog alfa	WW	06-Jan-15	905.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	75.00
palbociclib	WW	28-Jan-15	2250.00
palbociclib	WW	15-Jan-15	1000.00
palbociclib	WW	27-Jan-15	2050.00
palbociclib	WW	04-Feb-15	4938.00
pantoprazole	US	04-Feb-15	88.00
pantoprazole	US	13-Jan-15	125.00
parecoxib	WW	13-Jan-15	180.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	27-Jan-15	87.00
pegvisomant	WW	13-Jan-15	315.00
PF-04634817	WW	13-Jan-15	50.00
PF-04937319	WW	13-Jan-15	20.00
PF-06290510	WW	13-Jan-15	50.00
PF-2545920	WW	13-Jan-15	50.00
PF-4236921	WW	13-Jan-15	50.00
PF-489791	WW	13-Jan-15	50.00
PF-547659	WW	13-Jan-15	50.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	123.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	261.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	175.00
ponezumab	WW	13-Jan-15	50.00

[Return to Table of Contents](#)



pregabalin	WW	28-Jan-15	4692.00
pregabalin	WW	29-Jan-15	4808.00
pregabalin	WW	15-Jan-15	4915.00
pregabalin	WW	04-Feb-15	3907.00
pregabalin	WW	27-Jan-15	4189.00
Prevnar 13	WW	15-Jan-15	5840.00
Prevnar 13	WW	28-Jan-15	5752.00
quinapril hydrochloride	WW	13-Jan-15	5.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	841.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	450.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	671.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	428.00
rivipansel sodium	WW	13-Jan-15	50.00
SAM-760	WW	13-Jan-15	50.00
sertraline	WW	04-Feb-15	267.00
sertraline	WW	13-Jan-15	295.00
sertraline	WW	06-Jan-15	379.00
sildenafil citrate	WW	13-Jan-15	215.00
sildenafil citrate	WW	04-Feb-15	117.00
sildenafil citrate	WW	04-Feb-15	471.00
sildenafil citrate	WW	06-Jan-15	1560.00
sildenafil citrate	WW	28-Jan-15	664.00
sildenafil citrate	WW	15-Jan-15	590.00
sirolimus	WW	13-Jan-15	130.00
sirolimus	WW	27-Jan-15	103.00
sirolimus	WW	04-Feb-15	66.00
somatropin (growth disorder), Pfizer	WW	27-Jan-15	671.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	594.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	540.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	615.00
sunitinib	WW	15-Jan-15	1430.00
sunitinib	WW	27-Jan-15	1171.00
sunitinib	WW	04-Feb-15	993.00
sunitinib	WW	28-Jan-15	1015.00
taliglucerase alfa	WW	13-Jan-15	120.00
temsirolimus	WW	04-Feb-15	36.00
temsirolimus	WW	13-Jan-15	175.00
Thrombin-JMI	WW	13-Jan-15	50.00
tigecycline	WW	04-Feb-15	232.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1600.00

[Return to Table of Contents](#)



tofacinib (oral, inflammation), Pfizer	WW	27-Jan-15	1097.00
tofacinib (oral, inflammation), Pfizer	WW	13-Jan-15	1125.00
tofacinib (oral, inflammation), Pfizer	WW	04-Feb-15	1633.00
tolterodine	WW	04-Feb-15	110.00
tolterodine	WW	13-Jan-15	210.00
venlafaxine hydrochloride	WW	28-Jan-15	110.00
venlafaxine hydrochloride	WW	13-Jan-15	225.00
venlafaxine hydrochloride	WW	06-Jan-15	265.00
voriconazole	WW	06-Jan-15	284.00
voriconazole	WW	27-Jan-15	723.00
voriconazole	WW	13-Jan-15	585.00
voriconazole	WW	04-Feb-15	368.00
zaleplon	US	23-Jan-15	0.80
ziprasidone	WW - JP	13-Jan-15	160.00
ziprasidone	WW - JP	04-Feb-15	90.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	939.00
atorvastatin	WW	28-Jan-15	1310.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	730.00
azithromycin	WW	28-Jan-15	202.00
bosutinib	WW	28-Jan-15	215.00
celecoxib	WW	28-Jan-15	650.00
CP 526555-18	WW	28-Jan-15	695.00
crizotinib	WW	28-Jan-15	1100.00
dalteparin sodium	WW - US	16-Jan-15	250.00
desvenlafaxine	WW	28-Jan-15	830.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	4000.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	100.00
latanoprost	WW	28-Jan-15	400.00
linezolid	WW	28-Jan-15	310.00
nonacog alfa	WW	28-Jan-15	525.00
palbociclib	WW	28-Jan-15	2800.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	105.00
pregabalin	WW	28-Jan-15	4150.00
Pprevnar 13	WW	16-Jan-15	5490.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	585.00
sertraline	WW	28-Jan-15	275.00

[Return to Table of Contents](#)



sildenafil citrate	WW	28-Jan-15	70.00
sildenafil citrate	WW	28-Jan-15	1625.00
sirolimus	WW	28-Jan-15	95.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	1080.00
tigecycline	WW	28-Jan-15	230.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1550.00
tolterodine	WW	28-Jan-15	65.00
venlafaxine hydrochloride	WW	28-Jan-15	145.00
voriconazole	WW	28-Jan-15	595.00
ziprasidone	WW - JP	28-Jan-15	60.00

## 2019

### Cantor Fitzgerald and Co

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	231.90

### Jefferies and Co Inc

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	13-Oct-14	639.00
atorvastatin	WW	15-Jan-15	1212.00
atorvastatin + amlodipine	WW - JP	13-Oct-14	72.00
axitinib	WW	15-Jan-15	630.00
azithromycin	WW	15-Jan-15	151.00
bazedoxifene + conjugated estrogens, Pfizer	WW	13-Oct-14	225.00
bococizumab	WW	13-Oct-14	439.00
bosutinib	WW	13-Oct-14	200.00
celecoxib	WW	13-Oct-14	517.00
CP 526555-18	WW	15-Jan-15	489.00
crizotinib	WW	13-Oct-14	895.00
dacomitinib	WW	13-Oct-14	325.00
doxazosin	WW	13-Oct-14	152.00
ertugliflozin	JP	13-Oct-14	293.00
etanercept	WW - US	15-Jan-15	2691.00
EXC-001	WW	15-Jan-15	56.00
fosdagrocorat	WW	15-Jan-15	113.00
gedatolisib	WW	15-Jan-15	94.00
inotuzumab ozogamicin	WW	13-Oct-14	228.00
latanoprost	WW	13-Oct-14	210.00

[Return to Table of Contents](#)



linezolid	WW	15-Jan-15	360.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	113.00
nonacog alfa	WW	15-Jan-15	984.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	423.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	234.00
palbociclib	WW	13-Oct-14	4500.00
PF-04634817	WW	15-Jan-15	113.00
PF-06290510	WW	15-Jan-15	56.00
PF-4236921	WW	15-Jan-15	113.00
PF-547659	WW	15-Jan-15	113.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	83.00
ponezumab	WW	15-Jan-15	47.00
pregabalin	WW	15-Jan-15	2689.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	713.00
SAM-760	WW	15-Jan-15	113.00
sertraline	WW	15-Jan-15	181.00
sildenafil citrate	WW	15-Jan-15	84.00
sildenafil citrate	WW	15-Jan-15	543.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	580.00
sunitinib	WW	15-Jan-15	858.00
tolterodine	WW	15-Jan-15	44.00
venlafaxine hydrochloride	WW	15-Jan-15	135.00
voriconazole	WW	15-Jan-15	402.00

### Credit Suisse First Boston

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
gedatolisib	WW	08-Jan-15	35.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	175.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	150.00
PF-06290510	WW	08-Jan-15	35.00
Prevnar	WW	21-Oct-14	225.00

### Suntrust Robinson Humphrey Capital Markets

#### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	09-Nov-14	182.00
amlodipine	WW	09-Nov-14	869.00
atorvastatin	WW	09-Nov-14	1677.00
atorvastatin + amlodipine	WW - JP	09-Nov-14	122.00
axitinib	WW	27-Jan-15	901.00

[Return to Table of Contents](#)



azithromycin	WW	09-Nov-14	338.00
bazedoxifene	WW	09-Nov-14	230.00
bococizumab	WW	09-Nov-14	208.00
celecoxib	WW	09-Nov-14	985.00
CP 526555-18	WW	09-Nov-14	677.00
crizotinib	WW	27-Jan-15	901.00
dacomitinib	WW	27-Jan-15	42.00
dalteparin sodium	WW - US	09-Nov-14	408.00
desvenlafaxine	WW	09-Nov-14	859.00
doxazosin	WW	09-Nov-14	211.00
eletriptan	WW	09-Nov-14	81.00
eplerenone	WW	09-Nov-14	91.00
etanercept	WW - US	09-Nov-14	2659.00
fesoterodine fumarate	WW	09-Nov-14	421.00
fluconazole	WW	09-Nov-14	188.00
latanoprost	WW	09-Nov-14	343.00
linezolid	WW	09-Nov-14	431.00
medroxyprogesterone	WW	09-Nov-14	381.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	476.00
nonacog alfa	WW	09-Nov-14	925.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	34.00
palbociclib	WW	27-Jan-15	1485.00
pegvisomant	WW	09-Nov-14	285.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	09-Nov-14	200.00
pregabalin	WW	09-Nov-14	2116.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	09-Nov-14	847.00
sertraline	WW	09-Nov-14	338.00
sildenafil citrate	WW	09-Nov-14	110.00
sildenafil citrate	WW	09-Nov-14	770.00
sirolimus	WW	09-Nov-14	95.00
somatropin (growth disorder), Pfizer	WW	09-Nov-14	577.00
sunitinib	WW	09-Nov-14	836.00
tafamidis	WW	09-Nov-14	55.00
tigecycline	WW	09-Nov-14	200.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	1827.00
venlafaxine hydrochloride	WW	09-Nov-14	196.00
voriconazole	WW	09-Nov-14	398.00

## Sanford C Bernstein and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Jan-15	755.00
atorvastatin	WW	29-Jan-15	1464.00

[Return to Table of Contents](#)



axitinib	WW	29-Jan-15	630.00
azithromycin	WW	29-Jan-15	219.00
bococizumab	WW	29-Jan-15	401.00
celecoxib	WW	02-Dec-14	851.00
CP 526555-18	WW	29-Jan-15	634.00
crizotinib	WW	29-Jan-15	431.00
desvenlafaxine	WW	29-Jan-15	856.00
eletriptan	WW	29-Jan-15	108.00
etanercept	WW - US	29-Jan-15	2268.00
linezolid	WW	29-Jan-15	437.00
nonacog alfa	WW	02-Dec-14	636.00
palbociclib	WW	29-Jan-15	2725.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	207.00
pregabalin	WW	29-Jan-15	2412.00
Prevnar 13	WW	29-Jan-15	5931.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	616.00
sertraline	WW	29-Jan-15	280.00
sildenafil citrate	WW	29-Jan-15	131.00
sunitinib	WW	29-Jan-15	774.00
tigecycline	WW	29-Jan-15	197.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	1194.00
voriconazole	WW	29-Jan-15	525.00

## Undisclosed

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	13-Jan-15	155.00
alprazolam	WW	29-Oct-14	449.00
alprazolam	WW	04-Feb-15	179.00
amlodipine	WW	13-Jan-15	885.00
amlodipine	WW	27-Jan-15	1006.00
amlodipine	WW	04-Feb-15	855.00
amlodipine	WW	06-Jan-15	965.00
anidulafungin	WW	04-Feb-15	158.00
anidulafungin	WW	13-Jan-15	200.00
atorvastatin	WW	15-Jan-15	1785.00
atorvastatin	WW	27-Jan-15	1746.00
atorvastatin	WW	04-Feb-15	1481.00
atorvastatin	WW	28-Jan-15	1787.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	193.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	55.00
axitinib	WW	27-Jan-15	1227.00
axitinib	WW	06-Jan-15	585.00

[Return to Table of Contents](#)





axitinib	WW	04-Feb-15	550.00
axitinib	WW	13-Jan-15	1050.00
azithromycin	WW	13-Jan-15	240.00
azithromycin	WW	04-Feb-15	136.00
azithromycin	WW	06-Jan-15	292.00
bazedoxifene	WW	13-Jan-15	145.00
bococizumab	WW	28-Jan-15	454.00
bococizumab	WW	28-Jan-15	450.00
bosutinib	WW	28-Jan-15	350.00
bosutinib	WW	04-Feb-15	148.00
celecoxib	WW	15-Jan-15	915.00
celecoxib	WW	28-Jan-15	769.00
celecoxib	WW	27-Jan-15	842.00
celecoxib	WW	28-Jan-15	484.00
clindamycin	WW	13-Jan-15	120.00
clindamycin	WW	04-Feb-15	180.00
CP 526555-18	WW	04-Feb-15	692.00
CP 526555-18	WW	06-Jan-15	581.00
CP 526555-18	WW	15-Jan-15	970.00
CP 526555-18	WW	27-Jan-15	638.00
crizotinib	WW	04-Feb-15	887.00
crizotinib	WW	27-Jan-15	919.00
crizotinib	WW	13-Jan-15	1050.00
crizotinib	WW	06-Jan-15	750.00
dacomitinib	WW	13-Jan-15	75.00
desvenlafaxine	WW	27-Jan-15	798.00
desvenlafaxine	WW	04-Feb-15	755.00
desvenlafaxine	WW	13-Jan-15	1080.00
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	180.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	168.80
dofetilide	WW	13-Jan-15	190.00
doxazosin	WW	04-Feb-15	179.00
doxazosin	WW	06-Jan-15	164.00
eletriptan	WW	04-Feb-15	353.00
eletriptan	WW	13-Jan-15	265.00
epirubicin	WW	13-Jan-15	40.00
eplerenone	WW	13-Jan-15	345.00
ertugliflozin	JP	04-Feb-15	424.00
ertugliflozin	JP	28-Oct-14	184.00
etanercept	WW - US	27-Jan-15	3185.00

[Return to Table of Contents](#)



etanercept	WW - US	28-Jan-15	3100.00
etanercept	WW - US	04-Feb-15	2871.00
etanercept	WW - US	15-Jan-15	4325.00
EXC-001	WW	13-Jan-15	75.00
exemestane	WW	04-Feb-15	70.00
exemestane	WW	13-Jan-15	155.00
fesoterodine fumarate	WW	13-Jan-15	390.00
fesoterodine fumarate	WW	04-Feb-15	386.00
fluconazole	WW	04-Feb-15	103.00
fluconazole	WW	13-Jan-15	135.00
fosdagrocorat	WW	13-Jan-15	75.00
gabapentin	WW	13-Jan-15	95.00
gabapentin	WW	04-Feb-15	105.00
gedatolisib	WW	13-Jan-15	75.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
inotuzumab ozogamicin	WW	13-Jan-15	250.00
irinotecan	WW	04-Feb-15	25.00
irinotecan	WW	13-Jan-15	5.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	13-Jan-15	190.00
latanoprost	WW	04-Feb-15	234.00
latanoprost	WW	06-Jan-15	301.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	55.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	04-Feb-15	285.00
linezolid	WW	28-Jan-15	235.00
linezolid	WW	27-Jan-15	744.00
linezolid	WW	15-Jan-15	245.00
medroxyprogesterone	WW	13-Jan-15	250.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	10.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	350.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	17.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	75.00
nonacog alfa	WW	25-Jan-15	605.00
nonacog alfa	WW	13-Jan-15	395.00
nonacog alfa	WW	27-Jan-15	866.00
nonacog alfa	WW	06-Jan-15	905.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	100.00
palbociclib	WW	04-Feb-15	6166.00

[Return to Table of Contents](#)



palbociclib	WW	15-Jan-15	2000.00
palbociclib	WW	28-Jan-15	3000.00
palbociclib	WW	27-Jan-15	2152.00
pantoprazole	US	04-Feb-15	73.00
pantoprazole	US	13-Jan-15	110.00
parecoxib	WW	13-Jan-15	190.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	27-Jan-15	83.00
pegvisomant	WW	13-Jan-15	335.00
PF-04634817	WW	13-Jan-15	75.00
PF-04937319	WW	13-Jan-15	30.00
PF-06290510	WW	13-Jan-15	75.00
PF-2545920	WW	13-Jan-15	75.00
PF-4236921	WW	13-Jan-15	75.00
PF-489791	WW	13-Jan-15	75.00
PF-547659	WW	13-Jan-15	75.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	150.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	261.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	95.00
ponezumab	WW	13-Jan-15	75.00
pregabalin	WW	13-Jan-15	1725.00
pregabalin	WW	27-Jan-15	2513.00
pregabalin	WW	29-Jan-15	2347.00
pregabalin	WW	04-Feb-15	2764.00
pregabalin	WW	28-Jan-15	2626.00
Prevnar 13	WW	28-Jan-15	5769.00
Prevnar 13	WW	15-Jan-15	6210.00
quinapril hydrochloride	WW	13-Jan-15	5.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	671.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	27-Jan-15	867.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	383.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	405.00
rivipansel sodium	WW	13-Jan-15	75.00
SAM-760	WW	13-Jan-15	75.00
sertraline	WW	04-Feb-15	249.00
sertraline	WW	13-Jan-15	275.00
sertraline	WW	06-Jan-15	377.00
sildenafil citrate	WW	13-Jan-15	210.00
sildenafil citrate	WW	04-Feb-15	110.00
sildenafil citrate	WW	15-Jan-15	455.00

[Return to Table of Contents](#)



sildenafil citrate	WW	28-Jan-15	479.00
sildenafil citrate	WW	04-Feb-15	417.00
sirolimus	WW	13-Jan-15	90.00
sirolimus	WW	27-Jan-15	81.00
sirolimus	WW	04-Feb-15	25.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	582.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	590.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	508.00
somatropin (growth disorder), Pfizer	WW	27-Jan-15	671.00
sunitinib	WW	15-Jan-15	1500.00
sunitinib	WW	28-Jan-15	971.00
sunitinib	WW	27-Jan-15	1169.00
sunitinib	WW	04-Feb-15	910.00
taliglucerase alfa	WW	13-Jan-15	140.00
temsirolimus	WW	04-Feb-15	29.00
temsirolimus	WW	13-Jan-15	185.00
Thrombin-JMI	WW	13-Jan-15	40.00
tigecycline	WW	04-Feb-15	228.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1850.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	1856.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	1364.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	1350.00
tolterodine	WW	13-Jan-15	230.00
tolterodine	WW	04-Feb-15	104.00
venlafaxine hydrochloride	WW	13-Jan-15	205.00
venlafaxine hydrochloride	WW	06-Jan-15	255.00
venlafaxine hydrochloride	WW	28-Jan-15	68.00
voriconazole	WW	13-Jan-15	580.00
voriconazole	WW	06-Jan-15	259.00
voriconazole	WW	27-Jan-15	729.00
voriconazole	WW	04-Feb-15	347.00
zaleplon	US	23-Jan-15	0.80
ziprasidone	WW - JP	13-Jan-15	175.00
ziprasidone	WW - JP	04-Feb-15	90.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	899.00
atorvastatin	WW	28-Jan-15	1075.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	780.00
azithromycin	WW	28-Jan-15	177.00

[Return to Table of Contents](#)



bosutinib	WW	28-Jan-15	230.00
celecoxib	WW	28-Jan-15	585.00
CP 526555-18	WW	28-Jan-15	715.00
crizotinib	WW	28-Jan-15	1200.00
dalteparin sodium	WW - US	16-Jan-15	250.00
desvenlafaxine	WW	28-Jan-15	840.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	4080.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	125.00
latanoprost	WW	28-Jan-15	390.00
linezolid	WW	28-Jan-15	225.00
nonacog alfa	WW	28-Jan-15	440.00
palbociclib	WW	28-Jan-15	3600.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	90.00
pregabalin	WW	28-Jan-15	1950.00
Prevna 13	WW	16-Jan-15	5540.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	555.00
sertraline	WW	28-Jan-15	250.00
sildenafil citrate	WW	28-Jan-15	70.00
sildenafil citrate	WW	28-Jan-15	1250.00
sirolimus	WW	28-Jan-15	95.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	1045.00
tigecycline	WW	28-Jan-15	215.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	1900.00
tolterodine	WW	28-Jan-15	55.00
venlafaxine hydrochloride	WW	28-Jan-15	120.00
voriconazole	WW	28-Jan-15	525.00
ziprasidone	WW - JP	28-Jan-15	60.00

2020

## Cantor Fitzgerald and Co

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
bazedoxifene + conjugated estrogens, Pfizer	WW	28-Oct-14	259.70

[Return to Table of Contents](#)



## Jefferies and Co Inc

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
atorvastatin	WW	15-Jan-15	1084.00
axitinib	WW	15-Jan-15	439.00
azithromycin	WW	15-Jan-15	133.00
CP 526555-18	WW	15-Jan-15	260.00
etanercept	WW - US	15-Jan-15	2422.00
EXC-001	WW	15-Jan-15	81.00
fosdagrocorat	WW	15-Jan-15	163.00
gedatolisib	WW	15-Jan-15	131.00
linezolid	WW	15-Jan-15	287.00
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	15-Jan-15	163.00
nonacog alfa	WW	15-Jan-15	935.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	15-Jan-15	520.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	15-Jan-15	308.00
PF-04634817	WW	15-Jan-15	163.00
PF-06290510	WW	15-Jan-15	81.00
PF-4236921	WW	15-Jan-15	163.00
PF-547659	WW	15-Jan-15	163.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	65.00
ponezumab	WW	15-Jan-15	84.00
pregabalin	WW	15-Jan-15	2427.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	15-Jan-15	720.00
SAM-760	WW	15-Jan-15	188.00
sertraline	WW	15-Jan-15	155.00
sildenafil citrate	WW	15-Jan-15	68.00
sildenafil citrate	WW	15-Jan-15	268.00
somatropin (growth disorder), Pfizer	WW	15-Jan-15	562.00
sunitinib	WW	15-Jan-15	815.00
tolterodine	WW	15-Jan-15	39.00
venlafaxine hydrochloride	WW	15-Jan-15	112.00
voriconazole	WW	15-Jan-15	360.00

## Credit Suisse First Boston

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
gedatolisib	WW	08-Jan-15	55.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	08-Jan-15	200.00
oxycodone (oral, abuse-deterrent, controlled-release, ORADUR), Pain Therapeutics/Pfizer	US	21-Oct-14	175.00
PF-06290510	WW	08-Jan-15	90.00

[Return to Table of Contents](#)



Prevnar	WW	21-Oct-14	220.00
<b>Suntrust Robinson Humphrey Capital Markets</b>			
<b>Drug Details</b>			
Drug Name	Region	Publication Date	Value (USD million)
axitinib	WW	27-Jan-15	929.00
crizotinib	WW	27-Jan-15	946.00
dacomitinib	WW	27-Jan-15	47.00
meningococcal B rLP2086 vaccine, Pfizer	WW	09-Nov-14	594.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	09-Nov-14	41.00
palbociclib	WW	27-Jan-15	1809.00
tafamidis	WW	09-Nov-14	65.00
tofacitinib (oral, inflammation), Pfizer	WW	27-Jan-15	2005.00
<b>Sanford C Bernstein and Co Inc</b>			
<b>Drug Details</b>			
Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	29-Jan-15	717.00
atorvastatin	WW	29-Jan-15	1391.00
axitinib	WW	29-Jan-15	662.00
azithromycin	WW	29-Jan-15	210.00
bococizumab	WW	29-Jan-15	584.00
CP 526555-18	WW	29-Jan-15	387.00
crizotinib	WW	29-Jan-15	412.00
desvenlafaxine	WW	29-Jan-15	875.00
eletriptan	WW	29-Jan-15	106.00
etanercept	WW - US	29-Jan-15	1897.00
linezolid	WW	29-Jan-15	399.00
nonacog alfa	WW	02-Dec-14	576.00
palbociclib	WW	29-Jan-15	3078.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	29-Jan-15	197.00
pregabalin	WW	29-Jan-15	2129.00
Prevnar 13	WW	29-Jan-15	6110.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	29-Jan-15	599.00
sertraline	WW	29-Jan-15	266.00
sildenafil citrate	WW	29-Jan-15	118.00
sunitinib	WW	29-Jan-15	697.00
tigecycline	WW	29-Jan-15	208.00
tofacitinib (oral, inflammation), Pfizer	WW	29-Jan-15	1238.00
voriconazole	WW	29-Jan-15	536.00

[Return to Table of Contents](#)



## Undisclosed

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
alprazolam	WW	13-Jan-15	135.00
alprazolam	WW	04-Feb-15	170.00
amlodipine	WW	04-Feb-15	814.00
amlodipine	WW	13-Jan-15	845.00
amlodipine	WW	06-Jan-15	965.00
anidulafungin	WW	13-Jan-15	210.00
anidulafungin	WW	04-Feb-15	162.00
atorvastatin	WW	28-Jan-15	1867.00
atorvastatin	WW	04-Feb-15	1422.00
atorvastatin	WW	15-Jan-15	1830.00
atorvastatin + amlodipine	WW - JP	04-Feb-15	184.00
atorvastatin + amlodipine	WW - JP	13-Jan-15	45.00
axitinib	WW	06-Jan-15	592.00
axitinib	WW	04-Feb-15	400.00
axitinib	WW	13-Jan-15	1150.00
azithromycin	WW	04-Feb-15	123.00
azithromycin	WW	13-Jan-15	245.00
azithromycin	WW	06-Jan-15	292.00
bazedoxifene	WW	13-Jan-15	155.00
bococizumab	WW	28-Jan-15	1000.00
bococizumab	WW	28-Jan-15	972.00
bosutinib	WW	28-Jan-15	350.00
bosutinib	WW	04-Feb-15	159.00
celecoxib	WW	28-Jan-15	601.00
celecoxib	WW	15-Jan-15	895.00
celecoxib	WW	28-Jan-15	409.00
clindamycin	WW	04-Feb-15	176.00
clindamycin	WW	13-Jan-15	105.00
CP 526555-18	WW	04-Feb-15	417.00
CP 526555-18	WW	15-Jan-15	690.00
CP 526555-18	WW	06-Jan-15	355.00
crizotinib	WW	04-Feb-15	961.00
crizotinib	WW	06-Jan-15	750.00
crizotinib	WW	13-Jan-15	1150.00
dacomitinib	WW	13-Jan-15	100.00
desvenlafaxine	WW	04-Feb-15	748.00
desvenlafaxine	WW	13-Jan-15	1150.00
diclofenac (transdermal patch), Pfizer	US	13-Jan-15	190.00
diclofenac (transdermal patch), Pfizer	US	23-Jan-15	168.10
dofetilide	WW	13-Jan-15	200.00

[Return to Table of Contents](#)





doxazosin	WW	04-Feb-15	183.00
doxazosin	WW	06-Jan-15	151.00
eletriptan	WW	13-Jan-15	245.00
eletriptan	WW	04-Feb-15	344.00
epirubicin	WW	13-Jan-15	30.00
eplerenone	WW	13-Jan-15	365.00
ertugliflozin	JP	04-Feb-15	488.00
etanercept	WW - US	28-Jan-15	2852.00
etanercept	WW - US	15-Jan-15	4445.00
etanercept	WW - US	04-Feb-15	2663.00
EXC-001	WW	13-Jan-15	100.00
exemestane	WW	04-Feb-15	65.00
exemestane	WW	13-Jan-15	165.00
fesoterodine fumarate	WW	04-Feb-15	385.00
fesoterodine fumarate	WW	13-Jan-15	410.00
fluconazole	WW	04-Feb-15	86.00
fluconazole	WW	13-Jan-15	120.00
fosdagrocorat	WW	13-Jan-15	100.00
gabapentin	WW	04-Feb-15	93.00
gabapentin	WW	13-Jan-15	75.00
gedatolisib	WW	13-Jan-15	100.00
inotuzumab ozogamicin	WW	04-Feb-15	45.00
inotuzumab ozogamicin	WW	13-Jan-15	300.00
irinotecan	WW	13-Jan-15	5.00
lansoprazole	WW - US	13-Jan-15	5.00
latanoprost	WW	13-Jan-15	150.00
latanoprost	WW	06-Jan-15	286.00
latanoprost	WW	04-Feb-15	205.00
levonorgestrel + ethinylestradiol, Pfizer	WW	13-Jan-15	60.00
levothyroxine sodium, Pfizer	WW	13-Jan-15	5.00
linezolid	WW	28-Jan-15	213.00
linezolid	WW	04-Feb-15	181.00
linezolid	WW	15-Jan-15	195.00
medroxyprogesterone	WW	13-Jan-15	260.00
miglitol	US	13-Jan-15	10.00
misoprostol + diclofenac (oral), Searle	WW	13-Jan-15	5.00
morphine (oral, sustained-release, formulated with abuse-deterrent naltrexone), Pfizer	US	13-Jan-15	400.00
morphine (rapid-onset, extended-release, SODAS), Pfizer	US	23-Jan-15	16.70
multipotent adult progenitor cell therapy (ischemia/cerebral palsy/AMI/GvHD/PD/IBD), Athersys/Angiotech/Pfizer	WW	13-Jan-15	100.00
nonacog alfa	WW	06-Jan-15	905.00

[Return to Table of Contents](#)



nonacog alfa	WW	13-Jan-15	375.00
nonacog alfa	WW	25-Jan-15	572.00
oxycodone (formulated with abuse-resistant naltrexone), Pfizer	US	13-Jan-15	125.00
palbociclib	WW	28-Jan-15	4000.00
palbociclib	WW	04-Feb-15	6599.00
palbociclib	WW	15-Jan-15	3000.00
pantoprazole	US	04-Feb-15	61.00
pantoprazole	US	13-Jan-15	95.00
parecoxib	WW	13-Jan-15	200.00
pegaptanib	WW - US	13-Jan-15	15.00
pegvisomant	WW	13-Jan-15	355.00
PF-04634817	WW	13-Jan-15	100.00
PF-04937319	WW	13-Jan-15	40.00
PF-06290510	WW	13-Jan-15	100.00
PF-2545920	WW	13-Jan-15	100.00
PF-4236921	WW	13-Jan-15	100.00
PF-489791	WW	13-Jan-15	100.00
PF-547659	WW	13-Jan-15	100.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	15-Jan-15	135.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	04-Feb-15	73.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	06-Jan-15	261.00
ponezumab	WW	13-Jan-15	100.00
pregabalin	WW	15-Jan-15	1695.00
pregabalin	WW	04-Feb-15	1340.00
pregabalin	WW	28-Jan-15	1318.00
pregabalin	WW	29-Jan-15	1420.00
Prevnar 13	WW	15-Jan-15	6580.00
Prevnar 13	WW	28-Jan-15	5789.00
quinapril hydrochloride	WW	13-Jan-15	5.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	06-Jan-15	671.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	04-Feb-15	347.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	13-Jan-15	365.00
rivipansel sodium	WW	13-Jan-15	100.00
SAM-760	WW	13-Jan-15	100.00
sertraline	WW	04-Feb-15	232.00
sertraline	WW	13-Jan-15	265.00
sertraline	WW	06-Jan-15	375.00
sildenafil citrate	WW	04-Feb-15	104.00
sildenafil citrate	WW	13-Jan-15	210.00
sildenafil citrate	WW	28-Jan-15	417.00

[Return to Table of Contents](#)



sildenafil citrate	WW	15-Jan-15	325.00
sildenafil citrate	WW	04-Feb-15	302.00
sirolimus	WW	04-Feb-15	16.00
sirolimus	WW	13-Jan-15	60.00
somatropin (growth disorder), Pfizer	WW	04-Feb-15	571.00
somatropin (growth disorder), Pfizer	WW	13-Jan-15	565.00
somatropin (growth disorder), Pfizer	WW	06-Jan-15	477.00
sunitinib	WW	04-Feb-15	807.00
sunitinib	WW	15-Jan-15	1570.00
sunitinib	WW	28-Jan-15	923.00
taliglucerase alfa	WW	13-Jan-15	160.00
temsirolimus	WW	13-Jan-15	195.00
temsirolimus	WW	04-Feb-15	23.00
Thrombin-JMI	WW	13-Jan-15	30.00
tigecycline	WW	04-Feb-15	220.00
tofacitinib (oral, inflammation), Pfizer	WW	13-Jan-15	1575.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	2050.00
tofacitinib (oral, inflammation), Pfizer	WW	04-Feb-15	2035.00
tolterodine	WW	13-Jan-15	250.00
tolterodine	WW	04-Feb-15	100.00
venlafaxine hydrochloride	WW	06-Jan-15	248.00
venlafaxine hydrochloride	WW	28-Jan-15	60.00
venlafaxine hydrochloride	WW	13-Jan-15	200.00
voriconazole	WW	04-Feb-15	334.00
voriconazole	WW	06-Jan-15	237.00
voriconazole	WW	13-Jan-15	585.00
zaleplon	US	23-Jan-15	0.80
ziprasidone	WW - JP	04-Feb-15	90.00
ziprasidone	WW - JP	13-Jan-15	190.00

## Leerink Swann

### Drug Details

Drug Name	Region	Publication Date	Value (USD million)
amlodipine	WW	28-Jan-15	849.00
atorvastatin	WW	28-Jan-15	925.00
atorvastatin + amlodipine	WW - JP	28-Jan-15	165.00
axitinib	WW	28-Jan-15	825.00
azithromycin	WW	28-Jan-15	157.00
bosutinib	WW	28-Jan-15	245.00
celecoxib	WW	28-Jan-15	505.00
CP 526555-18	WW	28-Jan-15	400.00
crizotinib	WW	28-Jan-15	1275.00
dalteparin sodium	WW - US	16-Jan-15	250.00

[Return to Table of Contents](#)



desvenlafaxine	WW	28-Jan-15	850.00
doxazosin	WW	28-Jan-15	245.00
etanercept	WW - US	28-Jan-15	4080.00
exemestane	WW	28-Jan-15	140.00
inotuzumab ozogamicin	WW	16-Jan-15	150.00
latanoprost	WW	28-Jan-15	380.00
linezolid	WW	28-Jan-15	175.00
nonacog alfa	WW	28-Jan-15	375.00
palbociclib	WW	28-Jan-15	4250.00
piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho	WW	28-Jan-15	85.00
pregabalin	WW	28-Jan-15	1650.00
Pprevnar 13	WW	16-Jan-15	5590.00
recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth	WW	28-Jan-15	505.00
sertraline	WW	28-Jan-15	230.00
sildenafil citrate	WW	28-Jan-15	70.00
sildenafil citrate	WW	28-Jan-15	400.00
sirolimus	WW	28-Jan-15	95.00
somatropin (growth disorder), Pfizer	WW	28-Jan-15	670.00
sunitinib	WW	28-Jan-15	985.00
tigecycline	WW	28-Jan-15	205.00
tofacitinib (oral, inflammation), Pfizer	WW	28-Jan-15	2150.00
tolterodine	WW	28-Jan-15	50.00
venlafaxine hydrochloride	WW	28-Jan-15	95.00
voriconazole	WW	28-Jan-15	430.00
ziprasidone	WW - JP	28-Jan-15	60.00


[Return to Table of Contents](#)



## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	91	423	514
Neoplasm	58	393	451
Cardiovascular disease	51	378	429
Infectious disease	52	342	394
Inflammatory disease	61	330	391
Gastrointestinal disease	50	231	281


[Return to Table of Contents](#)

Metabolic disorder	38	214	252
Immune disorder	44	206	250
Psychiatric disorder	24	210	234
Respiratory disease	39	182	221
Endocrine disease	41	167	208
Musculoskeletal disease	34	138	172
Genitourinary disease	45	114	159
Hematological disease	33	103	136
Degeneration	14	108	122
Gynecology and obstetrics	31	79	110
Dermatological disease	28	73	101
Genetic disorder	13	74	87
Ocular disease	13	46	59
Nutritional disorder	1	52	53
Andrology	9	39	48
Growth disorder	9	22	31
Injury	0	31	31
Prophylaxis	11	17	28
Toxicity and intoxication	12	15	27
Unidentified indication	3	22	25
Ulcer	6	19	25
Otorhinolaryngological disease	6	9	15
Mouth disease	4	8	12
Surgical procedure	0	2	2
Temperature disorder	0	1	1
Fatigue	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Launched	200
Registered	1
Pre-registration	2
Phase 3 Clinical	14
Phase 2 Clinical	32
Phase 1 Clinical	41
Clinical	4
Discovery	66

[Return to Table of Contents](#)

Withdrawn	16
Discontinued	740
No Development Reported	1332

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	108	45	190	96	430
Drug - Commercialization License	90	14	70	24	195
Technology - Other Proprietary	34	1	144	6	184
Drug - Early Research/Development	27	5	97	12	141
Drug - Manufacturing/Supply	14	2	77	2	95
Drug - Discovery/Design	4	0	47	2	53
Technology - Delivery/Formulation	5	0	33	5	43
Drug - Development Services	6	0	35	0	41
Drug - Screening/Evaluation	9	0	27	2	38
Drug - Asset Divestment	11	0	9	1	21
Drug - Funding	12	0	5	1	18
Patent - Exclusive Rights	10	0	7	1	18
Patent - Non-Exclusive Rights	2	0	14	0	16
Technology - Target Validation	1	0	11	0	12
Drug - CRADA	3	0	2	0	5
Technology - Asset Divestment	2	0	2	0	4
Patent - Asset Divestment	1	0	0	0	1

[Return to Table of Contents](#)



## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	147	709
Neurological disease	40	583
Infectious disease	26	474
Inflammatory disease	45	383
Immune disorder	60	367
Gastrointestinal disease	50	359
Psychiatric disorder	28	353
Respiratory disease	33	350
Musculoskeletal disease	36	341
Endocrine disease	53	336
Genitourinary disease	40	310
Cardiovascular disease	29	277
Metabolic disorder	28	272
Gynecology and obstetrics	22	186
Hematological disease	45	176
Genetic disorder	18	151
Dermatological disease	16	140
Degeneration	7	136
Ocular disease	9	95
Toxicity and intoxication	12	76
Andrology	6	76
Growth disorder	7	45
Surgical procedure	8	41
Otorhinolaryngological disease	6	37
Nutritional disorder	1	28
Injury	0	13

[Return to Table of Contents](#)



Unidentified indication	0	12
Mouth disease	1	11
Ulcer	0	11
Prophylaxis	1	7
Temperature disorder	0	2
Fatigue	0	2

### Trials by Phase

Phase	Ongoing	All
Phase 4 Clinical	99	766
Phase 3 Clinical	88	849
Phase 2 Clinical	105	831
Phase 1 Clinical	79	1046
Phase not specified	42	290

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS

Indication	As Owner	As Third Party	Total
Neurological disease	3489	47	3536
Cardiovascular disease	3309	39	3348
Inflammatory disease	2947	46	2993
Neoplasm	2537	51	2588
Gastrointestinal disease	2347	40	2387
Immune disorder	2317	44	2361
Infectious disease	2291	59	2350

[Return to Table of Contents](#)

Metabolic disorder	2093	37	2130
Musculoskeletal disease	1785	23	1808
Endocrine disease	1775	32	1807
Psychiatric disorder	1680	16	1696
Respiratory disease	1593	33	1626
Genitourinary disease	1554	26	1580
Degeneration	1324	18	1342
Dermatological disease	1116	16	1132
Gynecology and obstetrics	831	14	845
Hematological disease	775	20	795
Andrology	688	9	697
Ocular disease	684	12	696
Nutritional disorder	668	13	681
Genetic disorder	663	7	670
Injury	580	6	586
Toxicity and intoxication	398	6	404
Growth disorder	388	5	393
Otorhinolaryngological disease	255	3	258
Ulcer	229	1	230
Prophylaxis	174	3	177
Mouth disease	160	2	162
Temperature disorder	102	0	102
Fatigue	41	0	41
Surgical procedure	16	2	18
Unidentified indication	13	1	14

[Return to Table of Contents](#)